

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
**WO 01/48192 A1**(51) International Patent Classification<sup>7</sup>: **C12N 15/11** (74) Agents: **HAWKINS, Michael, Howard et al.; Baldwin Shelston Waters, P.O. Box 852, Wellington (NZ).**(21) International Application Number: **PCT/NZ00/00256**

(81) Designated States (national): AE, AG, AL, AM, AT, AT

(22) International Filing Date:  
21 December 2000 (21.12.2000)

(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: **English**  
(26) Publication Language: **English**  
(30) Priority Data:  
60/171,678 23 December 1999 (23.12.1999) US  
09/724,864 28 November 2000 (28.11.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **GENESIS RESEARCH & DEVELOPMENT CORPORATION LIMITED [NZ/NZ]; 1 Fox Street, Parnell, Auckland (NZ).****Published:**— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WATSON, James, D. [NZ/NZ]; 769 Riddell Road, St Heliers, Auckland (NZ). MURISON, James, Greg [NZ/NZ]; 24 Calgary Street, Sandringham, Auckland (NZ).**

WO 01/48192 A1

(54) Title: **POLYNUCLEOTIDES, POLYPEPTIDES EXPRESSED BY THE POLYNUCLEOTIDES AND METHODS FOR THEIR USE**

(57) Abstract: Novel polynucleotides including partial and extended sequences, and open reading frames, are provided, together with probes and primers, DNA constructs comprising the polynucleotides, biological materials and organisms incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for using the polynucleotides and polypeptides.

## POLYNUCLEOTIDES, POLYPEPTIDES EXPRESSED BY THE POLYNUCLEOTIDES AND METHODS FOR THEIR USE

### 5 Technical Field of the Invention

This invention relates to polynucleotides believed to be novel, including partial, extended and full length sequences, as well as probes and primers, genetic constructs comprising the polynucleotides, biological materials incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for 10 using the polynucleotides and polypeptides.

### Background of the Invention

Sequencing of the genomes, or portions of the genomes, of numerous biological materials, including humans, animals, microorganisms and various 15 plant varieties, has been and is being carried out on a large scale. Polynucleotides identified using sequencing techniques may be partial or full-length genes, and may contain open reading frames, or portions of open reading frames, that encode polypeptides. Putative polypeptides may be determined based on polynucleotide sequences. The sequencing data relating to polynucleotides thus represents 20 valuable and useful information.

Polynucleotides may be analyzed for various degrees of novelty by comparing identified sequences to sequences published in various public domain databases, such as EMBL. Newly identified polynucleotides and putative polypeptides may also be compared to polynucleotides and polypeptides 25 contained in public domain information to ascertain homology to known polynucleotides and polypeptides. In this way, the degree of similarity, identity or homology of polynucleotides and polypeptides of unknown function may be determined relative to polynucleotides and polypeptides having known functions.

Information relating to the sequences of isolated polynucleotides may be 30 used in a variety of ways. Specified polynucleotides having a particular sequence may be isolated, or synthesized, for use in *in vivo* or *in vitro* experimentation as

probes or primers. Alternatively, collections of sequences of isolated polynucleotides may be stored using magnetic or optical storage medium, and analyzed or manipulated using computer hardware and software, as well as other types of tools.

5

Summary of the Invention

The present invention relates to polynucleotide sequences identified in the attached Sequence Listing as SEQ ID NOS: 1-35, variants of those sequences, extended sequences comprising the sequences set out in SEQ ID NOS: 1-35 and 10 their variants, probes and primers corresponding to the sequences set out in SEQ ID NOS: 1-35 and their variants, polynucleotides comprising at least a specified number of contiguous residues of any of the polynucleotides identified as SEQ ID NOS: 1-35 ( $x$ -mers), and extended sequences comprising portions of the sequences set out in SEQ ID NOS: 1-35, all of which are referred to herein, 15 collectively, as "polynucleotides of the present invention."

The polynucleotide sequences identified as SEQ ID NOS: 1-35 were derived from mammalian sources, namely, from mouse airways induced eosinophilia, rat dermal papilla and mouse stromal cells. Some of the polynucleotides of the present invention are "partial" sequences, in that they do 20 not represent a full-length gene encoding a full-length polypeptide. Such partial sequences may be extended by further analyzing and sequencing the EST clones from which the sequences were obtained, or by analyzing and sequencing various DNA libraries (e.g. cDNA or genomic) using primers and/or probes and well known hybridization and/or PCR techniques. The partial sequences identified as 25 SEQ ID NOS: 1-35 may thus be extended until an open reading frame encoding a polypeptide, a full-length polynucleotide and/or gene capable of expressing a polypeptide, or another useful portion of the genome is identified. Such extended sequences, including full-length polynucleotides and genes, are described as "corresponding to" a sequence identified as one of the sequences of SEQ ID NOS: 30 1-35 or a variant thereof, or a portion of one of the sequences of SEQ ID NOS: 1-35 or a variant thereof, when the extended polynucleotide comprises an identified

sequence or its variant, or an identified contiguous portion (x-mer) of one of the sequences of SEQ ID NOS: 1-35 or a variant thereof.

The polynucleotides identified as SEQ ID NOS: 1-35 were isolated from mouse and rat cDNA clones and represent sequences that are expressed in the tissue from which the cDNA was prepared. The sequence information may be used to isolate or synthesize expressible DNA molecules, such as open reading frames or full-length genes, that can then be used as expressible or otherwise functional DNA in transgenic mammals and other organisms. Similarly, RNA sequences, reverse sequences, complementary sequences, anti-sense sequences and the like, corresponding to the polynucleotides of the present invention, may be routinely ascertained and obtained using the cDNA sequences identified as SEQ ID NOS: 1-35.

In a first aspect, the present invention provides isolated polynucleotide sequences comprising a polynucleotide selected from the group consisting of: (a) sequences recited in SEQ ID NO: 1-35; (b) complements of the sequences recited in SEQ ID NO: 1-35; (c) reverse complements of the sequences recited in SEQ ID NO: 1-35; (d) reverse sequences of the sequences recited in SEQ ID NO: 1-35; (e) sequences having either 40%, 60%, 75% or 90% identical nucleotides, as defined herein, to a sequence of (a) – (d); probes and primers corresponding to the sequences set out in SEQ ID NO: 1-35; polynucleotides comprising at least a specified number of contiguous residues of any of the polynucleotides identified as SEQ ID NO: 1-35; and extended sequences comprising portions of the sequences set out in SEQ ID NO: 1-35; all of which are referred to herein as "polynucleotides of the present invention". The present invention also provides isolated polypeptide sequences identified in the attached Sequence Listing as SEQ ID NO: 36-65; polypeptide variants of those sequences; and polypeptides comprising the isolated polypeptide sequences and variants of those sequences.

In another aspect, the present invention provides genetic constructs comprising a polynucleotide of the present invention, either alone, or in combination with one or more additional polynucleotides of the present invention,

or in combination with one or more known polynucleotides, together with cells and target organisms comprising such constructs.

The polynucleotides identified as SEQ ID NOS: 1-35 may contain open reading frames ("ORFs") or partial open reading frames encoding polypeptides.

5 Additionally, open reading frames encoding polypeptides may be identified in extended or full-length sequences corresponding to the sequences set out as SEQ ID NOS: 1-35. Open reading frames may be identified using techniques that are well known in the art. These techniques include, for example, analysis for the location of known start and stop codons, most likely reading frame identification

10 based on codon frequencies, etc. Suitable tools and software for ORF analysis are available, for example, on the Internet at <http://www.ncbi.nlm.nih.gov/gorf/gorf.html>. Open reading frames and portions of open reading frames may be identified in the polynucleotides of the present invention. Once a partial open reading frame is identified, the polynucleotide may

15 be extended in the area of the partial open reading frame using techniques that are well known in the art until the polynucleotide for the full open reading frame is identified. Thus, polynucleotides and open reading frames encoding polypeptides may be identified using the polynucleotides of the present invention.

Once open reading frames are identified in the polynucleotides of the present invention, the open reading frames may be isolated and/or synthesized. Expressible DNA constructs may then be constructed that comprise the open reading frames and suitable promoters, initiators, terminators, etc., which are well known in the art. Such DNA constructs may be introduced into a host cell to express the polypeptide encoded by the open reading frame. Suitable host cells

25 may include various prokaryotic and eukaryotic cells.

Polypeptides encoded by the polynucleotides of the present invention may be expressed and used in various assays to determine their biological activity. Such polypeptides may be used to raise antibodies, to isolate corresponding interacting proteins or other compounds, and to quantitatively determine levels of

30 interacting proteins or other compounds.

In another aspect, the present invention provides isolated polypeptides encoded, or partially encoded, by the above polynucleotides. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins, wherein the amino acid residues are linked by covalent peptide bonds. The term "polypeptide encoded by a polynucleotide" as used herein, includes polypeptides encoded by a polynucleotide that comprises an isolated polynucleotide sequence or variant provided herein. Polypeptides of the present invention may be naturally purified products, or may be produced partially or wholly using recombinant techniques. Such polypeptides may be glycosylated with bacterial, fungal, mammalian or other eukaryotic carbohydrates or may be non-glycosylated. In specific embodiments, the inventive polypeptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 36-65.

Polypeptides of the present invention may be produced recombinantly by inserting a polynucleotide sequence that encodes the polypeptide into a genetic construct and expressing the polypeptide in an appropriate host. Any of a variety of genetic constructs known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with a genetic construct containing a polynucleotide that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, and higher eukaryotic cells. Preferably, the host cells employed are *Escherichia coli*, insect, yeast, or a mammalian cell line such as COS or CHO. The polynucleotide sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof.

In a related aspect, polypeptides are provided that comprise at least a functional portion of a polypeptide having an amino acid sequence encoded by a polynucleotide of the present invention. As used herein, the "functional portion" of a polypeptide is that portion which contains the active site essential for affecting the function of the polypeptide, for example, the portion of the molecule that is capable of binding one or more reactants. The active site may be made up

of separate portions present on one or more polypeptide chains and will generally exhibit high binding affinity.

Functional portions of a polypeptide may be identified by first preparing fragments of the polypeptide by either chemical or enzymatic digestion of the 5 polypeptide, or by mutation analysis of the polynucleotide that encodes the polypeptide and subsequent expression of the resulting mutant polypeptides. The polypeptide fragments or mutant polypeptides are then tested to determine which portions retain biological activity, using, for example, the representative assays provided below.

10 Portions and other variants of the inventive polypeptides may also be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the 15 commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2154, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems, Inc. (Foster City, California), and may 20 be operated according to the manufacturer's instructions. Variants of a native polypeptide may be prepared using standard mutagenesis techniques, such as oligonucleotide-directed, site-specific mutagenesis (Kunkel, *Proc. Natl. Acad. Sci. USA* 82:488-492, 1985). Sections of polynucleotide sequence may also be removed using standard techniques to permit preparation of truncated 25 polypeptides.

In general, the polypeptides disclosed herein are prepared in an isolated, substantially pure, form. Preferably, the polypeptides are at least about 80% pure, more preferably at least about 90% pure, and most preferably at least about 99% pure. In certain embodiments, described in detail below, the isolated polypeptides 30 are incorporated into pharmaceutical compositions or vaccines.

The present invention also contemplates methods for modulating the polynucleotide and/or polypeptide content and composition of an organism, such methods involving stably incorporating into the genome of the organism a construct containing DNA of the present invention. In one embodiment, the target 5 organism is a mammal, preferably a human, for example for human gene therapy. In a related aspect, a method for producing an organism having an altered genotype or phenotype is provided, the method comprising transforming a cell with a DNA construct of the present invention to provide a transgenic cell, and cultivating the transgenic cell under conditions conducive to regeneration and 10 mature organism growth.

The isolated polynucleotides of the present invention have utility in genome mapping, in physical mapping, and in positional cloning of genes. Additionally, the polynucleotide sequences identified as SEQ ID NOS: 1-35 and their variants may be used to design oligonucleotide probes and primers. 15 Oligonucleotide probes and primers have sequences that are substantially complementary to the polynucleotide of interest over a certain portion of the polynucleotide. Oligonucleotide probes designed using the polynucleotides of the present invention may be used to detect the presence and examine the expression patterns of genes in any organism having sufficiently similar DNA and RNA 20 sequences in their cells using techniques that are well known in the art, such as slot blot DNA hybridization techniques. Oligonucleotide primers designed using the polynucleotides of the present invention may be used for PCR amplifications. Oligonucleotide probes and primers designed using the polynucleotides of the present invention may also be used in connection with various microarray 25 technologies, including the microarray technology of Affymetrix (Santa Clara, CA).

The polynucleotides of the present invention may also be used to tag or identify an organism or reproductive material therefrom. Such tagging may be accomplished, for example, by stably introducing a non-disruptive non-functional 30 heterologous polynucleotide identifier into an organism, the polynucleotide comprising one of the polynucleotides of the present invention.

Detailed Description

Polynucleotides were isolated by high throughput sequencing of cDNA libraries prepared from mouse airway-induced eosinophilia, rat dermal papilla and mouse stromal cells as described below, in Example 1. Isolated polynucleotides of the present invention include the polynucleotides identified as SEQ ID NOS: 1-35; isolated polynucleotides comprising a polynucleotide sequence selected from the group consisting of SEQ ID NOS: 1-35; isolated polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of the polynucleotides identified as SEQ ID NOS: 1-35; polynucleotides complementary to any of the above polynucleotides; anti-sense sequences corresponding to any of the above polynucleotides; and variants of any of the above polynucleotides, as that term is described in this specification. The present invention also provides isolated polypeptide sequences identified in the attached Sequence Listing as SEQ ID NO: 36-65; polypeptide variants of those sequences; and polypeptides comprising the isolated polypeptide sequences and variants of those sequences.

The correspondence of isolated polynucleotides encoding isolated polypeptides of the present invention, and the functionality of the polypeptides, are shown, below, in Table 1.

20

Table 1

SEQ ID NO Poly-nucleotides	SEQ ID NO Poly-peptides	Activity Category	Functionality
1	36	Secretory molecule	Hypothetical 131.1 kDa protein
2	37	Secretory molecule/cytokine/cell signaling	ZCYTO7 belongs to a family of IL-17-related cytokines differing in patterns of expression and proinflammatory responses that may be transduced through a cognate set of cell surface receptors. IL-17 is a T cell-derived cytokine that may play an important role in the initiation or maintenance of the proinflammatory response. Whereas expression of IL-17 is restricted to activated T cells, the IL-17 receptor is found to be

			widely expressed, a finding consistent with the pleiotropic activities of IL-17.
3	38	Secretory molecule	Novel
4	39	Receptor/cytokine/ cell signaling	Tumor endothelial marker 1 precursor
5	40	Secretory molecule	ERO1-L (ERO1-like protein) is involved in oxidative endoplasmic reticulum (ER) protein folding in mammalian cells. Oxidizing conditions must be maintained in the ER to allow the formation of disulfide bonds in secretory proteins. A family of conserved genes, termed ERO for ER oxidoreductins, plays a key role in this process. ERO1-L is a type II integral membrane protein.
6	41	Secretory molecule	Novel
7	42	Receptor/transcription factor	EMR2 is an EGF-like module that is part of the epidermal growth factor (EGF)-TM7 proteins, which also include EMR1, (EGF-like molecule containing mucin-like hormone receptor 1) F4/80, and CD97. These proteins constitute a recently defined class B GPCR subfamily and are predominantly expressed on leukocytes. These molecules possess N-terminal EGF-like domains coupled to a seven-span transmembrane (7TM) moiety via a mucin-like spacer domain. EMR2 contains a total of five tandem EGF-like domains and expresses similar protein isoforms consisting of various numbers of EGF-like domains as a result of alternative RNA splicing. EMR2 share many characteristics with CD97, including highly homologous EGF-like domains and identical gene organization, indicating that both genes are the products of a recent gene duplication event. Both EMR2 and CD97 are highly expressed in immune tissues; however, unlike

			CD97, which is ubiquitously expressed in most cell types, EMR2 expression is restricted to monocytes, macrophages
8	43	Secretory molecule/ cell structure/motility, extracellular matrix	<p>Bone/cartilage proteoglycan I (BGN) is also known as biglycan or PG-S1. BGN is found in the extracellular matrices of several connective tissues, especially in articular cartilages. The two glycosaminoglycan chains attached to BGN can be either chondroitin sulfate or dermatan sulfate. BGN belongs to the small interstitial proteoglycans family. BGN is a small leucine-rich proteoglycan and is a nonfibrillar extracellular matrix component with functions that include the positive regulation of bone formation. It is synthesized as a precursor with an NH(2)-terminal propeptide that is cleaved to yield the mature form found in vertebrate tissues. Bone morphogenetic protein-1 (BMP-1) cleaves proBGN at a single site, removing the propeptide and producing BGN. Soluble BGN purified from rat thymic myoid cells had hemopoietic activity capable of inducing preferential growth and differentiation of monocytic lineage cells from various hemopoietic sources, including brain microglial cells. The haemopoietic BGN plays an important role in generating brain-specific circumstances for development of microglial/monocytic cells</p>
9	44	Secretory molecule	Tubulointerstitial nephritis antigen (TIN-ag) is a basement membrane glycoprotein reactive with autoantibodies in some forms of immunologically mediated human tubulointerstitial nephritis. TIN1 and TIN2 are alternatively spliced products of the TIN-Ag gene. The

			open reading frames of TIN1 and TIN2 indicates the presence of a signal peptide and putative pre-propeptide and both forms contain putative calcium-binding sites. TIN1 additionally contains a characteristic laminin-like epidermal growth factor (EGF) motif and significant homology within the carboxy terminus with the cysteine proteinase family of enzymes. The EGF motif bears important similarities in the positions of cysteines with two motifs in the propeptide of von Willebrand factor. The EGF motif and part of the region that is homologous with the cysteine proteinase family are removed from the TIN2 cDNA. The rest of the TIN1 and TIN2 sequences are identical. TIN-ag is expressed mainly in the kidney and in the intestinal epithelium.
10		Receptor-like molecule	Novel
11	45	Secretory molecule/gene/protein expression, RNA synthesis, transcription factors	Toso is a cell surface, specific regulator of Fas-induced apoptosis in T cells. Fas is a surface receptor that can transmit signals for apoptosis. Toso is expressed in lymphoid cells and expression is enhanced after cell-specific activation processes in T cells. Toso appeared limited to inhibition of apoptosis mediated by members of the TNF receptor family and was capable of inhibiting T cell self-killing induced by TCR activation processes that up-regulate Fas ligand. Toso inhibits caspase-8 processing, the most upstream caspase activity in Fas-mediated signaling, potentially through activation of cFLIP. Toso therefore serves as a novel regulator of Fas-mediated apoptosis and may act as a regulator of cell fate in T cells and

			other hematopoietic lineages.
12	46	Secretory molecule/gene/protein expression, RNA synthesis, transcription factors	<p>Surface glycoprotein CD59 is a phosphatidyl-inositol-glycan-anchored glycoprotein involved in T-cell activation and restriction of complement-mediated lysis. It is also known as protectin, and is ubiquitously expressed on benign and malignant cells. CD59 inhibits complement (C)-mediated lysis of target cells by preventing the formation of the membrane attack complex, in the terminal step of C-activation. Recent experimental evidence demonstrates that CD59 is the main restriction factor of C-mediated lysis of malignant cells of different histotypes. Additionally, a soluble form of CD59, that retains its anchoring ability and functional properties, has been identified in body fluids and in culture supernatants of different malignant cells. CD59 may protect neoplastic cells from C-mediated lysis, contributing to their escape from innate C-control and to tumor progression. The expression of CD59 by neoplastic cells may contribute to impair the therapeutic efficacy of C-activating monoclonal antibodies (mAb) directed to tumor-associated antigens. CD59 can be utilized to improve the therapeutic efficacy of clinical approaches of humoral immunotherapy with C-activating mAb in human malignancies.</p>
13	47	Secretory molecules/cell or organism defense, homeostasis, detoxification	<p>Cytochrome B561 (cyb561) is a secretory vesicle-specific electron transport protein unique to neuroendocrine secretory vesicles. It binds two heme groups non-covalently and is an integral membrane protein. It acts as an electron channel and mediates</p>

			equilibration of ascorbate-semidehydroascorbate inside the secretory vesicle with the ascorbate redox pair in the cytoplasm. The role for this function is to regenerate ascorbate inside the secretory vesicle for use by monooxygenases. The secretory vesicles contain catecholamines and amidated peptides. Cyb561 belongs to the eukaryotic b561 family.
14	48	Secretory molecule	Novel
15	49	Receptor-like molecule/ gene or protein expression, RNA synthesis, transcription factor	High affinity immunoglobulin epsilon receptor beta-subunit (FCER1) is also known as IgE Fc receptor, beta-subunit, FCER1b or FCE1b. FCER1 binds to the Fc region of immunoglobulins epsilon and is a high affinity receptor. FCER1 plays a role in initiating the allergic response where binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators, such as histamine. FCER1 is responsible for the manifestations of allergy and induces the secretion of important lymphokines. It functions as a tetramer consisting of an alpha chain, a beta chain, and two disulfide-linked gamma chains and is an integral membrane protein. Variants of the FCER1B gene have been identified, which are associated with an increased risk of developing atopy and bronchial asthma. Atopic dermatitis is a common skin disease frequently associated with allergic disorders such as allergic rhinitis and asthma.
16	50	Receptor-like molecule	Hypothetical 10.3 kDa protein
17	51	Secretory molecule/antigen processing	Lysosomal thiol reductase IP30 catalyzes disulfide bond reduction both <i>in vitro</i> and <i>in vivo</i> and is optimally active at acidic pH. IP30

			is important in disulfide bond reduction of proteins delivered to MHC class II-containing compartments and consequently in antigen processing. IP30 can be mediated by multiple lysosomal proteases. Proteins internalized into the endocytic pathway are usually degraded. Efficient proteolysis requires denaturation, induced by acidic conditions within lysosomes, and reduction of inter- and intrachain disulfide bonds. The active site, determined by mutagenesis, consists of a pair of cysteine residues separated by two amino acids, similar to other enzymes of the thioredoxin family.
18		Receptor-like molecule	RNA binding protein.
19	52	Secretory molecule/cellular	Notch4-like protein (ZNEU1) is part of the NOTCH4 family that encodes receptors responsible for cell fate decisions during development. These Notch receptors and their ligands, Delta and Jagged, have been implicated in several diseases. When truncated, constitutively active mutant forms of the Notch receptor appear to be involved in T-cell leukemia, mammary carcinomas and a tumorous germline phenotype. Notch4 genes are expressed specifically in endothelial cells.
20	53	Secretory molecule	Novel
21	54	Secretory molecule/transporter	Serotransferrin (siderophilin) (Tf) or beta-1-metal binding globulin is part of the transferrin family. Transferrins are iron binding transport proteins which can bind two atoms of ferric iron in association with the binding of an anion, usually bicarbonate. Tf is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and

			utilization. Serum transferrin also has a further role in stimulating cell proliferation. Tf gene expression is modulated by vitamin A, testosterone, and peptide hormones.
22	55	Secretory molecule/gene or protein expression, RNA synthesis, transcription factor	Insulin-like growth factor binding protein 5 protease (IGFBP-5) modulates the effects of insulin growth factors (IGFs) on cells. IGFBP-5 is synthesized by smooth muscle cells and binds to the extracellular matrix. It is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs. IGFBP-5 protease belongs to a family of serine-metallo proteases.
23	56	Secretory molecule/cellular development	Major epididymis-specific protein E4 is also known as epididymal protein BE-20. It belongs to WAP-type 'four-disulfide core' family and plays a role in the maturation of spermatozoa during its movement through the epididymis and the capacity of sperm to fertilize ova. Expression of E4 was located to the epithelial cells of the cauda epididymis and proximal segment of the ductus deferens by <i>in situ</i> hybridization. No expression was found in sections of the corpus and caput epididymis, testis, and liver.
24		Secretory molecule/cell signaling	TNFR-related death receptor-6 DR6 contains an extracellular region containing varying numbers of cysteine-rich domains and an intracellular region that contains the death domain. Death receptors are activated in a ligand-dependent or independent manner and transduce apoptotic signals via their respective intracellular death domains.
25	57	Receptor-like molecule	Novel

26	58	Secretory molecule/regulation	Channel inducing factor precursor (CHIF) or corticosteroid-induced protein induces a potassium channel when expressed in <i>Xenopus</i> oocytes and activates endogenous oocyte transport proteins. It is a type I membrane protein selectively present in the distal parts of the nephron (medullary and papillary collecting ducts and end portions of cortical collecting tubule) and in the epithelial cells of the distal colon. No expression is found in renal proximal tubule, loop of Henle and distal tubule, proximal colon, small intestine, lung, choroid plexus, salivary glands, or brain. CHIF belongs to the ATP1G1 /PLM / Mat-8 family and exhibits significant homologies with proteins that are putatively regulatory (phospholemman, gamma-subunit of Na <sup>(+)</sup> -K <sup>(+)</sup> -ATPase, Mat-8).
27	59	Secretory molecule	Hepatocellular carcinoma-associated antigen 112.
28	60	Receptor-like molecule/homeostasis	Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is a major receptor for hyaluronan (HA) on the lymph vessel wall molecule that binds both soluble and immobilized HA. LYVE-1 plays a role in the control of the HA pathway. The extracellular matrix glycosaminoglycan hyaluronan (HA) is an abundant component of skin and mesenchymal tissues where it facilitates cell migration during wound healing, inflammation, and embryonic morphogenesis. Both during normal tissue homeostasis and particularly after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver. LYVE-1 is similar to the

			CD44 HA receptor, but in contrast to CD44, LYVE-1 colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels.
29	61	Receptor-like molecule/cell signaling	G protein-coupled receptor GPR35 is an integral membrane protein that belongs to family 1 of G-protein coupled receptors (GPRC). The GPCR family shares a structural motif of seven transmembrane segments with large numbers of conserved residues in those regions.
30	62	Receptor-like molecule	Tumor-associated glycoprotein E4 is also known as Taal or Tage4 and belongs to the immunoglobulin superfamily. This family contains cell adhesion molecules which have wide-ranging functions and mediate a variety of homotypic and heterotypic cellular interactions playing a general role in cell surface recognition. The Tage4 gene product is closely related to the hepatocellular carcinoma antigen TuAg.1. Tage4 is a glycoprotein expressed at the surface of colon carcinoma cell lines, but at a very low level in normal adult colon and lung tissue and not in normal tissues tested.
31	63	Secretory molecule	Hypothetical 28.6 kDa protein is also known as plunc, for palate, lung, and nasal epithelium clone. Expression of plunc is associated with the palate, nasal septum, and nasal conchae. It is also expressed strongly in the trachea and bronchi of the adult lung. No significant homologies with known genes were observed at the nucleotide level and limited amino acid homology with two salivary gland-specific proteins was noted. The amino acid sequence revealed consensus sequences for N-glycosylation, protein kinase C and

			casein kinase phosphorylation, as well as a leucine zipper. In addition, an unique amino acid sequence repeat sequence is located near the amino-terminal portion of the protein.
32	64	Secretory molecule	Claudin-18 (Cldn18) is a component of tight junction (TJ) strands and belongs to the claudin family. Claudins are integral membrane protein component of tight junctions, a structure controlling cell-to-cell adhesion and, consequently, regulating paracellular and transcellular transport of solutes across epithelia and endothelia. The claudin family also includes occludin and 17 other distinct claudins. Claudin family members are tetraspan transmembrane proteins that are localized in cell-specific TJs. In multicellular organisms, various compositionally distinct fluid compartments are established by epithelial and endothelial cellular sheets. For these cells to function as barriers, TJs are considered to create a primary barrier for the diffusion of solutes through the paracellular pathway. Claudins are therefore responsible for TJ-specific obliteration of the intercellular space.
33		Secretory molecule	Glutamine repeat protein 1 (GRP-1) contains simple tandem repeats of the trinucleotide sequence CAG that encode homopolymeric stretches of glutamine. Although polyglutamine has been identified in diverse proteins, it is present predominantly in transcription factors. Greater than two-thirds of GRP-1 are only two amino acids, namely glutamine (50%) and histidine (18%). There are four polyglutamine motifs interspersed with histidine-rich regions. There is also a putative

			nuclear localization signal flanked by sites for possible serine phosphorylation. GRP-1 mRNA was expressed constitutively in some macrophage cell lines and B and T cell lines. Interferon-gamma or lipopolysaccharide augmented GRP-1 mRNA expression in the mouse macrophage cell line ANA-1. Because polyglutamine motifs can cause protein oligomerization and can function as transcriptional activation domains, GRP-1 is a transcription factor associated with interferon-gamma- or lipopolysaccharide-induced activation of macrophages.
34		Secretory molecule	Alpha-1 collagen
35	65	Receptor-like molecule/Cell signaling	Gdnf family receptor alpha 4, transmembrane isoform (Gfra4) is a members of the Gdnf protein family that signal through receptors consisting of a GPI-linked GFRalpha subunit and the transmembrane tyrosine kinase Ret. Gfra4 is expressed in many tissues, including nervous system, in which intron retention leads to a putative intracellular or secreted GFRalpha4 protein. Efficient splicing occurs only in thyroid, parathyroid, and pituitary and less in adrenal glands. A splice form that leads to a GPI-linked GFRalpha4 receptor is expressed in juvenile thyroid and parathyroid glands. In newborn and mature thyroid as well as in parathyroid and pituitary glands major transcripts encode for a putative transmembrane isoform of GFRalpha4. GFRalpha4 expression may restrict the inherited cancer syndrome multiple endocrine neoplasia type 2, associated with mutations in RET, to these cells.

The word "polynucleotide(s)," as used herein, means a polymeric collection of nucleotides and includes DNA and corresponding RNA molecules and both single and double stranded molecules, including HnRNA and mRNA molecules, sense and anti-sense strands of DNA and RNA molecules, and 5 comprehends cDNA, genomic DNA, and wholly or partially synthesized polynucleotides. An HnRNA molecule contains introns and "corresponds to" a DNA molecule in a generally one-to-one manner. An mRNA molecule "corresponds to" an HnRNA and DNA molecule from which the introns have been excised. A polynucleotide of the present invention may be an entire gene, or 10 any portion thereof. A gene is a DNA sequence which codes for a functional protein or RNA molecule. Operable anti-sense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all operable anti-sense fragments. Anti-sense 15 polynucleotides and techniques involving anti-sense polynucleotides are well known in the art and are described, for example, in Robinson-Benion *et al.*, *Methods in Enzymol.* 254(23): 363-375, 1995 and Kawasaki *et al.*, *Artific. Organs* 20 (8): 836-848, 1996.

Identification of genomic DNA and heterologous species DNA can be 20 accomplished by standard DNA/DNA hybridization techniques, under appropriately stringent conditions, using all or part of a cDNA sequence as a probe to screen an appropriate library. Alternatively, PCR techniques using 25 oligonucleotide primers that are designed based on known genomic DNA, cDNA and/or protein sequences can be used to amplify and identify genomic and cDNA sequences. Synthetic DNA corresponding to the identified sequences and variants may be produced by conventional synthesis methods. All of the polynucleotides described herein are isolated and purified, as those terms are commonly used in the art.

As used herein, the term "oligonucleotide" refers to a relatively short 30 segment of a polynucleotide sequence, generally comprising between 6 and 60 nucleotides, and comprehends both probes for use in hybridization assays and primers for use in the amplification of DNA by polymerase chain reaction.

As used herein, the term "x-mer," with reference to a specific value of "x," refers to a polynucleotide comprising at least a specified number ("x") of contiguous residues of any of the polynucleotides identified as SEQ ID NOS: 1-35. The value of x may be from about 20 to about 600, depending upon the 5 specific sequence.

As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins, wherein amino acid residues are linked by covalent peptide bonds. Polypeptides of the present invention may be naturally purified products, or may be produced partially or wholly using 10 recombinant techniques. Such polypeptides may be glycosylated with mammalian or other eukaryotic carbohydrates or may be non-glycosylated.

According to one embodiment, "variants" of the polynucleotides of the present invention, including the polynucleotides set forth as SEQ ID NOS: 1-35, as that term is used herein, comprehends polynucleotides producing an "E" value 15 of 0.01 or less, as described below, or having at least a specified percentage identity to a polynucleotide of the present invention, as described below. Polynucleotide variants of the present invention may be naturally occurring allelic variants, or non-naturally occurring variants.

Polynucleotide and polypeptide sequences may be aligned, and 20 percentages of identical residues in a specified region may be determined against another polynucleotide or polypeptide, using computer algorithms that are publicly available. Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms. Polynucleotides may also be analyzed using the BLASTX algorithm, which 25 compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database. The percentage identity of polypeptide sequences may be examined using the BLASTP algorithm. The BLASTN, BLASTP and BLASTX algorithms are available on the NCBI anonymous FTP server (<ftp://ncbi.nlm.nih.gov>) under /blast/executables/ and are 30 available from the National Center for Biotechnology Information (NCBI), National Library of Medicine, Building 38A, Room 8N805, Bethesda, MD 20894,

USA. The BLASTN algorithm Version 2.0.11 [Jan-20-2000], set to the parameters described below, is preferred for use in the determination of polynucleotide variants according to the present invention. The BLASTP algorithm, set to the parameters described below, is preferred for use in the 5 determination of polypeptide variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN, BLASTP and BLASTX, is described at NCBI's website at URL <http://www.ncbi.nlm.nih.gov/BLAST/newblast.html> and in the publication of Altschul, *et al.*, *Nucleic Acids Res.* 25: 3389-3402, 1997.

10 The FASTA and FASTX algorithms are available on the Internet at the ftp site <ftp://ftp.virginia.edu/pub/>, and from the University of Virginia by contacting David Hudson, Vice Provost for Research, University of Virginia, P.O. Box 9025, Charlottesville, VA 22906-9025, USA. The FASTA algorithm, set to the default parameters described in the documentation and distributed with the algorithm, 15 may be used in the determination of polynucleotide variants. The readme files for FASTA and FASTX Version 1.0x that are distributed with the algorithms describe the use of the algorithms and describe the default parameters. The use of the FASTA and FASTX algorithms is described in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444-2448, 1988; and Pearson, *Methods in Enzymol.* 20 183:63-98, 1990. The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity: Unix running command with default parameter values thus: blastall -p blastn -d embldb -e 10 -G 0 -E 0 -r 1 -v 30 -b 30 -i queryseq -o results; the Parameters are : -p Program Name [String]; -d Database 25 [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -r Reward for a nucleotide match (BLASTN only) [Integer]; -v Number of one-line descriptions (V) [Integer]; -b Number of alignments to show (B) [Integer]; -i Query File [File In]; -o BLAST report Output File [File 30 Out] Optional.

The "hits" to one or more database sequences by a queried sequence produced by BLASTN or FASTA or a similar algorithm align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally 5 represent an overlap over only a fraction of the sequence length of the queried sequence.

The BLASTN and FASTA algorithms produce "Expect" values for alignments. The Expect value (E) indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a 10 database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database, such as the preferred EMBL database, indicates true similarity. For example, an E value of 0.1 assigned to a hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a 15 similar score simply by chance. The aligned and matched portions of the sequences, then, have a probability of 90% of being the same by this criterion. For sequences having an E value of 0.01 or less over aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN or FASTA algorithm.

20 According to one embodiment, "variant" polynucleotides, with reference to each of the polynucleotides of the present invention, preferably comprise sequences having the same number or fewer nucleic acids than each of the polynucleotides of the present invention and producing an E value of 0.01 or less when compared to the polynucleotide of the present invention. That is, a variant 25 polynucleotide is any sequence that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters. According to a preferred embodiment, a variant polynucleotide is a sequence having the same number or fewer nucleic acids than a polynucleotide of 30 the present invention that has at least a 99% probability of being the same as the

polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters.

Alternatively, variant polynucleotides of the present invention may comprise a sequence exhibiting at least about 40%, more preferably at least about 5 60%, more preferably yet at least about 75%, and most preferably at least about 90% similarity to a polynucleotide of the present invention, determined as described below. The percentage similarity is determined by aligning sequences using one of the BLASTN or FASTA algorithms, set at default parameters, and identifying the number of identical nucleic acids over the best aligned portion; 10 dividing the number of identical nucleic acids by the total number of nucleic acids of the polynucleotide of the present invention; and then multiplying by 100 to determine the percentage similarity. For example, a polynucleotide of the present invention having 220 nucleic acids has a hit to a polynucleotide sequence in the EMBL database having 520 nucleic acids over a stretch of 23 nucleotides in the 15 alignment produced by the BLASTN algorithm using the default parameters. The 23 nucleotide hit includes 21 identical nucleotides, one gap and one different nucleotide. The percentage similarity of the polynucleotide of the present invention to the hit in the EMBL library is thus 21/220 times 100, or 9.5%. The 20 polynucleotide sequence in the EMBL database is thus not a variant of a polynucleotide of the present invention.

Alternatively, variant polynucleotides of the present invention hybridize to a polynucleotide of the present invention under stringent hybridization conditions. As used herein, "stringent conditions" mean prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65°C, 6X SSC, 0.2% SDS overnight; followed by two 25 washes of 30 minutes each in 1X SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65°C.

The present invention also encompasses allelic variants of the disclosed sequences, together with DNA sequences that differ from the disclosed sequences but which, due to the degeneracy of the genetic code, encode a polypeptide which 30 is the same as that encoded by a DNA sequence disclosed herein. Thus, polynucleotides comprising sequences that differ from the polynucleotide

sequences recited in SEQ ID NOS: 1-35, or complements, reverse sequences, or reverse complements of those sequences as a result of conservative substitutions are contemplated by and encompassed within the present invention. Additionally, 5 polynucleotides comprising sequences that differ from the polynucleotide sequences recited in SEQ ID NOS: 1-35, or complements, reverse complements, or reverse sequences as a result of deletions and/or insertions totaling less than 10% of the total sequence length are also contemplated by and encompassed within the present invention.

The polynucleotides of the present invention may be isolated from various 10 DNA libraries, or may be synthesized using techniques that are well known in the art. The polynucleotides may be synthesized, for example, using automated oligonucleotide synthesizers (e.g. Beckman Oligo 1000M DNA Synthesizer) to obtain polynucleotide segments of up to 50 or more nucleic acids. A plurality of 15 such polynucleotide segments may then be ligated using standard DNA-manipulation techniques that are well known in the art of molecular biology. One conventional and exemplary polynucleotide synthesis technique involves synthesis of a single stranded polynucleotide segment having, for example, 80 nucleic acids, and hybridizing that segment to a synthesized complementary 85 nucleic acid segment to produce a 5-nucleotide overhang. The next segment may 20 then be synthesized in a similar fashion, with a 5-nucleotide overhang on the opposite strand. The "sticky" ends ensure proper ligation when the two portions are hybridized. In this way, a complete polynucleotide of the present invention may be synthesized entirely *in vitro*.

SEQ ID NOS: 2, 3, 5, 7-9, 11, 12, 14, 15, 17, 19-21, 23, 26, 28 and 30-32 25 are full-length sequences. The remaining polynucleotides are referred to as "partial" sequences, in that they may not represent the full coding portion of a gene encoding a naturally occurring polypeptide. The partial polynucleotide-sequences disclosed herein may be employed to obtain the corresponding full-length genes for various species and organisms by, for example, screening DNA 30 expression libraries using hybridization probes based on the polynucleotides of the present invention, or using PCR amplification with primers based upon the

polynucleotides of the present invention. In this way one can, using methods well known in the art, extend a polynucleotide of the present invention upstream and downstream of the corresponding mRNA, as well as identify the corresponding genomic DNA, including the promoter and enhancer regions, of the complete gene. The present invention thus comprehends isolated polynucleotides comprising a sequence identified in SEQ ID NOS: 1-35, or a variant of one of the specified sequences, that encode a functional polypeptide, including full-length genes. Such extended polynucleotides may have a length of from about 50 to about 4,000 nucleic acids or base pairs, and preferably have a length of less than about 4,000 nucleic acids or base pairs, more preferably yet a length of less than about 3,000 nucleic acids or base pairs, more preferably yet a length of less than about 2,000 nucleic acids or base pairs. Under some circumstances, extended polynucleotides of the present invention may have a length of less than about 1,800 nucleic acids or base pairs, preferably less than about 1,600 nucleic acids or base pairs, more preferably less than about 1,400 nucleic acids or base pairs, more preferably yet less than about 1,200 nucleic acids or base pairs, and most preferably less than about 1,000 nucleic acids or base pairs.

Polynucleotides of the present invention comprehend polynucleotides comprising at least a specified number of contiguous residues ( $x$ -mers) of any of the polynucleotides identified as SEQ ID NOS: 1-35 or their variants. According to preferred embodiments, the value of  $x$  is preferably at least 20, more preferably at least 40, more preferably yet at least 60, and most preferably at least 80. Thus, polynucleotides of the present invention include polynucleotides comprising a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer, a 220-mer a 250-mer, or a 300-mer, 400-mer, 500-mer or 600-mer of a polynucleotide identified as SEQ ID NOS: 1-35 or a variant of one of the polynucleotides identified as SEQ ID NOS: 1-35.

Polynucleotide probes and primers complementary to and/or corresponding to SEQ ID NOS: 1-35, and variants of those sequences, are also comprehended by the present invention. Such oligonucleotide probes and primers are substantially complementary to the polynucleotide of interest. An

oligonucleotide probe or primer is described as "corresponding to" a polynucleotide of the present invention, including one of the sequences set out as SEQ ID NOS: 1-35 or a variant, if the oligonucleotide probe or primer, or its complement, is contained within one of the sequences set out as SEQ ID NOS: 1-35 or a variant of one of the specified sequences.

Two single stranded sequences are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared using, for example, the BLAST algorithm as described above, with the appropriate nucleotide insertions and/or deletions, pair with at least 80%, preferably at least 90% to 95%, and more preferably at least 98% to 100%, of the nucleotides of the other strand. Alternatively, substantial complementarity exists when a first DNA strand will selectively hybridize to a second DNA strand under stringent hybridization conditions. Stringent hybridization conditions for determining complementarity include salt conditions of less than about 1 M, more usually less than about 500 mM and preferably less than about 200 mM. Hybridization temperatures can be as low as 5°C, but are generally greater than about 22°C, more preferably greater than about 30°C and most preferably greater than about 37°C. Longer DNA fragments may require higher hybridization temperatures for specific hybridization. Since the stringency of hybridization may be affected by other factors such as probe composition, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one alone. The DNA from plants or samples or products containing plant material can be either genomic DNA or DNA derived by preparing cDNA from the RNA present in the sample.

In addition to DNA-DNA hybridization, DNA-RNA or RNA-RNA hybridization assays are also possible. In the case of DNA-RNA hybridization, the mRNA from expressed genes would then be detected instead of genomic DNA or cDNA derived from mRNA of the sample. In the case of RNA-RNA hybridization, RNA probes could be used. In addition, artificial analogs of DNA hybridizing specifically to target sequences could also be employed.

In specific embodiments, the oligonucleotide probes and/or primers comprise at least about 6 contiguous residues, more preferably at least about 10 contiguous residues, and most preferably at least about 20 contiguous residues complementary to a polynucleotide sequence of the present invention. Probes and 5 primers of the present invention may be from about 8 to 100 base pairs in length or, preferably from about 10 to 50 base pairs in length or, more preferably from about 15 to 40 base pairs in length. The probes can be easily selected using procedures well known in the art, taking into account DNA-DNA hybridization stringencies, annealing and melting temperatures, potential for formation of loops 10 and other factors, which are well known in the art. Tools and software suitable for designing probes, and especially suitable for designing PCR primers, are available on the Internet, for example, URL <http://www.horizonpress.com/pcr/>. Preferred techniques for designing PCR primers are also disclosed in Dieffenbach and Dyksler, *PCR primer: a laboratory manual*. Cold Spring Harbor Laboratory 15 Press, Cold Spring Harbor, NY, 1995.

A plurality of oligonucleotide probes or primers corresponding to a polynucleotide of the present invention may be provided in a kit form. Such kits generally comprise multiple DNA or oligonucleotide probes, each probe being specific for a polynucleotide sequence. Kits of the present invention may 20 comprise one or more probes or primers corresponding to a polynucleotide of the present invention, including a polynucleotide sequence identified in SEQ ID NOS: 1-35.

In one embodiment useful for high-throughput assays, the oligonucleotide probe kits of the present invention comprise multiple probes in an array format, 25 wherein each probe is immobilized in a predefined, spatially addressable location on the surface of a solid substrate. Array formats which may be usefully employed in the present invention are disclosed, for example, in U.S. Patents No. 5,412,087, 5,545,531, and PCT Publication No. WO 95/00530, the disclosures of which are hereby incorporated by reference.

30 Oligonucleotide probes for use in the present invention may be constructed synthetically prior to immobilization on an array, using techniques well known in

the art (see, for example, *Oligonucleotide Synthesis: A Practical Approach*, Gait, ed., IRL Press, Oxford, 1984). Automated equipment for the synthesis of oligonucleotides is available commercially from such companies as Perkin Elmer/Applied Biosystems Division (Foster City, CA) and may be operated 5 according to the manufacturer's instructions. Alternatively, the probes may be constructed directly on the surface of the array using techniques taught, for example, in PCT Publication No. WO 95/00530.

The solid substrate and the surface thereof preferably form a rigid support and are generally formed from the same material. Examples of materials from 10 which the solid substrate may be constructed include polymers, plastics, resins, membranes, polysaccharides, silica or silica-based materials, carbon, metals and inorganic glasses. Synthetically prepared probes may be immobilized on the surface of the solid substrate using techniques well known in the art, such as those disclosed in U.S. Patent No. 5,412,087.

15 In one such technique, compounds having protected functional groups, such as thiols protected with photochemically removable protecting groups, are attached to the surface of the substrate. Selected regions of the surface are then irradiated with a light source, preferably a laser, to provide reactive thiol groups. This irradiation step is generally performed using a mask having apertures at 20 predefined locations using photolithographic techniques well known in the art of semiconductors. The reactive thiol groups are then incubated with the oligonucleotide probe to be immobilized. The precise conditions for incubation, such as temperature, time and pH, depend on the specific probe and can be easily determined by one of skill in the art. The surface of the substrate is washed free of 25 unbound probe and the irradiation step is repeated using a second mask having a different pattern of apertures. The surface is subsequently incubated with a second, different, probe. Each oligonucleotide probe is typically immobilized in a discrete area of less than about 1 mm<sup>2</sup>. Preferably each discrete area is less than about 10,000 mm<sup>2</sup>, more preferably less than about 100 mm<sup>2</sup>. In this manner, a 30 multitude of oligonucleotide probes may be immobilized at predefined locations on the array.

The resulting array may be employed to screen for differences in organisms or samples or products containing genetic material as follows. Genomic or cDNA libraries are prepared using techniques well known in the art. The resulting target DNA is then labeled with a suitable marker, such as a radiolabel, chromophore, fluorophore or chemiluminescent agent, using protocols well known for those skilled in the art. A solution of the labeled target DNA is contacted with the surface of the array and incubated for a suitable period of time.

The surface of the array is then washed free of unbound target DNA and the probes to which the target DNA hybridized are determined by identifying those regions of the array to which the markers are attached. When the marker is a radiolabel, such as  $^{32}\text{P}$ , autoradiography is employed as the detection method. In one embodiment, the marker is a fluorophore, such as fluorescein, and the location of bound target DNA is determined by means of fluorescence spectroscopy. Automated equipment for use in fluorescence scanning of oligonucleotide probe arrays is available from Affymetrix, Inc. (Santa Clara, CA) and may be operated according to the manufacturer's instructions. Such equipment may be employed to determine the intensity of fluorescence at each predefined location on the array, thereby providing a measure of the amount of target DNA bound at each location. Such an assay would be able to indicate not only the absence and presence of the marker probe in the target, but also the quantitative amount as well.

In this manner, oligonucleotide probe kits of the present invention may be employed to examine the presence/absence (or relative amounts in case of mixtures) of polynucleotides in different samples or products containing different materials rapidly and in a cost-effective manner.

Another aspect of the present invention involves collections of a plurality of polynucleotides of the present invention. A collection of a plurality of the polynucleotides of the present invention, particularly the polynucleotides identified as SEQ ID NOS: 1-35, may be recorded and/or stored on a storage medium and subsequently accessed for purposes of analysis, comparison, etc. One utility for such sets of sequences is the analysis of the set, either alone or together with other sequences sets, for single nucleotide polymorphisms (SNPs)

between sequences from different tissues and/or individuals for genetic studies, mapping and fingerprinting purposes. Suitable storage media include magnetic media such as magnetic diskettes, magnetic tapes, CD-ROM storage media, optical storage media, and the like. Suitable storage media and methods for 5 recording and storing information, as well as accessing information such as polynucleotide sequences recorded on such media, are well known in the art. The polynucleotide information stored on the storage medium is preferably computer-readable and may be used for analysis and comparison of the polynucleotide information.

10 Another aspect of the present invention thus involves storage medium on which are recorded a collection of the polynucleotides of the present invention, particularly a collection of the polynucleotides identified as SEQ ID NOS: 1-35. According to one embodiment, the storage medium includes a collection of at least 20, preferably at least 50, more preferably at least 100, and most preferably 15 at least 200 of the polynucleotides of the present invention, preferably the polynucleotides identified as SEQ ID NOS: 1-35, or variants of those polynucleotides.

Another aspect of the present invention involves a combination of 20 polynucleotides, the combination containing at least 5, preferably at least 10, more preferably at least 20, and most preferably at least 50 different polynucleotides of the present invention, including polynucleotides selected from SEQ ID NOS: 1-35, or variants of these polynucleotides.

In another aspect, the present invention provides DNA constructs comprising, in the 5'-3' direction, a gene promoter sequence; an open reading 25 frame coding for at least a functional portion of a polypeptide encoded by a polynucleotide of the present invention; and a gene termination sequence. The open reading frame may be orientated in either a sense or antisense direction. DNA constructs comprising a non-coding region of a gene coding for an enzyme encoded by the above DNA sequences or a nucleotide sequence complementary to 30 a non-coding region, together with a gene promoter sequence and a gene termination sequence, are also provided. Preferably, the gene promoter and

termination sequences are functional in a host cell. More preferably, the gene promoter and termination sequences are common to those of the polynucleotide being introduced. Other promoter and termination sequences generally used in the art, such as the Cauliflower Mosaic Virus (CMV) promoter, with or without 5 enhancers, such as the Kozak sequence or Omega enhancer, and *Agrobacterium tumefaciens* nopalilin synthase terminator may be usefully employed in the present invention. Tissue-specific promoters may be employed in order to target expression to one or more desired tissues. The DNA construct may further include a marker for the identification of transformed cells.

10 Techniques for operatively linking the components of the DNA constructs are well known in the art and include the use of synthetic linkers containing one or more restriction endonuclease sites as described, for example, by Sambrook *et al.*, *Molecular Cloning: a laboratory manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The DNA constructs of the present invention 15 may be linked to a vector having at least one replication system, for example, *Escherichia coli*, whereby after each manipulation, the resulting construct can be cloned and sequenced and the correctness of the manipulation determined.

Transgenic cells comprising the DNA constructs of the present invention are provided, together with organisms comprising such transgenic cells. 20 Techniques for stably incorporating DNA constructs into the genome of target organisms, such as mammals, are well known in the art and include electroporation, protoplast fusion, injection into reproductive organs, injection into immature embryos, high velocity projectile introduction and the like. The choice of technique will depend upon the target organism to be transformed. In 25 one embodiment, naked DNA is injected or delivered orally. Once the cells are transformed, cells having the DNA construct incorporated in their genome are selected. Transgenic cells may then be cultured in an appropriate medium, using techniques well known in the art.

In yet a further aspect, the present invention provides methods for 30 modifying the level (concentration) or activity of a polypeptide in a host organism, comprising stably incorporating into the genome of the organism a

DNA construct of the present invention. The DNA constructs of the present invention may be used to transform a variety of organisms, including mammals, for example to make experimental gene knock out or transgenic animals.

Further, the polynucleotides of the present invention have particular application for use as non-disruptive tags for marking organisms, including commercially valuable animals, fish, bacteria and yeasts. DNA constructs comprising polynucleotides of the present invention may be stably introduced into an organism as heterologous, non-functional, non-disruptive tags. It is then possible to identify the origin or source of the organism at a later date by determining the presence or absence of the tag(s) in a sample of material.

Detection of the tag(s) may be accomplished using a variety of conventional techniques, and will generally involve the use of nucleic acid probes. Sensitivity in assaying the presence of probe can be usefully increased by using branched oligonucleotides, as described by Horn *et al.*, *Nucleic Acids Res.* 15 25(23):4842-4849, 1997, enabling to detect as few as 50 DNA molecules in the sample.

In particular, the polynucleotides of the present invention encode polypeptides that have important roles in processes such as induction of growth, differentiation of tissue-specific cells, cell migration, cell proliferation, and cell-cell interaction. These polypeptides are important in the maintenance of tissue integrity, and thus are important in processes such as wound healing. Some of these polypeptides act as modulators of immune responses, such as immunologically active polypeptides for the benefit of offspring. In addition, many polypeptides are immunologically active, making them important therapeutic targets in a whole range of disease states. Antibodies to the polypeptides of the present invention and small molecule inhibitors related to the polypeptides of the present invention may also be used for modulating immune responses and for treatment of diseases according to the present invention.

SEQ ID NOS: 1; 2; 4; 5; 6; 8; 9; 11; 12; 14; 17; 19-24; 26; 27; 31-34  
30 encode secreted polypeptides. SEQ ID NOS: 10; 15; 16; 18; 25; 28; 30; and 35  
encode polypeptides acting as receptors. SEQ ID NOS: 2; 4; 24; 29 and 35

encode polypeptides with cell signaling activity, which may be either intracellular or extracellular. Kinase genes, for example, encode polypeptides that phosphorylate specific substrates during cell-to-cell signaling. While some kinases are involved in normal metabolism and nucleotide production, others are 5 significant for altering the activity of many cellular processes through the phosphorylation of specific proteins. Polypeptides encoded by these genes are important in the transmission of intracellular signals resulting from the binding of extracellular ligands such as hormones, growth factors or cytokines to membrane-bound receptors. The utility of polynucleotides encoding kinases resides in the 10 manipulation of their signaling activities and downstream effects for the diagnosis and treatment of mammalian diseases that may be a consequence of inappropriate expression of these kinase genes.

SEQ ID NOS: 2 and 4 encode polypeptides with cytokine activity. Cytokine or growth factor polynucleotides encode polypeptides involved in 15 intercellular signaling and represent another important class of molecules. Polynucleotides encoding such genes have utility in the diagnosis and treatment of disease.

SEQ ID NOS: 7; 11; 12; 15 and 22 encode polypeptides with transcription factor activity. These polynucleotides encode polypeptides required for the control 20 of synthesis of proteins in tissue specific manner and have utility for the modification of protein synthesis for the control of disease.

SEQ ID NOS: 8 encode polypeptides acting in the extracellular matrix.

SEQ ID NOS: 11; 12; 15 and 22 encode polypeptides with RNA synthesis activities.

25 SEQ ID NO: 12 encodes a polypeptide having CD antigen activity. Such polynucleotides have utility as modulators of the composition, expression level and class of CD antigen expressed, which influence immune responses to self-antigens, neo-antigens and infectious agents.

Further exemplary specific utilities, for exemplary polynucleotides of the 30 present invention, are specified in the Table below.

SEQ ID NO:	UTILITY
2	Promoting immune response as part of a vaccine or anti-cancer treatment. Inhibitors of this molecule can be useful as anti-inflammatory treatment, e.g. for autoimmune diseases or allergies.
11; 19	Utility as a target for cancer treatment and as an immunoregulatory and anti-inflammatory molecule
12	Diagnostic for specific types of cancer and for development of an anti-cancer treatment.
15	As a target for antagonists in the treatment of diseases such as asthma and allergy.
22	Useful to inhibit or enhance the activity of the soluble molecule that binds this protein.
28	Useful to promote or block cell trafficking and therefore in the treatment as anti-inflammatory and/or vaccine adjuvant where it can promoter inflammation.
35	Useful for tissue and neural regeneration.

The following examples are offered by way of illustration and not by way of limitation.

5

Example 1

ISOLATION OF cDNA SEQUENCES FROM MAMMALIAN EXPRESSION LIBRARIES

The cDNA sequences of the present invention were obtained by high-throughput sequencing of cDNA expression libraries constructed mouse airways-induced eosinophilia, rat dermal papilla and mouse stromal cells. The cDNA libraries were prepared as follows.

*cDNA Library from Dermal Papilla (DEPA)*

Dermal papilla cells from rat hair vibrissae (whiskers) were grown in culture and the total RNA extracted from these cells using established protocols. Total RNA, isolated using TRIzol Reagent (BRL Life Technologies, Gaithersburg, MD), was used to obtain mRNA using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA), according to the manufacturer's

specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit (Stratagene).

5 *cDNA library from mouse airway-induced eosinophilia (MALA)*

Airway eosinophilia were induced in BALB/cByJ mice by administering 2 µg ovalbumin in 2 mg alum adjuvant intraperitoneally on day 0 and day 14, and subsequently 100 µg ovalbumin in 50 µl phosphate buffered saline (PBS) intranasally route on day 28. The accumulated eosinophils in the lungs were 10 detected by washing the airways of the anesthetized mice with saline, collecting the washings (bronchoelar lavage or BAL), and counting the numbers of eosinophils. The mice were sacrificed and total RNA was isolated from whole lung tissue using TRIzol Reagent (BRL Life Technologies). mRNA was isolated by using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA), 15 according to the manufacturer's specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit (Stratagene).

*cDNA Expression Library from Peripheral Lymph Node Stromal Cells (MLSA)*

20 The peripheral axillary and brachial lymph nodes of BALB/cByJ mice with the flaky skin (*fsn*) mutation (Jackson Laboratories, Bar Harbour, MN) were dissected out. Single cell suspensions were obtained from the lymph nodes and cultured in tissue culture flasks at  $10^7$  cells /ml in 20% fetal calf serum and Dulbecco's Minimum Essential Medium. After 2 days the non-adherent cells were 25 removed. The adherent cells were cultured for a further 2 days and then treated with 0.25 g/100ml Trypsin (ICN, Aurora, OH) and re-cultured. After a further 4 days, non-adherent cells were discarded and adherent cells removed by trypsinization. Remaining adherent cells were physically removed by scraping with a rubber policeman. All adherent stromal cells were pooled.

*cDNA Expression Library from Flaky skin lymph node stromal cells in pBK-CMV (MLSA)*

Stromal cells from Flaky skin mice lymph nodes were grown in culture and the total RNA extracted from these cells using established protocols. Total 5 RNA, isolated using TRIzol Reagent (BRL Life Technologies, Gaithersburg, MD), was used to obtain mRNA using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA), according to the manufacturer's specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit 10 (Stratagene).

cDNA sequences were obtained by high-throughput sequencing of the cDNA libraries described above using a Prism 377 sequencer (Perkin Elmer/Applied Biosystems Division, Foster City CA), and are provided in SEQ ID NO: 1-35, with corresponding polypeptide sequences in SEQ ID NOS: 36-65.

15

#### EXAMPLE 2

Analysis of cDNA sequences using BLAST algorithms

BLASTN Polynucleotide analysis

20 The isolated cDNA sequences were compared to sequences in the EMBL DNA database using the computer algorithm BLASTN. Comparisons of DNA sequences provided in SEQ ID NOS: 1-35, to sequences in the EMBL DNA database (using BLASTN) were made as of November, 2000, using Version 2.0.11 [Jan-20-2000], and the following Unix running command: blastall -p 25 blastn -d embldb -e 10 -G0 -E0 -r 1 -v 30 -b 30 -i queryseq -o.

The sequences of SEQ ID NOS: 1, 3, 4, 6-11, 13, 18, 21, 22, 24, 25, 28-30, 33 and 34 were determined to have less than 50% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above. The sequences of SEQ ID NOS: 2, 12, 30 14-16, 20 and 35 were determined to have less than 75% identity, determined as described above, to sequences in the EMBL database using the computer

algorithm BLASTN, as described above. The sequences of SEQ ID NOS: 17, 19, 23 and 27 were determined to have less than 90% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above. Finally, the sequences of SEQ ID NOS: 5, 26 and 32 were determined to have less than 98% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above.

**BLASTP Polypeptide analysis**

10 The sequences of SEQ ID NOS: 37, 41, 42, 44, 46-50, 55, 56 and 59 were determined to have less than 50% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. The sequences of SEQ ID NOS: 36, 38, 43, 45 and 60 were determined to have less than 75% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above.

15 Finally, the sequences of SEQ ID NOS: 39, 54 and 58 were determined to have less than 90% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above.

20 Finally, the sequences of SEQ ID NOS: 53, 57, 62 and 65 were determined to have less than 98% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above.

**BLASTX Polynucleotide Analysis**

25 The sequences of SEQ ID NOS: 2-4, 6-16, 18, 22-24, 26-30 and 33-35 were determined to have less than 50% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTX, as described above. The sequences of SEQ ID NOS: 1, 19, 20, 25 and 32 were determined to have less than 75% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTX, as described above. Finally, the sequences of SEQ ID NOS: 5, 17, 21 and 31 were determined to have less than 90% identity, determined as described above, to

sequences in the SwissProt database using the computer algorithm BLASTX, as described above.

5

### Example 2

#### ISOLATION AND CHARACTERIZATION OF THE HUMAN HOMOLOG OF muKS1

10 This example demonstrates that an isolated cDNA may be used to isolate its homologue from a different species, the corresponding polypeptide may be expressed and the function of the polypeptide can be determined, starting the whole process from an isolated cDNA obtained as described above.

##### *Analysis of RNA transcripts by Northern Blotting*

15 Northern analysis to determine the size and distribution of mRNA for the clone muKS1 (SEQ ID NO: 66; isolated from a mouse keratinocyte stem cell cDNA library using high-throughput sequencing as described above) was performed by probing murine tissue mRNA blots with a probe consisting of nucleotides 268-499 of muKS1, radioactively labeled with  $[\alpha^{32}\text{P}]\text{-dCTP}$ . Prehybridization, hybridization, washing and probe labeling were performed as 20 described in Sambrook *et al.*, *Ibid.* mRNA for muKS1 was 1.6 kb in size and was observed to be most abundant in brain, lung, muscle and heart. Expression could also be detected in lower intestine, skin and kidney. No detectable signal was found in testis, spleen, liver, thymus and stomach.

25 *Human homologue of muKS1*

MuKS1 (SEQ ID NO: 66) was used to search the EMBL database (Release 50 plus updates to June, 1998) to identify human EST homologues. The top three homologies were to the following ESTs: accession numbers AA643952, HS1301003 and AA865643. These showed 92.63% identity over 285 30 nucleotides, 93.64% over 283 nucleotides and 94.035% over 285 nucleotides, respectively. Frame shifts were identified in AA643952 and HS1301003 when

translated. Combination of all three ESTs identified the human homologue huKS1 (SEQ ID NO: 67) and translated polypeptide SEQ ID NO: 67. Alignment of muKS1 and huKS1 polypeptides indicated 95% identity over 96 amino acids.

5 *Bacterial expression and purification of muKS1 and huKS1*

Polynucleotides 269-502 of muKS1 (SEQ ID NO: 69), encoding amino acids 23-99 of polypeptide muKS1 (SEQ ID NO: 70), and polynucleotides 55-288 of huKS1 (SEQ ID NO: 71), encoding amino acids 19-95 of polypeptide huKS1 (SEQ ID NO: 72), were cloned into the bacterial expression vector pET-16b (Novagen, Madison, WI), which contains a bacterial leader sequence and N-terminal 6xHistidine tag. These constructs were transformed into competent *E. coli* BL21(DE3) (Novagen) as described in Sambrook *et al.*, *Ibid*.

Starter cultures of recombinant *E. coli* BL21(DE3) (Novagen) transformed with bacterial expression vector pET16b containing SEQ ID NO: 69 (muKS1a) and SEQ ID NO: 71 (huKS1a) were grown in NZY broth containing 100 µg/ml ampicillin (Gibco-BRL Life Technologies) at 37°C. Cultures were spun down and used to inoculate 800 ml of NZY broth and 100 µg/ml ampicillin. Cultures were grown until the OD<sub>595</sub> of the cells was between 0.4 and 0.8. Bacterial expression was induced for 3 hours with 1 mM IPTG. Bacterial expression produced an induced band of approximately 15 kDa for muKS1a and huKS1a.

MuKS1a and huKS1a were expressed in insoluble inclusion bodies. In order to purify the polypeptides, bacterial cell pellets were re-suspended in lysis buffer (20 mM Tris-HCl pH 8.0, 10 mM β-Mercaptoethanol, 1 mM PMSF). To the lysed cells, 1% NP-40 was added and the mix incubated on ice for 10 minutes. Lysates were further disrupted by sonication on ice at 95 W for 4 x 15 seconds and then centrifuged for 10 minutes at 18,000 rpm to pellet the inclusion bodies.

The pellet containing the inclusion bodies was re-suspended in lysis buffer containing 0.5% w/v CHAPS and sonicated for 5-10 seconds. This mix was stored on ice for 1 hour, centrifuged at 14,000 rpm for 15 minutes at 4°C and the supernatant discarded. The pellet was once more re-suspended in lysis buffer

containing 0.5% w/v CHAPS, sonicated, centrifuged and the supernatant removed as before. The pellet was re-suspended in solubilizing buffer (6 M guanidine HCl, 0.5 M NaCl, 20 mM Tris-HCl pH 8.0), sonicated at 95 W for 4 x 15 sec and centrifuged for 10 minutes at 18,000 rpm and 4°C to remove debris. The supernatant was stored at 4°C. MuKS1a and huKS1a were purified by virtue of the N-terminal 6x histidine tag contained within the bacterial leader sequence, using a Nickel-Chelating sepharose column (Amersham Pharmacia, Uppsala, Sweden) and following the manufacturer's protocol. Proteins were purified twice over the column to reduce endotoxin contamination. In order to re-fold the proteins once purified, the protein solution was dialysed in a 4 M-2 M urea gradient in 20 mM Tris-HCl pH 7.5 containing 10% glycerol overnight at 4°C. The protein was then further dialysed 2x against 2 litres of 20 mM Tris-HCl pH 7.5 containing 10% glycerol.

15 *Injection of bacterially expressed muKS1a into nude mice*

Two nude mice were anaesthetised intraperitoneally with 75 µl of 1/10 dilution of Hypnorm (Janssen Pharmaceuticals, Buckinghamshire, England) in phosphate buffered saline. 20 µg of bacterially expressed muKS1a (SEQ ID NO: 70) was injected subcutaneously in the left hind foot, ear and left hand side of the back. The same volume of phosphate buffered saline was injected in the same sites but on the right hand side of the same animal. Mice were left for 18 hours and then examined for inflammation. Both mice showed a red swelling in the ear and foot sites injected with the bacterially expressed protein. No obvious inflammation could be identified in either back site. Mice were culled and biopsies taken from the ear, back and foot sites and fixed in 3.7% formol saline. Biopsies were embedded, sectioned and stained with Haemotoxylin and eosin. Sites injected with muKS1a had a marked increase in polymorphonuclear granulocytes, whereas sites injected with phosphate buffered saline had a low background infiltrate of polymorphonuclear granulocytes.

Chemokines are a large superfamily of highly basic secreted proteins with a broad number of functions (Baggiolini *et al.*, *Annu. Rev. Immunol.* 15:675-705, 1997; Ward *et al.*, *Immunity* 9:1-11, 1998; Horuk, *Nature* 393:524-525, 1998). The polypeptide sequences of muKS1 and huKS1 have similarity to CXC chemokines, suggesting that this protein will act like other CXC chemokines. The *in vivo* data from nude mice supports this hypothesis. This chemokine-like protein may therefore be expected to stimulate leukocyte, epithelial, stromal and neuronal cell migration, promote angiogenesis and vascular development, promote neuronal patterning, hematopoietic stem cell mobilization, keratinocyte and epithelial stem cell patterning and development, activation and proliferation of leukocytes, and promotion of migration in wound healing events. It has recently been shown that receptors to chemokines act as co-receptors for HIV-1 infection of CD4+ cells (Cairns *et al.*, *Nature Medicine* 4:563-568, 1998) and that high circulating levels of chemokines can render a degree of immunity to those exposed to the HIV virus (Zagury *et al.*, *Proc. Natl. Acad. Sci. USA* 95:3857-3861, 1998). This novel gene and its encoded protein may thus be usefully employed as regulators of epithelial, lymphoid, myeloid, stromal and neuronal cells migration and cancers; as agents for the treatment of cancers, neuro-degenerative diseases, inflammatory autoimmune diseases such as psoriasis, asthma and Crohns disease; for use in wound healing; and as agents for the prevention of HIV-1 binding and infection of leukocytes.

SEQ ID NOS: 1-72 are set out in the attached Sequence Listing. The codes for nucleotide sequences used in the attached Sequence Listing, including the symbol "n," conform to WIPO Standard ST.25 (1998), Appendix 2, Table 1.

All references cited herein, including patent references and non-patent publications, are hereby incorporated by reference in their entireties.

While in the foregoing specification this invention has been described in relation to certain preferred embodiments, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details

described herein may be varied considerably without departing from the basic principles of the invention.

We claim:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of: (1) sequences recited in SEQ ID NOS: 1-35; (2) complements of the sequences recited in SEQ ID NOS: 1-35; (3) reverse complements of the sequences recited in SEQ ID NOS: 1-35; (4) reverse sequences of the sequences recited in SEQ ID NOS: 1-35 (5) sequences having at least a 99% probability of being the same as a sequence recited in (1) – (4) above as determined using computer algorithm BLASTN; (6) sequences having at least 50% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (7) sequences having at least 75% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (8) sequences having at least 90% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (9) sequences having at least 95% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (10) nucleotide sequences that hybridize to a sequence recited in (1) – (4) above under stringent hybridization conditions; (11) nucleotide sequences that are 200-mers of a sequence recited in (1) – (4) above; (12) nucleotide sequences that are 100-mers of a sequence recited in (1) – (4) above; (13) nucleotide sequences that are 40-mers of a sequence recited in (1) – (4) above; (14) nucleotide sequences that are 20-mers of a sequence recited in (1) – (4) above; and (15) nucleotide sequences that are degeneratively equivalent to a sequence recited in (1) – (4) above.

2. An oligonucleotide comprising at least 10 contiguous residues complementary to 10 contiguous residues of a nucleotide sequence recited in claim 1.

3. A genetic construct comprising an isolated polynucleotide of claim 1.

4. A host cell transformed with a genetic construct of claim 3.
5. An isolated polypeptide encoded by a polynucleotide of claim 1.

5        6. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOS: 36-65; (b) sequences having at least a 99% probability of being the same as a sequence of SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (c) sequences having at least 50% identity to a sequence provided in  
10      SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (d) sequences having at least 75% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (e) sequences having at least 90% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; and (f) sequences having at  
15      least 95% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP.

7. An isolated polynucleotide encoding a polypeptide of claim 6.

20        8. An isolated polypeptide comprising at least a functional portion of a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOS: 36-65; (b) sequences having at least a 99% probability of being the same as a sequence of SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (c) sequences  
25      having at least 50% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (d) sequences having at least 75% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (e) sequences having at least 90% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer  
30      algorithm BLASTP and (f) sequences having at least 95% identity to a sequence

provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP.

9. A composition comprising a polypeptide according to any one of 5 claims 6 and 8 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

10. A composition comprising a polynucleotide according to claim 1 and at least one component selected from the group consisting of 10 pharmaceutically acceptable carriers and immunostimulants.

11. A method for treating a disorder in a mammal comprising administering a composition according to claim 9.

15 12. A method for treating a disorder in a mammal comprising. administering a composition according to claim 10.

13. A diagnostic kit comprising at least one oligonucleotide according to claim 2.

20

14. An organism comprising a host cell according to claim 4.

## SEQUENCE LISTING

<110> Watson, James D  
Murison, James G

<120> Polynucleotides, polypeptides expressed  
by the polynucleotides and methods for their use.

<130> 1050U1PCT

<160> 74

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 2401  
<212> DNA  
<213> Rat

<400> 1

gaggccacacag	ttatcaccac	ggagaagaga	gagaggccag	cgccccctag	agagctcctg	60
gtaccccagg	cagaagtgcac	agcacgtac	ctccggctcc	agtgggtccc	tggcagcgat	120
ggggcctccc	cgatccgta	ctttaccgtg	caggtgcgag	agctgccggg	tggagaatgg	180
cagactact	cctcgcttat	cagccacgag	gccacactct	gtgctgttga	aaggctgagg	240
cctttcacct	cctacaagct	gcgcctgaag	gccaccaacg	acattgggaa	cagtgacttc	300
agtgcagaaa	cagaggctgt	gaccacactg	caagatgttc	caggagagcc	accaggatct	360
gtctcagcca	caccgcacac	cacgtcctca	gttctgtatcc	agtggcagcc	tccccgggat	420
gagagcttga	atggccttct	gcaaggctac	aggatctact	accgtgagct	ggagtccgag	480
acaggcctga	gccctgaacc	caagacactc	aagagccct	ctgccttacg	tgctgaactc	540
acggctcaaa	gcagcttcaa	gaccgtgaac	agcagctcca	cattaacgac	ctatgaatta	600
acacatctga	agaagtaccc	gctgtatgaa	gtcatcatga	ctgcctataa	catcattgg	660
gagagcccaag	ccagtgtacc	agtggaggtc	ttcgttggtg	aggctgcccc	agcaatggcc	720
ccacagaaca	tccaggtgac	cccactcaca	gccagccagc	tggaggtcac	atgggaccgg	780
ccaccccccag	agagccagaa	tggaaacatc	caaggttaca	aggttacta	ctgggaggca	840
gacagtgcata	atgagacgga	gaaaatgaag	gtccttttc	tccctgagcc	tgtgttaaag	900
attaaggatc	tcaccagcca	cacaaagtac	ctggtcagca	tctcagcctt	caacgctgct	960
ggtaaaaaac	ccagaagtga	cccatgccaag	ggacgcacac	accaggcagc	tccagggccc	1020
ccaaatccat	tggaaatttcc	agaaaataaca	tctaccacac	tcaacgtatc	ctggggggag	1080
ccatcggcag	ccaaacggcat	cctacagggc	tatcgagtgg	tgtatgaacc	cttagcacca	1140
gtgcaaggcg	tgagcaaggt	ggtgaccgtg	gatgtgaaag	ggaacttgca	acggtggctg	1200
aagggtgcggg	acctcaccaa	gggagtgacc	tattttttcc	gtgttcaggc	gcgaaccatc	1260
gcctacgggc	cagaactcca	agccaatgtc	actgcagggc	cagccgaggg	gtccccagga	1320
tctccaaagaa	atgtccttgt	caccaaatact	gcctctgagc	tgacccttca	tggtacagagaa	1380
ggaaacacacag	ggaacacacc	cactcaggcc	tacgtcatag	aagccagacc	atcagatgaa	1440
ggctttatggg	acatgttgc	aaaggacatt	cccaggatg	ctacgttata	caccgtgggt	1500
ctggacaaggc	tgcggcaagg	ggtgacctac	gagttccggg	tggtggccgt	gaacaaggca	1560
ggctttgggg	aacccagggc	cccttccatt	gcagtgtcag	cacaagctga	agccccgttc	1620
tatgaggagt	ggtggttct	gctggtgata	gcgctctcca	gcctctctt	cgtcctcttg	1680
gtggcttcg	tgctggtct	gcatggcata	agcaagaatg	acaagaactg	tggttcaggt	1740
aagggcatct	ccaacatgga	ggagacagt	accctggata	atggagggtt	tgccgccttg	1800
gaactcaaca	gtcgtaacct	caatgtcaag	agcacctct	caaagaagaa	cggaaccaga	1860
tccccacccc	gaccaagccc	cggaggctctg	cactactctg	acgaagacat	ctgcaacaaa	1920
tacaacggtg	cggtgctgac	agagagtgt	aacctcaagg	agaaatcggt	ggatgggtcg	1980
gaatcggagg	cttctgactc	agactacgag	gaagccctgc	ccaagcaetc	ctttgtcaac	2040
cactacatga	gcgacccac	ctactacaac	ttttggaagc	ggcgtccccc	tgccgcagca	2100

ccgcacaggt acgaggcggt	ggcaggggcc	gaagctggcc	cgcacactgca	cacagtcatc	2160
accacacaga	gcgcggcg	agtttacaca	ccagctggcc	ccggagcccg	2220
accggcttct	cctcattctgt	gtgacgtcac	gcctccatca	ggtagacgg	2280
tctggagtct	attttggta	agacaatcaa	ctccgataac	tgagctgaat	2340
aaaaaaaaata	ataataattt	tgataagcga	aaaaaaaaaa	aaaaaaaaaa	2400
a					2401

<210> 2  
<211> 1258  
<212> DNA  
<213> Mouse

<400> 2

cacacgcccc	gcgtgtcg	agcccttatt	tacttcgcag	aagagccttc	agaccccctc	60
ctaacaagt	tggaaagcat	cacggcagc	cgatgttggg	gacactggtc	tggatgctcg	120
cggtcggctt	cctgctggca	ctggcgcgg	gccgcgcggc	gggcgcgcgt	aggacccgg	180
ggcgcggcgc	gcccgcgcgg	gactgcgcgg	accggccgga	ggagctcctg	gagcagctgt	240
acggccggct	ggcggccggc	gtgctcagcg	ccttccacca	cacgctgcag	ctcggccgc	300
gcgagcaggc	gcaatgccc	agctgcccgg	ccggggcag	ggccgcgcac	cgccgcttcc	360
ggccacccac	caacctgcgc	agcgtgtcgc	cctggcgta	caggatttcc	tacgaccctg	420
ctcgcttcc	gaggtacctg	cccgaagcct	actgcctgt	ccgaggctgc	ctgacccgg	480
tctacggg	ggaggactt	cgcttgc	gcacacccgt	tttctctcca	gcccgtgg	540
tgcggcgcac	agcggcctgc	gccccggcc	gctctgtgt	cgccgaacac	tacatcacca	600
tcccggtgg	ctgcac	gtggccgagc	cggacaagtc	cgccggacagt	gcgaacttca	660
gcatggacaa	gctgtgtcg	ggggccgcgg	acaggcctgc	ggggcgctga	tgccgggg	720
tgcggccat	ggcccgat	cctgc	tcaggcccc	ttggccctgac	aaaacccacc	780
ccatgatccc	tggccgctgc	ctaattttc	caaaaggaca	gtacataa	ctttaat	840
attttcaaa	gtagacacta	catacttaca	actatttga	atagtggcag	aaactat	900
catatttagt	attagagca	agcatgtt	ttttaaactt	cttgatata	caagcacatc	960
acacacatcc	cgtttctc	tagtaggatt	cttgagt	taattgt	gtcagatga	1020
acttccttct	gctgcactgt	gcccgttccc	tgagtc	ctgtggccca	agttactaa	1080
ggtgataatg	agtgc	ccgg	ctaa	aggtccctg	gagagggagg	1140
gatgtgggg	ggctagga	caagc	tttgc	tttgc	tttgc	1200
tttataaaga	ttaa	tttgc	tttgc	tttgc	tttgc	1258

<210> 3  
<211> 3043  
<212> DNA  
<213> Mouse

<400> 3

cgcgtctccc	gccgcaccca	cccg	tatcaagcaa	aagcgaaagg	aagccgagcg	60
gtcccgctg	gcgtggcg	ggcggggagg	tggctgc	ctctagtc	gccccggcc	120
gctccgcctt	tgt	actca	ccgg	aaaa	cccc	180
cccg	ccgt	ccct	ccgc	ggcc	ccct	240
ggcc	ccgg	ccccc	ggag	ttcc	ccgt	300
ggcc	ccgg	ccccc	ggat	ccgg	ttct	360
ctct	ccgg	ccccc	ccgg	ccgg	ccgg	420
cttgg	ccgg	ccccc	atcat	ccgt	ccgt	480
acc	ccct	ccccc	atgt	ccgg	ccgg	540
gat	ccct	ccccc	acac	ccgg	ccgg	600
tttgc	ccgg	ccccc	actt	ccgg	ccgg	660
tttgc	ccgg	ccccc	tttgc	ccgg	ccgg	720
tttgc	ccgg	ccccc	tttgc	ccgg	ccgg	780
tttgc	ccgg	ccccc	tttgc	ccgg	ccgg	840
tttgc	ccgg	ccccc	tttgc	ccgg	ccgg	900
tttgc	ccgg	ccccc	tttgc	ccgg	ccgg	960

atcacgttgt gaggcgcate tggatgttgc ccgtggctt tggtttatt ttctattcc	1020
taacattcat ccaagatttc cagagtgtca ctctaaggat atccacagaa atcaatgacg	1080
actttgaaa gatcgagaat cctgtctcat tcagggagt tcgcagacag tttctgaaag	1140
tggacagagg acggacgggc ttggatgtca ccctgatggg gactttatct gtggcacatc	1200
cgggacttga atttcattaa gagttcttag tagttcaatt tacaaggta tgttccctg	1260
gaggatggat agcaccacg aactgttagc aatattttt tattttctaa aacaatctt	1320
tatgaacaaa ttcatatgca aagaagacga ggcattgcg aaaggggagg attattctg	1380
tatagattct ttagacttt tatgtataa tgatttatga aaatacacta agagaaaaaa	1440
atgttaagtt tagtacttt tattaaagaa gccaaatcag ggcataattca ctttaaaatt	1500
tcatttttta aatacagtga cctgcataca ttttcatcac aagagcactt atacaattca	1560
attcatatgtt attatatacc ctaatggtat agattttagt aataaacgaa cactttaaag	1620
caactctgaat ttcagtgca ttaaacaat gctttatag tgaaggactc aaaaccattt	1680
acagtgcaca ttaaccagcg aatgtggaaag acctcggtc gaaaatttag cccctcatt	1740
tacttctcca agggaccac agctttactg ccgctttaa tggtgggccc gggactaat	1800
tccaggtagg atgggctcat caggccagct tagaaatgat caaactgcoc ttctctgtga	1860
ccggcagca caagtcaat tcacttctca gtttccctgt aagccaaaga gaatgcagat	1920
ccaagtcaagg gagaaggag agcgtcata gaaacttca gatgtgggt gctgcctatc	1980
tgctcttatac aatgcctgtg gcccactata agggagtcg gccccttccg aagcaaggcc	2040
tggagactct acctttcatg cagttcacca atggcaaaga aacgcccagt gttgtggagg	2100
aagaagtggta aacaagacc cccagtcgt ggcagtagg agctggccca agggcacgtt	2160
ccaaggacag agaccattt gacagccta gtgaaagggt acctggcgat gaaggggcac	2220
acagcagtgc ctcccttggc tgctaagtga agggtgcgtc tcagcaggca cttctgcatt	2280
gacatcctgt gtcttcttcc tcagtggtca gtggggcaaa ccaacgttca tttctgagtc	2340
ccctgttaact tttcacagta cggAACATGC ccattttaac actggaaacag aaagacagtg	2400
gctgtcattc ttagtgcgtg gaggaggtc gatacatttctgttggaaagc tggggcggac	2460
tgaatgcattg ctgttctttt ctttgagcgg gagecttggt tgatgccttc ccagaatgca	2520
cttggctctc ttgccttcca ctggagaccc gaccacgtgc ctttaccat agtggaaacac	2580
agtgccttgtt ggcattcaat aggtgtttaa taaatactca ttgaatgtat gcacgcataa	2640
atggatgaac aagtaacacg tagggatgtt tgagggtcta agggttttt ttactctagt	2700
tcacgggtat tctaagggtca acagotagtc tggccaatt agtaatgtt tctgttttgc	2760
tttgtgaact attctcgittt ccacctgttc cagctgtgt agcttcatga ttgtgtgaca	2820
actctctctt ggacagatag cacagaaatt gttacatggg ctaaacctgtt ctggcaaac	2880
cgaggaggcc cccaaatcac actctgcaga ttccatgcga cttctagtt tattccctgtt	2940
ttgggtttat ttttaatttca tacaatatg tatttcattt gactttgtac ccgagaaagt	3000
aaaataaaat atttctttat tttaaaaaaa aaaaaaaaaaaa aaa	3043

<210> 4  
 <211> 2515  
 <212> DNA  
 <213> Mouse

<400> 4	
gctgcgcctg ctgctggctt gggggccgc ggtgcgcga ctggggccagg tccctggac	60
gccggagccct cgagccgcgt gggggccgc cagctgtac gcgccttttcc cccggccgc	120
cacattcctg gaagcttggc gggcgtggc cgaattgggg ggcaacctgg ccacaccgc	180
gaccccgag gaggcccagc gtgtggacag cctgggggg gtggggccgg ccaacgggct	240
gtctatggatt ggggtgcgc ggcaggctag gcaatggccag cccgcggcc cactgcgggg	300
cttcataatgg accacgggg accaggacac cgccttcacc aactggggcc agccggctac	360
ggaaggaccc tggccagccc agcgctgtgc agccctttag gcccggccag agcatcgctg	420
gtcgaaggc tcgtgcacac tggctgtcga cggctaccc tggcagtttgg ttttgaggg	480
tgcctgcctt gccttgcgc ttgaggtggg tcagggccgtt cccgctgtct acaccacacc	540
cttcaacctg gtttccagcg agttcaatgt gctgcctttt ggctccgtgg cagctgtgca	600
gtgccaagct ggcaggggag cttctctgtct gtgcgtaaa cagccttcag gtggcggtgg	660
ctgggtccag actggccgc tggcccagg gactggctgt ggtcctgaca atgggggttg	720
cgaacatgag tgggtggaaag aggtggacgg tgctgtgtcc tggcgtgcgtca gtgaaggctt	780
cggcttagca gcagatgggc acagttgtga agaccctgtt gcccaggccc cctgtgagca	840
gcagtgtaa cctggaggggc cacaaggctt tagctgcac tgcgccttgc gttccggcc	900

agctgaggat gatccacacc	gctgcgtgga	cacggatgag	tgccagattt	ctggtgtgtg	960
ccagcagatg tggcaact	atgttgggg	ctttgagtgt	tactgcagcg	agggtcacga	1020
gcttggggca gatggatca	gctgtagccc	tgcaggagcc	atgggtcccc	aggcttccca	1080
ggatctcaga gatggatgc	tggatgatgg	agaagaaggg	gaggatgaag	aggagccctg	1140
ggaggactt gatggcacct	ggacagagga	acagggatc	ctatggctgg	cactacaca	1200
tccacctgac tttggcctgc	cctataggcc	caacttccca	caggatggag	agcctcagag	1260
attgcacctg gaggctaccc	ggccacccccc	acttaaggcc	cccaaggggcc	cccaacaacc	1320
cccaagggggg gccgcaaaa	cgcccaaggg	gaaccccgcc	aacccaaccc	acactacctt	1380
ctgcccacaa gacctctgtt	attcagcta	cacgcccacc	cctgagccct	gtccacccac	1440
ctgccatggc ccctgcccaca	cctccagctg	tgttctctga	gcaccagatc	cccaaaaatca	1500
aggccatta tccagacctg	ccttttggcc	acaaggctgg	gataacctcg	gccactcacc	1560
cagcacggcc tcctccgtac	cagccccccca	ttatctcaac	caactatccc	caagtcttcc	1620
ctccccacca gccccctatg	tctccagata	cccacactat	cacttattt	cctccagtc	1680
ccccctcacct tgatcctggg	gataccactt	ctaaagccca	tcaacacccct	ttgctccag	1740
atgctccagg tatcagaacc	caggccccc	agctttctgt	ctcagctctc	cagccccctc	1800
ttcctaccaa ctccaggtct	tctgtccatg	aaactctgt	gcctgtgcc	aaccagcccc	1860
cagccttccc ttcttctccc	ctccccctc	agaggccac	taaccagacc	tcatctatca	1920
gccctacaca ttccttattcc	agagccccctc	tagtccaaag	ggaaggagtt	cccaagtccca	1980
aatcaatgtgcc acagctgccc	tcgggtccct	ccacagcagc	tccaacagcc	ctggcagagt	2040
caggcttgc aggccaaaggc	caaaggatg	accgctggct	gctggtgca	ctccctgggtc	2100
caacatgtgt ttcttgggt	gtgctgctt	ccctggcat	tgtgtactgc	actcgctgtg	2160
gctccacgc acccaacaag	cggatcacgg	actgctatcg	ctgggtcaca	catgctggga	2220
acaagagctc aacagaaccc	atgccccccca	gaggcagcct	tacaggggta	cagacactgt	2280
gaaccagtgt gtgatggggt	gcagatgccc	cttggggta	tagaagaaaa	ggacttgctt	2340
tggacacatg gctgagacca	caccaaggac	ttatggggc	tgcccagctg	acagaggagg	2400
ttctgttctt tgagcccaagc	atccatggca	aaggacacac	caggactcca	ggacctcaag	2460
gggtgggtgc tggatcttc	tccaaataaaat	gggggtccaa	cctctaaaaaa	aaaaaa	2515

&lt;210&gt; 5

&lt;211&gt; 1587

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 5

gcggcgccgg tagagggcgg	tggcgccgca	gcggcgatgg	gccgcgcctg	gggcttgctc	60
gttggactcc tggcgctgt	gtggctgtg	cgcttggcc	acggcgagga	gcggcgccgg	120
gagacagcgg cacagcgctg	cttctgcca	gttagtggtt	acctggacga	ctgtacctgt	180
gatgtcgaga ccatacgataa	gtttaataac	tacagacttt	tcccaagact	acaaaagctt	240
cttggaaagtg actactttag	atattacaag	gtgaacttga	agaaggctt	tcctttctgg	300
aatgacatca accagtgtgg	aagaagagac	tgtccgtca	aaccctgcca	ttctgtatgaa	360
gttcctgtatg gaattaagtc	tgcgagctac	aagtattctg	aggaagccaa	ccgcattgaa	420
gaatgtgagc aagctgagcg	acttggagcc	gtggatgagt	ctctgagtg	ggagacccag	480
aaagctgtac ttcaatgtgac	caagcatgtat	gattcgtag	acagttctg	cgaaattgac	540
gatatacagt ccccccgtgc	tgagtatgt	gacttactcc	ttaacccctga	gcgcctacaca	600
ggctacaagg ggccagacgc	ttggaggata	tggagtgtca	tctatgaaga	aaactgtttt	660
aagccacaga caattcaaaag	gcctttggct	tctggcgag	aaaaaagtaa	agagaacaca	720
ttttacaact ggcttagaagg	cctctgtgt	aaaaagagag	cattctacag	acttataatct	780
ggcctgcacg caagcataa	tgtcattt	agtgcaggt	atcttttaca	agataacttg	840
ctggaaaaaa aatggggtca	caatgtcaca	gatgtccagc	agcgtttga	tggattctg	900
actgaaggag aaggcccacg	aaggctgagg	aactttaact	tcctgtacct	gatagagtta	960
agggtctct ccaaagtgt	tccat	gagcgtccag	attttca	cttcactgg	1020
aataaaatgttcc	aggatgcaga	aaacaaaagcg	ttacttctgg	agataactca	1080
tcatttcctt tgcacttcg	tgagaattct	ttttttctgt	gggataaaaa	cgaagcacat	1140
aaactaaagg aggactttcg	gctacacttt	aggaacattt	caagaatcat	ggactgtgtt	1200
ggctgttca agtggccct	gtggggcaag	ttcagacgc	agggcttgg	cactgctctg	1260
aagatcttgt ttccgaaaaa	actgatgcga	aatatgcgg	aaagcggacc	aagttatgag	1320
ttccagctaa ccagacaaga	aatagtatca	ctgtttaatg	catttggaaag	gatttccaca	1380

agtgtgagag aactagagaa cttcaggcac ttgttacaga atgttca	aggaggacgg	1440
ttgaaatgtg cctgtttctg cacagggaa tttgaaggc aaaatctttt	ttagccccat	1500
ggttgcataat tactgtccca agcccaacgt ttatataaac ctgctttgt	taaagaaaaaa	1560
aaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaa		1587

<210> 6  
 <211> 2494  
 <212> DNA  
 <213> Rat

<400> 6

acttgaactg gcagataaaa aagtatgaca ccaaggcagc ttactgccag	agcaagttgg	60
ctgttgcct cttcaccaag gagctgagtc gcccgcgtca aggcaactgg	gtgactgtca	120
atgcgcgtca ccctggcggt gccaggacgg agctggggcg acatacaggc	atgcacaact	180
ctgcgttctc tggcttcatg ctggccctt tcttctggct gctgttcaag	agtccccagc	240
tggcgccca gcccagcaca tacctggctg tggcagagga actggagagt	gtctctggga	300
agtactttga tggactcaga gagaaggctc catctccgtga ggctgaagat	gagaagtag	360
cccgaggct ttggactgaa agtgcattt tggggctt ggacatggct	catgggtcct	420
ctgggagagg acattccatc tccagataac cttcagaaat ccagatggag	cctcatcatc	480
ctctaggggc agtgttgta ttgttagaat ctcaagactg tggatgttgg	ctgccatgac	540
cctcatcatc ctctaggagc agtgttgta tactcgaact gaagactgtg	gatgctggct	600
gccatcctctt ggggtggctgt gttggcctta gcattattgt tagctggctg	cttgggttg	660
gaccacggga tggcaggcac atgtactctt ttgggtactg gggagatagt	ccattgggtgc	720
ctcctacagg aatctaaaag cggggaaagct gatggaggag tcagtcactc	tagttatggg	780
cagtgtccaa agacagtggc caccaaagct gcagtagtgg actgattgtat	ccactgtgaa	840
agagcaagta atcagacaaa tatggctgtg gagcttggc ggcccttgc	catgtctgca	900
tcctctctga cttggctgtt gttcttagtt gctttctgtt gctgtgataa	ataccatgac	960
caaaatcaac ttggggagga aaagggttta tttaaatctt aggttataat	ttaccatggaa	1020
agagggaaac cagggaagaa actcaggaca agaactgaa gcagatacc	gataacaacgg	1080
agggttgcgc caggcataatc atcagatacc ttatattttt tttattattt	gttatttttt	1140
tatagagagg gtctcacattt gtaaccctgg cttcccttgc acttgcattt	tagatcaggc	1200
tggcctaaa ctcacagaga cctgccttctt gggattaaag gtttgaattt	ttaggcttgg	1260
cccaggtacc agtgcaggctt acctggccag ggtatggcacc atctgcagtg	gggttctacc	1320
tcccatatca actagcaatc aagaaaatgc tccacaaaaca ttccctcagg	gcagttctgg	1380
ctaagcgtt cttcaggcga gggctgtct gtctatcttc taggtatgcc	aggttgacaa	1440
acaaatgaac cagacggcgc ttgattgcaaa actgcaaaagg gtgtctgtca	cctcagggtat	1500
gggtgtggcc tgaagctttt gccaactca gtaaaggcgt gctgtggaca	cttgggtact	1560
ggacactggc tgaggggctg ggatccagtgc gaaaccctgg cttttgttag	ccctgaagta	1620
atcaggacag aatggagtgaa aagactgtca gctgtgcct cagaaaatga	gtgtgacctg	1680
ggatcacat cttccatgtt cctgtgtat tttaaaccttgc	catgttggttt	1740
gattataata acaagctaga tagaggtatgt ggcacacttc agtagctcca	gcacttaaga	1800
gggagaggca ggagtatcaa aagtccaaagg tcatccgagg ccaggctggg	ctatatgaga	1860
ttctggccaa acaaagcaaa acggtgagat ctccaaatgg ctgattcata	gattaaaaat	1920
aaagacatac atttagtgta cgagtgtgt tactatgtgt gtgtatgtgt	acgggtatgt	1980
gcacgtgccc ttgtatgtgc attacatgtat ggaggtcaga ggacaaactg	tggaaatcag	2040
ttctctcttc gtgaatcccg aggatccaaatc tcaatggccttgg	gcaaggccct	2100
tcaccctctga accatagtgcc cagcccttag tcatagggtt ttttttatac	cttctgtat	2160
gggattttt ccacatacaa ttatcttttta atcccttttta agaaactaag	acattcaatt	2220
gttgacaaga caatgatttt ccaacaactc cctcgatattt ctcatctatc	ctgttctgtct	2280
taaatttaggc tagatcaact tccccttcc cccctttttt ttttttggaga	cagagttca	2340
ctctatatac caggctaaac ttgggtcttc aggctcccttgc tcaagcctc	tggagttccag	2400
agatgacggg tctgccacac cctgcgttta caatcgtgt ttacaatcaa	ataaatggaa	2460
ataaacattt ctatcaaaaa aaaaaaaaaaaa aaaa		2494

<210> 7  
 <211> 1859  
 <212> DNA

&lt;213&gt; Mouse

&lt;400&gt; 7

gctcaaagtg	gccaactaca	gcaactcagg	cagattcaag	aagaggttca	tgtatcctgt	60
aggatatggg	cttcctgtt	ttattgtgc	tgcatgctgc	aatagctggc	cacaagaatt	120
atggaacaca	caaccactgc	tggctcagcc	ttcatcgagg	attcatctgg	agcttcttgg	180
ggccagcggc	agccattatc	ttgataaaacc	tggtggtcta	cttctaaata	atatggattt	240
tgagaagcaa	actttcttct	ctcaataaaag	aagtttctac	acttcaagac	acaaaggta	300
tgacatttaa	agccattgtc	cagttatttg	tgttggatg	ttcttggggc	attggcttgt	360
ttatttcat	tgaagttggg	aagacagtga	gactgatgt	tgcctatctg	ttcaccatca	420
tcaatgtcct	gcagggtgtt	ttgatattt	tggtacattt	tctgtcttaat	cgcagggtgc	480
ggatgaata	taagaagttg	tttcatagac	tgcggaaagga	agttgaaagt	gaaagcactg	540
aagtgtctca	ttctactact	cacacaaaaaa	tgggtcttcc	tctgaacctg	gaaaatttct	600
gccccaaacagg	aaacacctcat	gatccttctg	actccatct	tccaagtact	gaagtagcag	660
gtgtatatact	aagcacaccc	aggctcaca	tgggtctga	ggatgtgaac	tcaggtactc	720
acgcttactg	gagcagaact	attagtattt	gaatcagctc	cttcccccaa	gcctcttaca	780
gtacatttaa	acttgtactg	tgccatgcac	atgaagctat	aattgctagt	ctgtaaaac	840
aactgttgc	tattccatga	tcatttcatt	ttatctctac	ttgcaaaagt	tagcttctt	900
tttatatcat	ttttattttt	cttcttttgc	tttatataaa	gcttcagttt	agtgggtttc	960
tagtcttaat	gttcttagatc	actattttct	tttcagttaa	cctttatttt	tatttagttc	1020
ctgtgttagt	tataccactg	gaatattttt	atttctttaa	ttttgagggtt	aaaatatagt	1080
taacatcattt	ttcccttttt	tcttccac	aatccctctg	tataactttt	ccctgggtgc	1140
tattttattt	tttcttacatg	catatatttt	ttatgcaaaa	catatataatg	tataaataata	1200
aatatataatt	tttatatgc	tgaaaaccat	ctacttcata	caaataatgt	tccttctatg	1260
tatgtttca	ggacaggggac	aacaatagct	atggtagcat	ggcaggggaa	agcccacagg	1320
acctcagcct	tatacaaaga	atcagaggca	actgaggagt	gtcgaggat	aggaattgtc	1380
ttaccagg	gagggcacat	taattggta	tctaatacaa	aatgttcagc	cccaaaaactg	1440
ttaagataaa	agcctatata	catcttagga	atgtatctacc	tttgcatacacc	tttattggaa	1500
tatcatccac	atgtttattt	tgtgttctga	agagggcttg	ttgaattttt	aagggttgat	1560
cagtttaatt	gtgccatttt	atattcaggg	tgtttggctt	tgtttagtgc	aataatgcta	1620
tatcccctg	tatgtgtcat	cttgcactgt	tatttttcc	tggcaatact	ttattcaaca	1680
agaacctaga	gccttgggtt	attactttt	cttccataga	aaaactattt	gtcttccagg	1740
attagatata	atcaatattt	tttatatgc	tgtatcaaata	atcatgtatg	aatatattac	1800
tgtgtataat	taataactgg	caataaaatgc	caaggaaaaaa	ggaaaaaaaa	aaaaaaaaaa	1859

&lt;210&gt; 8

&lt;211&gt; 2305

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 8

gaatctgtgg	aagcagttt	ttccagttatc	accaggagc	agccacacag	aggctggtag	60
gagggtctgg	ttttgttct	cttttttct	tttcattttaa	tgtacacatt	tttattttt	120
tcttccttgg	gagtctttag	gatacttaca	ttgcagttaa	gtgtacagg	gtggataaat	180
tctactttga	agaaaaacttc	tctccctgt	caagggttgg	cttgcatacaca	ggccagcatg	240
aaggagttat	tgtgtctact	gtttttggct	gtgtgtctg	ccaaaccctt	tttagccct	300
tcccacacag	cactgaagaa	tatgtatgtt	aaggatatgg	aagacacaga	tgtatgcgt	360
aacgatgtat	acgacaactc	tcttttccaa	acgaaaagagc	cagtgaaccc	tttttccct	420
ttcgatttgt	ttccaacatg	tccattttgg	tgccaatgtt	actctcgagt	tgttcaactgc	480
tctgtatctag	gtctgacatc	ggttccaaac	aacatccat	ttgatactcg	aatggttgac	540
tttcaaaaata	ataaaatcaa	ggaaaattttaa	gaaaatgact	ttaaaggact	cacttcactt	600
tatgtcttgc	ttctgtaccaa	caacaagcta	acaaagattc	acccaaaaac	cttcttaacc	660
acaaagaaat	tgagaaggct	atatttatacc	cacaaccaac	taagtgaat	tccacttaat	720
cttcccaaat	cattagcaga	actcagaatt	catgataata	aagttaaagaa	gataaaaaag	780
gacacgttca	aggaaatgaa	tgctttacat	gttttggaaa	tgagtgcataa	ccctcttgag	840
aacaacgg	tagaaccagg	ggcatttgaa	ggggtgacag	tattccatata	caggatcgct	900
gaagcaaaac	taacactcaat	tccaaaaggc	ctaccaccaa	ctttgtgga	gtttcattta	960

caggctggcg	gaagccccca	gatatcacag	ccggaactgg	gaagggccct	gttggaaac	1680.
tgcaggag	atagacagat	tccaggtccc	tggcagcca	ggccaagacc	acaggagcta	1740
agacacccca	acctcatcac	cctcttaccc	accctctc	tcatcttctt	tttgatgaat	1800
tctgtccatc	tccctagcct	ccatTTTgg	tgtacccttc	cattctcagt	actgctttct	1860
tatttttaa	agatatttt	tttcttttc	attaaaataa	aaccaaagta	ttgataaaaaa	1920
aaaaaaaaaa						1930

<210> 10  
 <211> 2617  
 <212> DNA  
 <213> Mouse

<400> 10							
ggcggcggga	agatgcgggt	gcggctccta	gchgctggcg	cgcccggtgt	gctgggtccg	60	
gccccggaaag	tctgtggc	tctcaatgtc	acgggtccc	caggacctgt	gttggactac	120	
ttggaaagggg	aaaatgcac	cctctctgc	cacgtctccc	agaagagacg	gaaggacagc	180	
tgctggccgt	gchgctggtc	ttcgccccctg	acggctccca	ggaggccttg	atgttgaaga	240	
tgacgaagct	ccggataatt	cagactatg	ggaacttcag	ccggactgccc	aaccaggcaga	300	
ggctacgcct	gctcgaggag	cgtcgagggg	tgctgtacag	gctgtctgtc	ctgacgcgtcc	360	
ggcccacaga	tcaagggcag	tatgtctgca	aagtgcaga	aatcagcaag	caccgcaaca	420	
agtggacagc	ctggtccat	ggctcctcg	cgacgaaat	gagagtgtac	tcctctaaag	480	
ctggcgaaga	ttcatcattt	gagaaaaaga	aggtgacttg	ggcatttttt	gaagatctct	540	
atgtgtacgc	tgtccttgc	tgtcgctgg	ggatcctcag	tgttctgtc	ttcacccctgg	600	
tcattgcctg	cagtctgt	ttcacaagag	gaaatcaaga	gtgagacatt	atttggtgaa	660	
gtgcctcag	aacagctcag	gggagactgt	caccagtgt	accagtttg	ccccactgca	720	
gccacagaag	ggttaagggc	agaagaagaa	ggttagatgtt	ccacctgcag	tccctgccaa	780	
agcggcgata	gccaccac	ttccacaaacc	aaagctgctg	aaaccacaga	ggaaagtgcgc	840	
cctgccaag	atcaccgagg	aaaacttgac	ctatggcag	ctggagctga	tcaaaccaca	900	
cagggctgcc	aaaggcgcc	ccaccagcac	cgtgtatgca	cagatcctct	tcgaggagaa	960	
ccagctgtag	cgataacctc	tctctggctg	tcatgtttc	tcccagtgt	ttatgacact	1020	
cagaacaaa	ctccctagtt	ttgtattttc	acccgtgcct	tcagtgtat	ggggagcccc	1080	
ttcccacagc	gttctgtatgt	cttctaagag	gtacacactt	cccagaagag	aagggaccag	1140	
ctcttggcca	tgcctccaa	gataagaggc	ccctggctg	attctgagca	caaggactct	1200	
gcttctgaga	gcattgtca	gccaaccgta	ccaacttctc	ctcttcttaa	gccttaaagt	1260	
tttgagggaa	aaatcaaatac	ttaattttaa	tcagcccccc	ttgttctgt	taacaaggcat	1320	
ccagttata	gccacaggaa	atgctgtaaa	ggtcacagag	agaaatggg	tatatggact	1380	
gacaagttct	ctaaggctct	gggacacccca	ggacagagca	aacccttgg	ggtgggtggca	1440	
ggagccactt	atgatgacat	ccattgtctt	taatagatgc	tctgaaactg	gccatgtgag	1500	
ggcagagatg	ctgatgggt	aaagccggag	atctggctca	gaaaattctg	gtcttatgtc	1560	
tttagagcca	tacttcacca	gggctgtaga	tctacaagaa	cacccttgc	aagtgtttgt	1620	
ccccctttag	cagaatggac	ctagagagac	atattgttct	ctcttttcc	aagacttggag	1680	
tatggctcca	gtgggtacat	cggttaagt	agcaaagcat	gcaagctcag	tcaactccat	1740	
tcaagataga	gtggagcctt	tcaccatttc	ctcagcagag	aatgaaagc	acaaggcatg	1800	
ccggaaact	atgtccagga	ggactcaacc	cttggcaagt	gctttgaccg	tctcaatctt	1860	
ggatgagaac	catgattgcc	ttgggtggat	gtcaggggac	catgggacat	aagtccgtgg	1920	
ggaagtgtact	ctgtggacct	aaacaatgt	caaaaatgtc	agacttaatg	gaagtaagag	1980	
agtccaccc	atttcccgag	tgttattgt	gcttcttgc	gtatactctg	gtggccactt	2040	
actgcactt	ataaaacattt	tctggcttt	taattttaca	atgtatata	gataaaattat	2100	
ctatTTTaaa	cacagctagg	gtgtcattt	tgccctctgt	ctcaactgtt	gacttgagtt	2160	
tttttattacc	ttaacttgg	tcacagctac	acaagttgt	ggaatgggg	aacccactga	2220	
acattgcctt	ttaatgggaa	atagaaggct	cacagcatcc	ctgcccagct	tgtctctctg	2280	
actTTTcaa	agggaaaccg	cagcagcacc	ctcagagcag	ggacaatgag	cagtttgat	2340	
ctggtgctt	tttgaagtaa	catatTTTgg	ggttcttgc	cagaaaaatgt	gtcttagtcgc	2400	
tcttcctta	ccacatagac	caactaccgt	gaattgacat	ttctgaagct	aagtggaggag	2460	
aagcatccat	catctggaaa	gtgcaaaggg	ttcttcttgc	gacaaggcat	caataggagc	2520	
ggtgatgtaa	tcactgagta	gtccccaaa	tggacagctg	tttccagtgt	tccatgcaat	2580	
taaagcaagc	atgacctcaa	aaaaagaaaa	aaaaaaaa			2617	

gatTTtaata	aaatttcaac	ggTggaactt	gaagatctta	aacggTacag	ggaactgcaa	1020
aggctgggtc	ttggaaacaa	cagaatcaca	gatattgaaa	atggaaCTT	tgctaatata	1080
ccacgtgtga	gagagatac	cttggAACAC	aataaactaa	aaaaaATCC	ttcaggatta	1140
caggagtgtga	aatacctcca	gataatcttc	cttcattata	attcaattgc	aaaagtggga	1200
gtgaatgact	tctgtccaa	agtgcAAAG	atgaagaaat	ctttatacag	tgcataaagt	1260
ttattcaaca	acccaatgaa	gtactggaa	atacaacctg	caacatttcg	ttgtgttctt	1320
ggcagaatga	gtgttcagct	ttggaaatgtt	ggaaaataat	tcatgacatc	cattaaatat	1380
aaaattcaaa	aatgtataca	tttggaaatac	ttgaactgtc	ctagtaatgg	tagtattata	1440
cacataagca	aaattctatt	ctatatggtc	aatgacaaaa	aatttcaaca	gaattttgcc	1500
taattattga	tgctcagaat	aaatttctat	tgcagtgtcc	ttctgcacat	gaatgattct	1560
tgcgtaaatc	ttttgcttga	acattctttt	tttcgcaaa	aaaagatatt	tagtatttaa	1620
cccttcatta	tcaagtcagt	caaaacagaat	tgtactgtaa	acagaatgtc	tgacttagta	1680
acatttgtgt	catactttg	cttttagaaaa	aacaaaactg	gcaagaacag	cattttgaag	1740
agtacatata	tttttagtag	ttttttaaaa	aaaacttgg	cagtactgt	atgtttccaa	1800
taatgttgg	atacatatag	tttgacagaa	tcaaaaattct	caactcataa	taaagcttca	1860
agtattcaca	gataatattc	atcagagttt	gtttgggcta	taacacatga	atatctttt	1920
taaatttatta	actggctata	aaattgtaaa	aatataatga	ctgctaata	aaaatctata	1980
atgtgcattt	tatgatcagt	tatataagct	ttgaagaaca	cagtaactgt	tagttacat	2040
agtgttatta	cttcaactag	gaatatttca	ggatatccct	ttggaacagt	atggacgcca	2100
atcaatttta	tatcaactta	tctttcaaa	tatgcacatt	gggtaatgcc	tggaaacata	2160
gctaaggtga	caaaaactga	aaactgaaca	aaacttaata	gtactttcat	gtgtttttt	2220
taaactgata	ttcattatga	attaagtaaa	aagtgacaat	aaggaaaaaca	ttaaatactg	2280
gttttcaata	aaaaaaaaaa	aaaaaa				2305

&lt;210&gt; 9

&lt;211&gt; 1930

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 9

gcggaggcgc	gcagggcagc	ctgggtccag	cccacacccc	tcaccaggag	gcaccatgt	60
gggatgtgg	ctggggctgc	tctgtctgc	gctggctggc	caggctgccc	tggaggcccg	120
gcggagtcgt	tggcgcaagg	agctggcgcc	agggtgcac	ctgcggggca	tccgggacgc	180
cggtgtgcaga	tactgccaag	agcaggacat	gtgctgtcg	ggccgtgtcg	acgagtgtgc	240
cctgcctac	ctgggagcca	cctgttactg	tgacctttc	tgcaaccgca	ccgtctctga	300
ctgctgcccc	gacttctgg	acttctgcct	cgggatttca	cccccttcc	ctccccgtcca	360
agggtgcatg	catggggccc	ggatctaccc	agtcttcgga	acctactgg	acaactgcaa	420
tcgatgcacc	tgccatgagg	gagggcattt	ggagtgcac	caggagccgt	gtctagtgg	480
cccagacatg	attaaagcca	tcaaccgagg	caactacggg	tggcaggctg	gaaaccacag	540
tgcctctgg	ggcatgaccc	ttggatgaggg	cattcgtac	cgcctggca	caatccgccc	600
atcctccact	gtcatgaata	tgaatgagat	ttatacgg	ctggggccaag	gggaagtgt	660
acccactgcc	tttgaagctt	cagagaagt	gcccacact	atccacgac	cattggacca	720
ggcaattgt	gcagggttct	gggcttctc	cacagcagct	gtcgcatct	atcgctgtctc	780
tatccattct	ttgggacaca	tgacacccat	cctatcacc	caaaacctgc	tgtctgtgt	840
tacccaccac	cagcagggt	gcccgggtgg	gctgtttgt	ggcgcttgg	ggttctgtcg	900
gcggccgggg	gtgtgtctg	acaactgtt	cccattctcc	ggccgtgac	agaacgaggc	960
cagccccact	cctcgttga	tgatgcacag	ccgcggcat	gggcggggca	agcgcacaagc	1020
cacttcccgc	tgcccccaat	gtcagggttga	ttccaacgac	atctaccagg	tcacgcctgc	1080
ctaccgcctg	ggctctgtat	agaaggagat	catgaaggag	ctaatggaaa	acggccctgt	1140
tcaaggactc	atggaaagtac	acgaggactt	tttctgtac	cagcgtgca	tctacagcca	1200
cacacctgt	agccagggg	ggccggagca	gtacccgaga	catgggactc	actcagtcaa	1260
gatcactgg	ttggggagaag	agacgctgccc	agacggaaagg	accattaagt	actggactgc	1320
tgccaactcg	ttggggccat	ggtgggggtga	aaggggccac	ttccggatcg	tgctgtggcac	1380
caacgagtgc	gacatcgaga	cttcgtgtc	ggcgcttgg	ggtcgcgtgg	gaatggagga	1440
catggggcac	cactgagtct	cagccactag	gcgagggtgg	atccacagcc	acagaagagg	1500
ccttgggggc	catgcccgtat	gaagccttgt	gtgcacttcg	ggaccagggt	ctaatctcta	1560
cagactcaga	tccgcgcgtg	cgcgctaagg	cagaatccca	ccttaggagac	aaagatgcac	1620

<210> 11  
<211> 1480  
<212> DNA  
<213> Mouse

<400> 11

gggctccca	gtgatcggt	tgtgtcagcc	tcactccagg	gcctccaggg	aaccatggac	60
tttgcctt	gttactta	cttcctgcca	gtgtctgggg	ccctgagagt	cctccagaa	120
gtacagctga	atgttagagt	gggtggatcc	attatcatcg	aatgcccact	ccctcaacta	180
cacgtaa	tgatctgt	tccgcagatg	gccaaacctg	ggatatgtc	cactgtggtg	240
tccaa	ttgtcaagaa	ggaatatgaa	aggcgagtca	ccctgacgcc	atgcttggat	300
aagaagctat	tcctagtgga	gatgacacag	ctgacggaaa	atgacgatgg	aatctatgcc	360
tgtgtgtgg	gcatgaagac	agacaaaaggc	aagaccaga	aatcaccct	aatgtccat	420
aatgaatacc	cagaaccatt	ctgggaagat	aatggacct	ctgagcggcc	aagatggtt	480
cacagattt	tgcagcacca	gatgccttg	ctccacggga	gtgaacatcc	cagctttct	540
ggagtcatag	ccaaagtta	cacgcacagct	tcaaagactg	aggccctcc	gttaccagg	600
ccctccagca	tcacttcagt	aacccaacat	cccagagtt	acagaggatt	ttctgtgtca	660
gctaccaagt	ccccagcgct	cctgcccagca	accacaggct	caaagacttc	cactcagcaa	720
gcaatcaggc	ccctagaggc	cagctacagc	caccaccca	gacttcatga	gcaaaggaca	780
cgccaccatg	gcccacacta	tgggagagaa	gaccgaggc	ttcacatccc	catcccagaa	840
tttcacatcc	tgattccgac	cttcctgggc	tttcttgc	tggttcttt	gggactggtg	900
gtaaaaaagag	ccattcaaa	gaggagagcc	tectccagac	gtgcggggcg	actggcgatg	960
aggaggcgag	gccggggggc	ttcccccggc	ttccccacac	agcgggggga	tgcccccgcag	1020
aggccgcgt	cgcagaacaa	cgtctacagc	gctgtcccc	ggcgccacg	gggaccagac	1080
agcttgggtc	cagcggggc	tccgctctc	aacgccccag	cctcagcgtc	ccccgttct	1140
ccgcaggatc	ttgaagctcc	ttggcccccac	acccatctc	tgaagatgag	ctgtgaatac	1200
gtgagcttgg	gcttccatcc	tgtgtcaac	cttggaaagacc	ctgattcaga	tgattacatc	1260
aatattctg	accatctca	tctccatcc	tatgccccag	ggcccgatc	ttcatgccaa	1320
tgagttctgc	ctgtttgtc	atgtctagca	cgtttccctt	ataggatccc	tgtcatggcg	1380
tatgtcctat	accctaagtc	gactctcacc	tgactatctg	aatgccttga	aatgtatcaa	1440
ttacaggcta	atttttacc	ccaaaaaaaaa	aaaaaaaaaa			1480

<210> 12  
<211> 802  
<212> DNA  
<213> Mouse

<400> 12

gctgagccag	gatgaaggct	ctcagggtcg	tcctcctgat	cttgctacta	agtggacagc	60
cagggagtgg	ctgggcacaa	gaagatgtt	atgcggaccc	ggagccagag	aactacaact	120
acgatgtga	cgatgtgaa	gaggaagagg	aggagacca	catgatccct	gaaagcaggg	180
acagagcacc	tctacaatgc	tacttctgtc	aagtgttca	cagcggggag	agctgcaatc	240
agacacagag	ctgctccagc	agcaaaaccct	tctgcatcac	gctcgcttcc	cacagcgaa	300
ccgacaaagg	ttacctgact	acctactcca	tgtgtgtac	tgatacttc	cagcccatca	360
tcaagacagt	gggaggcacc	cagatgactc	agacctgtt	ccagttccaca	ctgtgcaata	420
ttccaccctg	gcagaacccc	caagtccaga	accctctggg	ttggccgggca	gacagcccc	480
tggaaagtgg	gactagacat	cctcagggtt	gcaagttag	ccaccccccag	tttgtcaagg	540
ctgctcatcc	tcagagcgat	ggggctaact	tgccttaagag	tggcaaggt	aaccagcccc	600
aggaaagtgg	ggcaggatata	ccttcaggct	ggacccaaatt	tggtaatata	gccctcctgc	660
tcagcttctt	cacttgtctg	tggcggtcag	gggcctgaag	accgccttc	ctccaaccag	720
gacccctgg	cctctccctc	ctgacaacca	gttcagaga	ataaacttga	atgtcggttg	780
ccatctaaaa	aaaaaaaaaa	aa				802

<210> 13  
<211> 2112  
<212> DNA

&lt;213&gt; Mouse

&lt;400&gt; 13

gggtgctcag	acggtgaaaa	tcagagatca	ggccaccttt	ctgtgagcct	tcagctgagt	60
ctaaagggt	tattgatcag	aatggcttc	ggatggttt	acctgtcctg	catggtgctg	120
ggatcgtgg	gatcgatgt	catcctcttc	actgcctact	ggatgcagta	ctggcgcgg	180
ggcttgcct	gggatggcac	ggtgctcatg	tttaactggc	acccagtgt	catggttgcc	240
ggcatgggg	tgctctatgg	agctgcctca	ctgggttacc	gcctgccttc	atcggtgggt	300
gggcccaggc	tgccctgaa	agttctccat	gcagcaactc	acctgtggc	cttcacactc	360
actgtgggg	ggctgattgc	cgtctttcg	tttcacaacc	actcgagaat	cgcacacactc	420
tactccctgc	acagctggt	gggtatcacc	actgttagtcc	tttcgcctg	ccagtgggtc	480
ctgggcttt	ctgtcttcct	cctgcctgg	gcatcccagt	ggctgcgaag	cctctgaaa	540
cctctgcatg	tattcttgg	agcctgcata	cttccctgt	ccatcacatc	tgttatttcc	600
ggcatcaatg	agaagcttt	ctttgtttt	aaaaatgcca	ccaagcccta	ctccagcctg	660
cctgggagg	ctgtcttgc	caacagcaca	gggcttgg	ttgtggctt	tggcttgcgt	720
gttctctatg	ttctctggc	ttcatcatgg	aagcgtccag	atccaggagc	tctgactgtat	780
agacagcccc	tgttgcata	caggaaatga	agcggcagg	ggctctggg	aacggtcagc	840
gatgcggtct	ctgctccctc	agaagttctg	ctgtactgg	gctcctgg	gttttcagca	900
acagacttct	cttgggcccag	agacccaacc	ttgctactcc	agttgcaggc	tctcgctgtc	960
cagccactag	ctgttccct	gctttcttgc	tggcttggc	ttattgcctg	tttttctgg	1020
tcctccattg	gcacaaaagac	cttcttgcct	tggcacaca	tgtctttct	gctggctgtc	1080
agattgggc	tgcttcctt	accactccta	gggatgtggg	agaagccaaa	gctgggggtc	1140
aaatgcagtc	tacacgtgt	aaatacaaaag	tctgctct	gtgggagcat	ttgtcttagt	1200
taggtatgt	tccccctctg	ctctgtcctg	gatgtgtatt	tgggtggca	ttgtcattga	1260
ggggtcattc	atgggacagt	ggcagccgg	gaagcctctg	ctgtaaagtc	aggtgcccag	1320
tactctgtc	ttttcactt	gatgtgtgt	attgtgtgg	ttgtgacctt	gttattcccc	1380
ctcttcata	tgctgtccca	gctgtttcc	ggatcccgc	ctttccctgt	gacttacatg	1440
cctgttcccc	tcaggtagca	tgacgagccg	ttaaacagtt	ctcccaagaa	cacatgtct	1500
gtcccttagag	tcctcccccag	tgtatgatct	gaggtttctt	tggccttcct	ttctgtccct	1560
ttgtgggtat	gggctttct	gcctcctcta	gttatgtct	cccctgacag	ggccccagcc	1620
caactatgaaa	ttgaaaaccag	cattatgaag	caatttgctg	ggagccattc	actgtgtctg	1680
ctttcagaga	tgttccttag	ttagtagtgg	gtgcttctgt	tccccaaaag	gtcaactcagc	1740
taccctctat	gctataccag	aatgtgagct	ttgctttct	gaatagaaaac	tggtagagaa	1800
gggaggagtc	ttgccccact	cctttgtgtt	agccctgcca	ggtccctcaa	caggcaggca	1860
ggcaggcaag	caggcagaca	ggcaggcaga	gttgggtcc	tgaactct	gcagacagt	1920
gccaggctc	cagacgttgg	gaggagggtc	ggcatggatt	tgctgactaa	atgaaaggcct	1980
gaacacatag	cgatgactt	tggcaccac	atgaacatct	tcctggttca	ctcatgagt	2040
gttattttac	ttcatgaatc	ttattttat	taaatatgtt	ttaaacatc	agaaaaaaaaa	2100
aaaaaaaaaa	aa					2112

&lt;210&gt; 14

&lt;211&gt; 915

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 14

ggaagtaagt	tcagaggcca	tgagactgcc	tctgccactg	ttgctactgt	tcgggtgcag	60
ggctatctcg	ggggagcggcc	gggatagggt	ttccctctcg	gcttcggctc	ccacactgg	120
tgtatgaagag	aagtactcgg	ctcatatgcc	ggcteacactg	cgctgcgtatg	cctgcccgg	180
tgtggccttc	cagatggggc	aacgtctggc	gaaagcagag	gttaaatctc	acactccaga	240
cgcgcgttgc	ttgcaggagc	ttagtgaatc	cacgtacaca	gatgtcttgc	accagacactg	300
ctctcagaac	ttggcagtcc	atggagttca	tgaagtgaac	cagatgaagc	gtctcacgg	360
cccaggactt	agcaaggggc	cagagccaa	aatcagcgtg	atgatttctg	ggggctccctg	420
ccccaaatgg	ctctccaaga	cgtgtttcca	ctacctgggt	gagtttgag	aggaccagat	480
ctatgaagcc	taccgccaag	gccaagcgaa	tctggaggcg	ctgctctgt	ggggcaccac	540
ttggccctgc	tcacaggaga	tcctggccca	gagagaagag	ctttagtcca	acctgtgtca	600
cttctggatc	ttctctaatt	ttattttat	taatggctga	ttagaggcag	gtctctatca	660

tgttaggccag	gctggcctta	aacttgtcat	cctgctcagc	ctcgaaagtq	ctgcattaa	720
gtcctgagcc	tttttgtct	tgaccctct	atataattt	ttcaactgtq	gtgggggaa	780
ggggacaggg	aagcctgact	ctagctgtca	atcttctccc	tccacctctc	gatggggta	840
tgggactgag	gctgccttcc	tactttcaaa	taaagctttq	aaagacaaaa	aaaaaaaaaa	900
aaaaaaaaaa	aaaaaa					915

<210> 15  
 <211> 1308  
 <212> DNA  
 <213> Mouse

<400> 15						
gtgagagctc	agctggaagt	gactgggtga	caaggcgac	aggctcagcc	gtggaagctc	60
catcatgatt	ccacaagtag	tgaccagtga	gactgtcaca	gtgatttac	caaattggaaat	120
cagcttccc	caaacagaca	aaccccgcc	ttcccaccag	agccaagaca	gactgaagaa	180
acatctaaag	gctgagatca	aagtgtggc	ggcaatccag	atcatgtgtq	ctgtgatggt	240
gtttagtctg	ggaatcattt	tggcatctgt	tccctccaat	ctacactta	cctcagtgtt	300
ttccatcctg	ttagaatctg	gctaccattt	tgttaggagct	ttgttttttq	ccatctctgg	360
aattctgtct	attgtcacag	agaaaaaagat	gactaagctt	ttgggttccaca	gcagcctagc	420
cctgagcatc	ctgagtgtcc	tctctgctct	tacaggcatc	gctattctct	ctgtcagttt	480
ggctgcttta	gagcctgcct	tgcagcaatg	taagctggct	ttcacacaac	tagacacaac	540
ccaagacgct	tatcatttct	ttagccctga	gccatcaaac	agctgctcgt	tggccaaagc	600
tgctctgact	ggagtctttt	cactgtatgc	aatcagcagt	gtgttggagc	ttggccttggc	660
tgtccctact	gccacactgt	ggtggaaaca	gagctccctct	gttttctctg	ggaatgtgtat	720
tttccctgtct	cagaactcaa	agaataaaatc	cagtatct	tcagagtcac	ttttaacc	780
acatatatgaa	aacatatgt	cttcataaga	attaaatgata	ggttatata	cagaaaaatc	840
tgtcttaaac	atgatttaga	aaagccattt	actgtgtgac	aacaatgttt	aatatcttaa	900
tatcttaatg	tgtgtattgg	ttaatcagca	accataaaa	acataactaa	tggctgggtt	960
cagtagcacc	cttttgattt	ggcgtcagtc	aaaacacaga	cctgtaaatt	ccaattttat	1020
tagtggtaaa	agagccccaa	ttatttctc	aaaaaactgg	aagaatgttt	cataggatca	1080
ttgtggagcc	aatgggcaac	agtcttctt	atcctgtca	cttggctgca	ggaggtactg	1140
actagggcct	gagatcatat	tctgtgtcg	tggcatggac	ttcatggcat	ctattttatt	1200
cataagcaca	tgaaaacaag	tcatctctta	tgaagtctca	aagagcataa	aaaagttagc	1260
ctccaaataa	agtctttatg	taatcccaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1308

<210> 16  
 <211> 1288  
 <212> DNA  
 <213> Mouse

<400> 16						
gctccagctc	ctccatcctg	tagttacag	ggtgtaccct	atgtcgggac	caatgtgacc	60
ctgaactgca	agtccccaaag	gagtaaacct	actgtcagt	accagtggga	gaggctggc	120
ccatccccc	aggctttctt	tggaccagcc	ttagatgtq	ttcgtggatc	ttttaagctc	180
actaacctt	ccattgcac	gtctggagtc	tatgtctgca	aggctaaaaa	cagagtgggc	240
tttgccttgc	gcaacgtgac	cttggacgt	atgacaggct	agtaaggggg	tccaaggctg	300
cagtggcgc	tggagcagg	ttggggactt	ttgttgggtt	gtgtctgata	gctgggctgg	360
tccttgttgc	ccagcgcgg	agcaagacct	tggaaagagct	ggccaatgat	atcaagggaa	420
atgcattgc	tccccggacc	ttgccttgg	ccaaaggctc	agacacaatc	tccaagaatg	480
ggacacttcc	ttcggtcacc	tcagcacgag	ctctgggccc	acccaaggct	gctcctccaa	540
gacctggcac	atttactccc	acacccagg	tctctagcca	ggccctgtcc	tcaccaagac	600
tgcccagggt	agatgaaccc	ccacccctcagg	cagtgtccct	gaccccaagg	gggtttctt	660
cttctgtct	gagccgcatt	ggtgctgtgc	ctgtgatggt	gcctgcacag	agtcaaggctg	720
ggtctctgt	gtatagccc	aggcactcat	tagtacatc	tggtatctga	ccttctgtta	780
aaggcttcct	tgtggcacag	aggactcaat	tttgggagga	tgcccacatt	ctagacctcc	840
agtctttgc	tccttacccctcc	ttctattgtt	gaaatactgg	gcctcagtaa	gactaaaatc	900
tgggtcaaaag	gacaaaagga	gaaaatggac	ctgaggtagg	gggttgggg	tgaggaggct	960

tcacttcctc	cctgcttctc	cctgaagcca	gatgaatgct	gcggaagatc	ggctaccctc	1020
caaggcctct	ggaggagact	gccagtca	gatgcccctg	gctctgtat	ctgtacaaca	1080
cccttatcta	atgctgtctt	ttgcccgtcg	ctccatctcc	ctgtattaaat	ataacctgtc	1140
ctgctggctt	ggctgggttt	tgtttagca	ggggatagg	aaagacattt	taaaatctga	1200
cttgaattt	atgttttgtt	tttattttt	caaattccaa	taaagataca	tcgcatttgc	1260
atggccaaaa	aaaaaaaaaa	aaaaaaaaaa				1288

&lt;210&gt; 17

&lt;211&gt; 999

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 17

gccagctttt	tcctccgcag	ccatgtccctg	gtctccgatc	ctaccattt	tgtcccttct	60
gtttctgctg	ttcccactcg	aggccccca	agcagccact	gcgtccctt	cgcaagcata	120
ctccgaaggc	acaaccaccc	gcaagggtcca	cgatgtgtc	ctttggggc	cacgcccatt	180
gcccccttca	ccacctgtca	gagtca	gtattatgag	tccctgtgt	gagcttgc	240
ctacttcctc	gtccgggatt	tgttcccaac	ctggctgtat	gtatggaaa	tcatgaacat	300
caccctggtg	ccctacggga	atgcacagga	gagaaatgtc	agcggta	gggagttcac	360
gtgccagcac	ggggagctgg	atgttagact	gaacatgggt	gaggcgttc	tgctggataa	420
gctggaaaag	gaggcagcgt	tcctaaaccat	cgtctgtat	gaggagatgg	atgatatgg	480
gaagaaaactg	ggaccgtgcc	tgca	tgctccgt	gtgtcaccag	agagtatcat	540
ggagtgcgcc	acaggaaaac	ggggcacaca	gctcatgtat	gagaatgccc	agtcacaga	600
tgccttacac	ccaccccaacg	atgtgtcc	ctgggtgt	gtcaatgaga	aacctttgaa	660
ggacccca	gagctctgt	gcata	tcagctggac	cagggaaacgg	agaagccaga	720
catctgctcc	tcatttgc	acttccccaa	gaaggctgt	tataagtaaa	ggcataac	780
caaactcg	ccagaaaact	gcccagttt	ttcaaaattgc	caacctgca	gagctgtc	840
ctcgat	aaaccttgc	catgtcccc	aaagccaga	ctccagactt	ctcagagaca	900
aggatctgc	tttattttca	aatgggtct	aatttaatt	catagaataa	atcatctata	960
tcctgtat	tccttttcc	aaaaaaaaaa	aaaaaaaaaa			999

&lt;210&gt; 18

&lt;211&gt; 2123

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 18

gctgtccgt	gtcctgtgt	ggaaactgct	gcttcttc	agctctgc	tcctgtc	60
agggccttca	gggaccgc	cagccagca	ctctctgt	tctgagtc	tggtagctt	120
ggcagccg	acccaggctg	tgtacgt	ccagagcccc	cgcatgtgt	ggacccaaga	180
ccggctgtat	gatcgccagc	gcgtggtcca	ctgggaccc	agcggggacc	cgggcagcca	240
acggcgc	cttggata	tgatttgc	gggtga	cgcgtgtac	agccgcgc	300
tcgcgaccgc	tcctgtgt	cgccctctgc	tttccac	ggcaacttct	cgctgtcat	360
tcgcgtgt	gagagaggcg	atgaagggt	gtacac	aacctgc	atcactact	420
ccacccgtat	gagagccctt	ctgtgc	cgagg	gacgatccc	tattaagtgc	480
cgcatactgg	gacgggtgaga	agaagtgtt	ggtgtggcc	catggcgc	cgccactgt	540
gacctgc	aaacgtgc	acgtgtggac	tgacccat	ttagaggagg	cgccagg	600
ggtccattgg	gaccgcac	tacctggat	gtcacac	cgccggacc	gcctgtt	660
cctgtatgca	tctggcg	gcccgcctt	tggccccc	ttctgtgt	atcgctgt	720
agttaacacc	aaacgtttt	cacgcgggt	tttctcc	cgcatgtat	agctggagcg	780
agctgtat	ggcatctt	cctgcccac	gcacat	tactgtgt	tcacagcg	840
ccgagtctt	cacccat	tcacagagcc	tgcctt	ccaccat	gtgttctt	900
tggcaatgg	tctggt	gca	gatgtgt	cccaccc	cccgaggcca	960
cacatcatc	aatgttatt	tc	ccacagag	tttcc	aactgggct	1020
cgtgttggcc	acgtgtgt	tcttcat	gtgt	actgtat	tggttacac	1080
acatcg	acggaggat	gca	gacaaaaaa	gctggaa	caaaggggaa	1140
ggatgt	atggtggag	ttgtgt	cacaaggat	cagg	cttactgt	1200

ggacatccag	ctagattaca	aaaacaacat	cctgaaggag	agggctgagc	tggccatag	1260
tcctctgcct	gccaaggatg	tggatctgga	taaagagttc	aggaaggagt	actgcaaata	1320
aatggaccct	gagttctgg	ctggccagc	agctctgtat	caaaggacat	ctccctgacc	1380
ctcctgcgtt	attcctggct	cttctcagcg	gctggccga	cttacctaga	aacttggcct	1440
aaacttggca	gagcagctgc	ctgtactttg	cccttccat	aatcgccacc	cctcatcttgc	1500
gtgagacaact	gtgggttccc	tagagactct	ggtatagtagc	gattgctgccc	cttcagtcac	1560
ctgtgcccac	tgatggtcgg	accccaact	taaacacaac	aaagatccct	tgttaatatc	1620
caccaaatgc	aaagtccctc	gtggcctctt	actgctaggg	tcaggaagac	acttaaaaat	1680
tccaggtaaa	actcccttagc	caccagttaa	acacattagc	cattgtcctg	gggggggggg	1740
ggtcttcctg	agctgcatacg	tgctctgtgc	ctgctcagag	ccctgctgtt	atagggttgt	1800
actcatgggc	ccgccttgct	gcttgggca	acttgaggct	agcccgaggc	cctttctctg	1860
cttctgattc	cttctgccc	aatgcctccc	aagagctaca	ccagcagttt	ctgggttaccg	1920
tatgaccctt	ggccttgaca	tccctcccta	ggctggagtc	tgggggttggg	gccccatttg	1980
tcctctgttt	tggctgaaga	tggggtgaag	atttggctga	gtggcctatg	ctgtcacatc	2040
aaacagctat	catttactcc	tacttggaaa	gttgcatagt	gacaataaaa	gatacatttg	2100
acttttaaaa	aaaaaaaaaa	aaa				2123

&lt;210&gt; 19

&lt;211&gt; 1391

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 19

gctggcaggc	tgctgtgcag	tccacgagga	aggcttcgtt	cgacaggaca	ggcgtgcaga	60
cttcaggagg	gaccctgggc	agcagacatt	cccttggagg	gcaggttgc	ttgcatagg	120
ggctcatgga	ggcagcagag	gtggcctcag	ccaggcctgg	gcagcatcag	ccccccggcag	180
cagcaagacg	ctggcttgc	cacccctccc	caagaacagc	caccacagt	accaggggaa	240
tgactagcgg	ccggaccaca	ggccacaaaa	agaagaaggc	taccccaactt	acagatgcag	300
accatgtggg	gttccggaga	actgtttgt	gcatgtttc	tagtgttgc	agcagatgg	360
actactgagc	atgtctacag	accacggcg	agagtgttgc	ctgtggggat	ttccggaggt	420
tccatctcg	agacctttgt	gcagcgtgt	taccaggc	acccatccac	ttgcacgg	480
cacagagcct	gcagcaccta	ccgaaccatc	taccggact	cctatcgcc	tagccctggg	540
gtgactcccg	caaggcctcg	ctatgttgc	tgcctgggt	ggaagaggac	cagtgggctc	600
cctggggctt	gtggagcagc	aatatgcca	cctccatgt	ggaatggagg	gagttgcac	660
cggccaggac	actgccgtc	ccctgtggg	tggcaggag	atacttgc	gacagatgtt	720
gatgaatgca	gtacaggaga	ggccagttgt	ccccagcgt	gtgtcaatac	tgtggaaagt	780
tactggtgcc	aggatggg	gggacaaagc	ccatctgc	atgggacgc	ctgcctgtct	840
aaggagggc	cctcccccgt	ggcccaaaac	cccacagc	gagtggac	catggcgaga	900
gaggagggt	acaggctgc	ggctcgggt	gatgtgt	aacagaaact	gcagttgg	960
ctggcccccac	tgcacagcc	ggcctctcg	tccacagagc	atggctaca	agatcctgg	1020
agcctgctgg	cccatccctt	ccagcagct	gaccgaattt	attcaactg	tgacgggt	1080
tccttcttgg	aggaacatct	ggggctctgc	tcctgc	aagatctgt	ataacctctc	1140
accacccagg	ctggatagag	cagtcatccc	tagatcc	gtagccag	ttcaggcg	1200
gtctgggtgt	gcctatgagc	agaaggccct	gcctcattgt	cccttcttct	taggggtt	1260
ctaggacttgc	ggcatgggg	gtggggctt	gtgtgact	tcagtgggg	tccctgtcta	1320
agtggtaagg	tggggatgt	ctccatctt	gtcataataa	agctgagact	tgaaaaaaaaaa	1380
aaaaaaaaaa	a					1391

&lt;210&gt; 20

&lt;211&gt; 1864

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 20

ggcaccgcgc	gggcggctat	ggagcgagcc	tgaggcccgc	caggatatga	attggctccc	60
tctgaccgc	atttcagtgc	ttttaagtgt	gaggtcagca	actgcagct	acagattgt	120
aactgtcgaa	cccccggaaat	tgtggaggca	ctgcagtc	gaaatatgt	atcatggaaat	180

ctccttgcta atcgtcacca cctgttccct	gtgataagcc	agccaggacg	tggctgagg	240
agaaggaaaa gagggcacca	tgaagctgaa	gcagcgagtt	gtgctgttag	300
cgtcattttt atcttaccca	aagttttcct	gatagataat	ttagatacat	360
ccgagaggac cagagggctt	ttcaccgaat	gatgactggc	ttgcgggtgg	420
caagtggac cataccctgc	agtctcctt	ggagattgca	gcccagtggg	480
ggaagtgtat cctgaagaga	caccagagct	gggagacatc	atgcattgca	540
gaaaatcatt aaagctgacg	tggctataa	agggacacag	ctaaaagctt	600
tgaaggagga cagaaaggta	tcttaagcc	taagcgtac	agcagagact	660
aggggagcca tacgctggtt	atgacagaca	caatgcagag	gtggcggct	720
caggattctg gtttccgccc	gagctccctt	gggtggggc	agatatgta	780
agaagtttaag cctgttgc	cgagcagct	gctgagcacc	tccctaactg	840
tacttgttcc tatgggaagt	gctactactg	ccgagaaaca	gagccagcat	900
tgacatgatg gagggtctg	tcacacttt	gcttcagat	gtgtggcctc	960
tcgacatccc tggggcagga	cctaccgaga	aggcaactg	gccaggtggg	1020
gagctactgc gatgctgtg	agaaaacatc	cccctatgac	tcaggcccc	1080
catcattgac acggctgtct	ttgattactt	gattggcaat	gctgatcgcc	1140
gagctttcaa gatgatgaag	gcgcgagcat	gcttattctt	tttgataatg	1200
tggaaacccc tcgctggatg	agagaagcat	tcttgcctt	ctctatcagt	1260
tcgggtttca accttggata	gactgaatta	tctaaagaat	ggagtactaa	1320
aaaatctgcc atggcccacg	accccatctc	ccctgtgctc	tccgatccac	1380
tgtggaccag cggcttctga	atgtcttggc	caccatcaag	cagtgtactg	1440
gacggatact gtgctgggg	aagacaggat	gccactctcc	cacttgtaat	1500
aaacaagtgg aactgattt	acaaagatag	agaaacacga	caatcaattc	1560
gcgtatggctc	gcagggtggcc	acagtgggtg	ctgggtggcag	1620
agtgtcggt	gttttctgca	gtcaagcta	cgaccacag	1680
ggctgccagc	agcagctctg	ctcagtcctt	attcccacac	1740
cataggctaa ggaagtgttt	ccagagtgta	cgtctcggtt	cagagggcga	1800
tacacccatg	gattctctga	aaacactttt	gagtttcctt	1860
aaaa			tgtcttaaaa	aaaaaaaaaa
				1864

&lt;210&gt; 21

&lt;211&gt; 2324

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 21

gggtctgtac tccccgttcc	tcgcccacaca	cacaccgaga	ggatgaggct	caccgtgggt	60
gccctgttgg	cctgcgcgc	cctggggctg	tgtctggctg	tccccgacaa	120
tggtgccag	tgtcagagca	cgagaataacc	aatgcata	gcttcgtga	180
accgttcc	cgcctgtatgg	ccccccggctt	gcctgtgt	agaaaacactc	240
tgcataagg	ccatttctgc	aagtgaagcc	gatgtatga	ccttggatgg	300
tacgtgccc	gcctgtactcc	gaacaacctg	aagccctgtt	cgccggagtt	360
gtggaaacatc	cacagaccta	ctactacgct	gtggctgtgg	taaagaaggg	420
cagctgaacc	agctcgaagg	caagaagtcc	tgccacacag	gcctggaaag	480
tgggtcatcc	ccattggctt	gctttctgt	aagctgtcgg	agcccccgcag	540
aaagctgtgt	ccagtttctt	ctcggggcag	tgttccctt	gtcagatcc	600
cccaaactgt	gtcaactgt	cccaggctgt	ggctgtctt	ccactcaacc	660
tacgttaggcg	cattcaatgt	tcttggat	ggcgggtgggg	atgtggcctt	720
acaacccat	ttgagggttt	gcccggagaag	gctgacaggg	accaatatga	780
cttgacaata	cccgcaagcc	agtggatcag	tatgaggatt	gctacctggc	840
tctcatgtcg	ttgtggctcg	aaaaaacaat	ggcaaggaag	acttgcattt	900
aaagtggcac	aggaacactt	tggcaaaggc	aaatcaaaag	acttccaaact	960
cctcttggga	aagacctgtc	gtttaaagat	tctgccttt	ggctgttaag	1020
aggatggact	acaggctgt	ccttggccat	aactatgtca	ctgcccattcg	1080
gaaggcgtgt	gcccggaggg	ctcgatcgac	aactcgccag	tgaagtggtg	1140
cacctggaga	gaaccaagt	tgacgagtg	agcatcatca	gtgagggaaa	1200
gagtcagcag	agaccactga	ggactgcatt	gaaaagattt	tgaacggaga	1260

atgactttgg	atggaggaca	tgcc tacatt	gcagggcagt	gtggtctagt	gcctgtcatg	1320
gcagagtact	acgagagctc	taattgtgcc	atcccacac	aacaaggat	cttcctaaa	1380
gggtattatg	ccgtggctgt	ggtgaaggca	tcggacacta	gcatcacctg	gaacaacctg	1440
aaaggcaaga	agtccctgcca	caactgggtt	gacagaaccg	ctgggtgaa	catccctatg	1500
ggcatgctgt	acaacagat	caaccactgc	aaattcgatg	aattttcag	tcaaggctgc	1560
gctcccggt	atgagaagaa	ttccacccttc	tgtgacctgt	gtattggccc	actcaaatgt	1620
gctccgaaca	acaaggagga	atataatggt	tacacagggg	cttcagtg	tctcggttag	1680
aaaggagatg	tagccttgg	gaaacaccag	actgtccctgg	ataacaccga	aggaaagaac	1740
cctgccgaat	gggctaagaa	tctgaagcag	gaagacttcg	agttgctctg	ccctgatggc	1800
accaggaagc	ctgtgaaaga	tttgcgcagc	tgccacctgg	cccaagctcc	aaaccatgtt	1860
gtggctcac	gaaaagagaa	ggcagcccg	gttaaggctg	tactgactag	ccaggagact	1920
ttatttgggg	gaagtgactg	caccggcaat	ttctgttgt	tcaagtctac	caccaaggac	1980
cttctgttca	gggatgacac	caaatagtttc	gttaaacttc	cagagggtac	cacacctgaa	2040
aaataacttag	gagcggagta	catgcaatct	gtcggtaaaca	tgaggaagt	ctcaacactca	2100
cgactcctgg	aaggctgcac	tttccacaaa	cattaaaatc	caagagggtgg	gttgcactg	2160
tggtgagac	agatgctccc	tcccggtggcc	catgggttc	tcttggtctt	catgccctga	2220
ggggttgggg	ctaactggtg	tagtctcgc	tgctgtgcct	taccacatac	acagagcaca	2280
aaataaaaac	gactgctgac	tttaaaaaaaa	aaaaaaaaaa	aaaa		2324

&lt;210&gt; 22

&lt;211&gt; 1859

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 22

ggcgcaccta	ccccagccta	tgtgcgtcc	gcaaggagaa	ccgagccgt	cgccagcggg	60
gcgcgctccc	ggctgtgcc	gtgcagaagg	gtgcgtcg	ggaagcagg	accacaagag	120
cagggcggt	ccggagaaag	tacaactca	tcggccagt	ggtggagaag	gtggcccg	180
ctgtggtcca	cttgcagctg	ttccgcagat	gacagacaca	caggttccca	caetgatcta	240
aaggaggaga	caccatctg	gaccaggatc	tcaagtgtgt	tcaaggaaaga	tggccaggac	300
gagcttcagg	caagtcacaa	agcacatgg	atggatcac	ctctcacaa	ccaggaaatc	360
cttccctcca	gcggctctgg	gttcatagtg	tctgaggatg	ggctcattgt	caccaatgcc	420
cacgtcctca	ccaaccagca	gaagatccag	gtagagctcc	agagcggggc	ccggatgaa	480
gccaccgtca	aagacatcga	ccataaaactg	gaccttgac	tgattaagat	cgagccagat	540
actgagctc	cagtactgct	gttggccgaa	tcctctgacc	tccggctgg	agagttgtg	600
gtagcttgg	gcagccatt	ttctctgcag	aacaccgtg	ctgcaggat	tgtcagcac	660
acacagagag	gccccagaga	gttggactg	aagaattcag	acatagacta	tatccagacg	720
gatgccatca	ttaaccatgg	aaattctggg	gttccgtgg	tgaacttgg	tggcagctg	780
atggtataa	acactctgaa	ggtgactgca	gggatcttt	ttgcgatccc	ctctgatcg	840
atcagacagt	tcctggaaaga	ctatcatgag	cgccagttg	aaggcaaggc	ccctttgcag	900
aagaaatacc	tgggtcttcg	aatgctgcct	ctcactctg	accccttca	ggaaatgaa	960
aggcaagatc	cagagtcccc	tgtatgtgat	tctggagttt	ttgtatatg	agtgattcag	1020
ggatcggctg	ctgcaagtc	ggggttgaga	gaccatgt	taattgtcag	cataaacggg	1080
caacctgtca	ccaccacaa	tgtatgtcatt	gaagctgtt	aggacaatg	cttctctcc	1140
atcattgtgc	ttcgaggaag	tcaaaccctt	tttctgacag	tcacacctg	aataatcaat	1200
taagtatctt	actttgagaa	actgccttagc	aaaaccagt	atattacctg	gttttgtatc	1260
gaagagggtc	cagagatggc	agggtcttct	ggagatcaag	aaaaatggat	gtttaaatg	1320
cagaagttca	tgtttgtgt	catacatcaa	cacacacaca	cacacacaca	cactcatgga	1380
tcctgggtt	gagagtgtct	ttctggccga	aaacccttct	aactcaaatg	gaaacagcta	1440
tggtgatctg	ataaaaacttg	atgacagat	gaactggaaa	gcaggcaatt	cctaactaa	1500
tcttgatagg	aaactttgt	tacctcctat	acagccacaa	actggatgt	cacgcacatg	1560
tacacataat	tacctacaa	atattaagaa	cctgaatctg	gagtaaaagag	gtaatcacat	1620
tttaaataat	accctttgt	atactgaatt	tcccaggtt	tatccactt	gggcccagggt	1680
ttgtggatag	aaaggtcatc	acctataaga	catcttggag	ctgatgacat	catactacca	1740
cacaggagtg	tgtatcattt	ggaggtagaa	acaatttcgg	accttttagag	tttctgagaa	1800
tgtcttctat	ttcttattaa	ataatttttc	gaaccgttaa	aaaaaaaaaa	aaaaaaaaaa	1859

<210> 23  
<211> 724  
<212> DNA  
<213> Mouse

&lt;400&gt; 23

atgcctgcct	gtcgccctctg	cttgctggcc	gctggcctcc	tactagggtt	gctactgttc	60
accccccatt	cagccacagg	caccgatgca	gagaaacccg	gcgagtgccc	ccagctcgaa	120
ccaattacgg	actgtgtgtt	ggagtgcact	ttggacaagg	actgtgcgg	caaccgcaag	180
tgctgccagg	cgggctgcag	ctctgtctgc	tccaaagccta	atggaccgag	cgaaggagag	240
ctctcaggga	cagatactaa	actctcagag	actggacta	ctactcaatc	agcgggcctt	300
gaccacacta	ctaaaccacc	gggaggtcaa	gtctccacga	agccaccggc	tgtgaccagg	360
gaaggcttag	gtgtccgaga	aaacgcgggc	acctgcccc	gcgtggacat	acccaagctc	420
ggcctctgtg	aggaccagtg	tcaagggtggac	agccagtgtt	ctggcaacat	gaaatgctgc	480
cgcaatggat	gtgggaagat	ggcctgcacc	acacccaaat	tctgagcttc	agcctccagc	540
agcctgagga	acggagagag	gttggttctg	ccggactgtg	catctggagt	cgttcctgtg	600
gcctccccc	tctctggct	ttgcatttct	tcctggtccg	acgaaagcat	ctcccttttc	660
taaccaataa	agtgatcggtt	ttcagcaatg	gagaagctat	aaaaaaaaaa	aaaaaaaaaa	720
aaaa						724

<210> 24  
<211> 2395  
<212> DNA  
<213> Mouse

&lt;400&gt; 24

gaaagaatag	agacagagaa	ggaggttctg	cattttggg	atcacaaacc	agaccatgaa	60
agctggcatt	cagaatgcct	gcctaccaaa	agtctcagca	aggcccagca	agctccacag	120
gatgttttc	aagggtggct	ctgtgtgtt	gttacggca	aagggtggga	aagccagtct	180
ttggggcag	actctttgtt	ggagtctgccc	tttccctctt	ccccctgccc	ctccactctg	240
acagccacag	tggttatgtat	gagggccaa	atgtggaca	tctatgctca	gatattaaac	300
ctaagctcac	gtttaaaatgt	ggccaaagact	ggccctgggtt	tgtctgttaag	agacccagag	360
tttcccaacc	ccccctgcacat	gagcttagtgc	atcacactaa	tttgggtatgt	tttgcctctg	420
tttgccttaa	ggatagtgac	cttgcctgt	cgccagatgtc	atgttttaggc	attaagtgtc	480
cataggtcat	tccgtaggc	atctagtaca	cgtcggttca	caaatactact	tccaaagaccc	540
tcagaatcct	tcattaaagg	gttgggcctg	gttgtctgaa	tttctgtatgt	gttccctgca	600
atatggtaa	atgcactata	actggagggtc	agaggcttag	aaccgggggg	agcagagcc	660
ccttgtaaat	gttacatggc	taatcacaat	gagatggccc	cactgttagc	tacgtctca	720
cctccatca	ctcttgcgtc	cttccacaa	gtgtgttaca	tctgggacac	ttgtgccccca	780
ttcccaggcc	atacaaggct	gaaagggtgg	ctggacagcc	tcctccctga	cctacatgg	840
aaggctctc	cttttcttcc	cgcccttttt	tctaatgtgg	atgtttccat	taatcctctg	900
tttctggagc	tttggaaat	ctgtttccca	tttgcatttcatc	cacccatcca	tcattcaaca	960
tgaatggtc	atgtcacgt	tttgggtgcaa	gggatactct	ttcaaaaacaa	tccctcacga	1020
gactcacagt	ctagtgaaga	gcacacgcca	gaaaccaatt	agagaagcta	ccaaaccacga	1080
tggaacatca	gggattcaaa	acctcggtt	gagagggagc	ctactttctc	tgtgtttctc	1140
taagagccct	gatggctctc	gattgtctg	aacagagggtc	cacttggtcc	atgtctatca	1200
tgggtagtgc	ccacgagggt	tccccagaga	atactactgt	agagcatct	atactccca	1260
caggagagaca	ggaaaggatt	cccagagcc	tggctttaa	gatggtcctc	gaaggaaaat	1320
ccagtcattt	ccaaatggc	cttgcaccc	gaggctatgg	ggaggcttcc	agaagtcctg	1380
gaagagtgcac	aacacccggag	tcccaggagc	tctgtatgg	caaccttctc	ccttgaacac	1440
cctttccat	ttttgagcat	cgagttggag	aggtagttct	gggacagggt	gtgtatattt	1500
gtgtgttta	aacacattca	catgtaaatgt	gcctgagggg	aggggatgtt	tgcctctagc	1560
tcagtccttc	tggagctgg	ggatgtatgt	gtctgagggt	ctttagggcc	atattgtaca	1620
ccacccatgt	acaaacggac	tcccctccct	tcctccctct	tttctatct	ccttcccttc	1680
cttccttc	cagggtgtcc	aagggtatat	gggacagcga	caggcataac	gatcacctgt	1740
tgccttaatgt	aactttccac	agctcactgc	tggtaggtc	gtagagttt	tccttgcctt	1800
tgaggccca	aggaaggagg	ccaatctaaa	gtgtcccca	tacttcccc	ttgggggctt	1860

ttctgtataa cttgtttaaa aattgttctg atgatcatga tggaaacaga cagaccac	1920
tagaaccaga ggcctgaaag cctgacctga ccagcacaga ttcccacttc agaacc	1980
ggctatggaa gtgccttgc ccaacgctat gggaaatagtc ctgtgggtg tctctgctt	2040
ccactgtggc cagcattcca gtgcctacag ccacctgtgc ctacagccac ctgtgccat	2100
agaagtgcct ctccgtct atgcctgtca tttggatgc taagaagagg tgagggtgt	2160
agcgagaaca gatccaccct tctccttaggt aggatcagct ctcatttgtt gcttac	2220
agttatcaaa gaacagcaga gacagctgcg ttatccaaga agcaagtatt aggacaaa	2280
cctgttactg tatttaaagg aacttagtt tgctatctt acattttat aaagtactgt	2340
aattcagggg gtgggtatg caacagagac agactaaccct atgtttgtca tttgc	2395

&lt;210&gt; 25

&lt;211&gt; 881

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 25

gtgaggaatg ggcacccccc tttaaaaag gtgcagggtcg aggatggggg tttgtatacc	60
tgttacgcca tgggggagac tttcaacgag acactgtctg tggagttgaa agtgtataac	120
ttcacccctgc acggacacca tgacaccctc aacacagctt acactaccct gttgggtgt	180
atccctcaggc tggttctgtt cctcatatac ttgtacccca ccccttgcgc ctgtgtgt	240
cgggggtgtgg agaaaacccctc cagccaccaa ggagatagcc tcagctttc tatgctcagt	300
accacaccca accacgaccc tatggctggt ggggacaaag atgatggtt tgaccggcgg	360
gtggccttcc tggaaacctgc tggaccgggg cagggtcaaa atggcaaaact caagccaggc	420
aacactctgc cggtgcccgaa agctacaggc aaggccaaac ggaggatgtc cgatccagag	480
tcggtcagct cggtctttt cgtatcaccc attgtgggtt gaggcgtta ggctgtatggg	540
gaggttctgc cccaggagag gtacccctga gggatatgac agggtggaa agagggtctgg	600
atgccaagg gatgggttc ctccgtacca ccagggaaatc ggtcacaggg gcccggaggag	660
gcaagacccc agtgagggtg tggatgtgc gagtttaccat tatggatatc ctcaggcaga	720
tgccacaccc ctacccaaag cttggctat tctcaatgtt ggggaggggg acaggaacga	780
ggaaaggcg gaggggagga gcaaattccc taaactttt tgaggcatac cctagctcct	840
taagagaaaa ccattgtaaa aacaaaaaaa aaaaaaaaaa a	881

&lt;210&gt; 26

&lt;211&gt; 556

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 26

gcaccactcc cctggctcga gtcatctccc gggacactga aacacagaga tattacctgc	60
taagtccacac acctgcctgc agtctcaccct tgggtcctga tatggagaa atcacctgt	120
cctttctctt gctgctagca ggtctgcccgg ctttggaaatc cagtgcacca gttgataaaag	180
acagttccctt ctactatgac tgggagagcc tgcagctggg aggatttattt tttggaggcc	240
tcctgtcat cgctggattt gccatggccc tggatggcaatgtt gtcacatgtt aggcttacc	300
ataagcccaag ttcccttaccc gaaaaagccaa ctccactcat cattccaggc tctgccaata	360
cctgtgtac tgaacacagg accaaatgtt gaggcagggtt ttgcacaact ttctgcccgt	420
cttctctctt ggagacccttc ctctccaggaa tggcttccctt agaacataact gttaaatgtt	480
cattgacagg aaagggtgtg gcaaagctga ttttatatta aactggtctt gctgctaaa	540
aaaaaaaaaaaaaaa aaaaaaaaaa	556

&lt;210&gt; 27

&lt;211&gt; 750

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 27

gctgagtgtg gttctgggtg gaaccctcta cataggccat tatttagcca ttttattccgtt	60
aggcgccccc ttctggactg ggatcgtggc tatgtgtgtt ggagctgttgc cttcccttca	120

caagaaaacgg	ggtggtacct	gtggggccct	gatgaggacc	cttcttgc	tggcaagttt	180
ctgcaccgct	gtggctgcca	tcgttattgg	gtctcgtag	ttgaattatt	actggtattt	240
tctcgagat	gatgtctgtc	aaagagactc	ttcatatgga	tggtccacca	tgcttagaac	300
caactccagtt	cccgaaagaag	ctgataggat	tgccttgc	atatactaca	caagcatgct	360
aaagacccctg	ctcatgagcc	tccaaagctat	gctcttgggt	atctgggtgc	tgtgctcct	420
ggcttctctc	acccctgtat	gtgtctacat	ctggaaaaga	tttttcacaa	aggcggaaac	480
agaggagaag	aaactgctgg	gtgcagctgt	gatctagctt	ttcctcttgc	tccggcgtc	540
cctcctactg	aagcctgaaa	gaagaatcag	gcaggactaa	gaagacccctc	ccccactagc	600
agggccatgg	ccactgcctg	gttctgccc	gcaccacagc	agctctcagc	agcaacttgct	660
tgtctctcca	tccttcaccc	tcctatatcc	ctcctcaggc	agcaacttga	taataaaactc	720
tcctgttatt	gctggcaaaa	aaaaaaaaaa				750

&lt;210&gt; 28

&lt;211&gt; 1896

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 28

gtgaacatct	gtctccctta	ctgcgggtgg	ccagccacag	tgcggggag	ggatctgcac	60
aatgctccag	cacactagcc	tgggttact	cctcgctct	atttggacca	ctaggcaccc	120
agtccaaagg	gccgacctcg	tgcaagacct	ttccatttct	acatgcagaa	tcatggcggt	180
tgcccttgc	ggcagaaaca	aaaacccaca	gatgaattt	acagaagcca	acgaggcctg	240
taagatgctg	ggactgactc	tggccagcag	ggaccaggt	gagtgcgc	agaaatctgg	300
ctttagact	tgcagctatg	gatgggttg	agaacagt	tctgtcatcc	ctcggat	360
ctcaaaaccc	aggtgtggg	agaatggca	aggtgcctg	atggatg	ctccctccag	420
ccaaaagtcc	aaagcctatt	gccacaactc	atccgacac	tgggttaact	cctgcattcc	480
agaaatcg	accacattt	accgggtt	ggacactcaa	acacccgca	cagagttt	540
tgtcagcagc	agcgcctact	tggcttc	ccctgactcc	acaacacctg	tttctgccac	600
cacccggct	ccaccttga	cctccatggc	acggaagaca	aaaaagattt	gtatcacgga	660
agtttataca	gaacctatca	ccatggctac	agaaacagaa	gcatttgg	caagtggagc	720
agcatcaag	aacgaagcag	ctgggtttgg	aggtgtcccc	accgcctgc	tgggtctggc	780
tctccttcc	tttggtgctg	ccgctgtgct	ggctgtttgc	tacgtaaaa	gttatgtgaa	840
ggcctccct	ttcacaacca	agaatcaaca	gaagggaaat	atcgaaacca	aggttgtaaa	900
ggaagagaag	gctgatgacg	tcaacgctaa	tgaagaatca	aagaaaacca	taaaaaccc	960
agaggaggcc	aagagtccac	ccaaaactac	ggtgcgatgc	ttagaagctg	aagtttagat	1020
gcaagagagt	ggagaaggt	cacacgaggc	aagttcatg	ccccggaaac	caaagaagca	1080
agccactgtc	agttcctgca	aaaaaagact	gcagagttca	ccagaaggag	ccctctcctt	1140
actgcagtct	tctctggact	ctaccctctg	gcctccaacc	tcccacagc	ctccctaacc	1200
cttctgtggc	tcacagcaga	ccagagagta	gagggagctt	tcaaagtacc	aggtcctaaa	1260
acagctctta	agctcacact	cagagacagg	cttccaggtt	gcctgacccc	catgaaaggc	1320
cagatccct	gagacatggc	cagccccata	gttcaaatac	tcccacagg	gaaatacacc	1380
acctggccgt	gctctttgg	accaggcaca	tgtaaaataa	ggaaaggaaa	acaacagaag	1440
gtcatggaga	gcctgggtga	cttgagactt	aatctctgga	aagccaaat	aaacagagca	1500
tgagatggga	gctggggcc	cagatagcag	cettgttggc	tgagactgt	aatacaggct	1560
ggggctgaga	agcctctcg	ttaattgtac	tgcagcacgt	agacagactt	tctttcttt	1620
ttactgtgc	tgggtttctc	tagagacaa	tacacgttta	taagaaacct	aaaagcagga	1680
gagccagga	gctgactcag	tggtaaagca	cttgcggc	atgtacaaac	aaggcttcca	1740
gtccaaatccc	cagaatccac	tgacccac	cacacaaa	aacaaacaca	agtatgcatt	1800
tccattttt	acttgaat	caggacccat	ggctgagaaa	ataactgtgt	taaaaggta	1860
aaaaaaaa	aaaaagtaca	aaaaaaaaaa	aaaaaa			1896

&lt;210&gt; 29

&lt;211&gt; 1854

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 29

gccccacatgg	tctggggccaa	cttggctgtg	tttgcacatct	gtttcctgcc	cttgcacatgtg	60
gtcctgaccg	tgcaggcttc	cctgaacctc	aataactgtg	ctgcccggaga	cacccctcagc	120
cgtgcctgt	ccatcacagg	taaactctca	gacaccaact	gctgcctgga	tgccatctgt	180
tactactaca	tggccagaga	gttccagggaa	gcgtccaagc	cagccacgtc	ttccaacaca	240
ccccacaaga	gccaagattc	ccagatcctg	agcctcacct	agaagaagtg	aacacatgcc	300
aaggcccaga	ggaacctgtg	atgtgagcaa	ggagccctgg	atcagcctga	acccctgtg	360
gggtctgagc	actctaggag	accaggattgg	actagagagg	ctgcacatctgc	tcccctgaaa	420
ggaccagagg	actcaggctc	taacgtccga	cctgagggac	cctggAACAA	gaccacatat	480
ctcccatattcc	agatctagaa	accctggca	ccagaatggg	gccttgatgg	ctagccactg	540
agtttaggat	acaccctcc	ccagagttgg	tcctggcaag	gtcctctgtc	acccatgc	600
aagtgtatgg	agataaaagga	cagacatacg	gctcagagaa	ccaggagaca	tctttccaga	660
ggaccctcaa	atggcttctt	ccttttagga	cctttaact	tcatgccaca	tgttagggttg	720
ggcaaaagg	cagcagctgt	ggctctggca	gctgtccctcc	aaggcccatt	actgtcactg	780
ttgctccagc	tctgtattat	gagggttcca	gctcaggaga	cccagggttc	ataacatcat	840
gttgagcaat	cggacctgag	cctcttctgg	ttattttccat	tctatagttg	gactgttgat	900
tcctgaggac	agtggctatg	gtagagggtct	ctggagttt	ttgtgaggaa	gattgtgtt	960
tggtattcat	gtctctgtg	gatgtggccc	caggcttcga	ggatctctgg	agtaaaaggat	1020
gagccacaaa	gccagctttg	agtccaggagc	acatttggag	atgtggtagc	cctgggcttc	1080
cccctcaatg	ctttgatttt	tgtcttggtc	caaattgtac	agctgtaccc	agagccagag	1140
cccctccagc	tcaggggagg	ggggtaactgg	ctctccctac	tctctacccc	tacttcatcc	1200
aaggctact	gcctaaactga	ccctttttt	tgtatgacct	tttctacaaa	aaccaaaaat	1260
ctgttcatcc	ttcagacacc	agagaaaagg	ttccactcaa	gtataaattt	gtgaactgtat	1320
ttcctggagt	tacttacaaa	agcacgggt	ctcttgggtg	ctcagtcact	gaaaaggctc	1380
actcagcata	gataacaatc	cccaaaactgc	accgttagat	taccaatccc	cactaaactt	1440
ccacccatca	cacacacttgc	gacacccatgc	ctgtccaga	aaaaaatgtg	cctagggtgt	1500
gaggaagctg	tggctggac	ccaaagggtgt	ctgaccctct	tcgctctgcc	aaggactact	1560
aacagcttca	tgtatcatcg	cctattcgcc	acagccgtat	tttgcttggtt	tcactggcat	1620
gactgttagc	cgagctgttc	tgtggatcg	agcagcgctt	ttcctgttca	ctgctgtatga	1680
tcatcctaag	ccagagaaaat	ggcttctctg	ccacactggc	ccactctccc	tccagttctc	1740
acatccccctc	caccctctgt	tctgcagttat	tatctaaacc	ttcaccttgg	aaggaaggga	1800
tggtgatct	atataatatc	aagatatagg	atccacaaaaa	aaaaaaaaaa	aaaa	1854

&lt;210&gt; 30

&lt;211&gt; 2866

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 30

ggtttccggag	agataaggcg	cttggccgtt	actaactgga	ctacaaagag	ctggatcgga	60
ccggaaccac	atggctcaac	tcgcccggac	cacccctcc	ccgctgtcat	ggctgctgt	120
gctgtctgc	tatgcactcc	ggaaaggcgg	tggggatata	cgtgtctgg	tgcctacaa	180
ttcgacaggc	gtcttggag	ggtcgaccac	ttgcactgt	agtctgactt	ctaatgagaa	240
tgtactatc	actcaataaa	cctggatgaa	gaaggattca	ggtggatccc	acgctctttgt	300
ggctgtcttc	caccccaaga	agggggccaa	catcaaagag	ccagagaggg	tgaatttttt	360
ggctgccc	caggatctga	ggaacgcattc	tctggccatc	tcgaacttaa	tgttagaaga	420
cgaaggcatc	tatgaatgtc	agattggccac	attccccaga	ggcagtagaa	gcaccaatgc	480
ctggctgaag	gtgcaggccc	gacctaagaa	cactgcagag	gccctggagc	cctctccac	540
cttgatactg	caggatgtgg	ctaaatgcatt	ctctgccaat	ggtcacccctc	ctggacgaaat	600
ctcttggccc	tcgaatgtga	atggaaatgtc	ccgtgaaatg	aaggaaccag	ggtcccagcc	660
gggcaccacc	acagttacca	gctacctctc	catggtacct	tctcgccagg	cagacggcaa	720
gaacatcacc	tgcacggtgg	agcatgaaag	cttacaggag	ctggaccagc	tgctggtgac	780
cctttccaa	ccctatccac	ctgaaaaacgt	gtccatctct	ggctatgacg	gcaactggta	840
tgttggctc	actaacttga	ccctgacctg	tgaagctac	agcaaaaccag	cgccctgacat	900
ggctggatat	aactggagca	cgaacacggg	tgactttccc	aactctgtt	agcggccaggg	960
caatatgctt	ctaatctcca	ccgttagagga	tggctcaat	aacacggtca	ttgtgtgcga	1020
agtcaccaat	gcccttagggt	ctggcaggg	ccaagtgcac	atcattgtt	aagagaaacc	1080
tgagaatatg	cagaaaaata	caagattaca	cctaggctac	atctttctt	tcgtctttgt	1140

cctcgctgt	gtcatcatca	tcgcagcact	atacactata	cgaagatgca	ggcatggtcg	1200
tgctctgcag	tccaatccct	cagagaggga	gaacgtccag	tattcatctg	tgaacggcga	1260
ctgtagactg	aacatgggc	caaacagcac	aagggtacgg	tgctgggtag	acagaactaa	1320
ggaacttcaa	ggcatagcaa	ctggAACCT	actctcataa	atgaagaagc	ctccagagag	1380
actggctgt	cagtgtatg	agcatagcaa	gtttgggggg	tctccagga	tgctgcccga	1440
ttccacgtt	tcaaaaggac	ccatggaggc	cagtgtttg	gctcactctt	gacatctcag	1500
caagctgggg	gggggggggg	gagcataaaag	caaggtttag	tctagctgg	gctatagagc	1560
aaagccctgt	ccatacaca	acaagctaag	gggcttttag	acggtcagaa	actaagtct	1620
tgctttgggt	aaggtaa	ctctaccgca	tgtatgtct	agacttggaa	gacttccaca	1680
cagacctctt	tataagtga	ctccattggg	gctatcccct	cctctcttga	caagggtctct	1740
gtatgtgcc	aaggctaggc	tcaaactcac	agagatatgt	ctgcttctac	ctccccagtg	1800
ctagagttga	aagtatttg	gccactgcac	ttttcttagt	cttctttaa	tgaagtaaag	1860
tatatattta	taaaaagcta	tttagttata	tatatatata	tttttgagac	tatttcata	1920
agcccaagct	aaccta	ttactatgt	gccaagagtg	atggtaaact	aatttatttt	1980
aatttatttg	tcttcaattt	taaccatcac	ccaacccctg	ctcccttcca	tatcttcttt	2040
caatccattt	cattgtctt	ttcttccag	acactattct	gacttacgtc	tccattacaa	2100
acattttatt	gaactacata	aaaatgtgt	aaccacaaaa	aaaaaatgt	tttgtcaaaa	2160
ttgttagttgt	cttctgagg	ctgacctgag	ttctctgata	ccattctctc	cagttgtatc	2220
cagtttctg	taaacaatgt	gactttgtt	ttctcagtag	ctaaaacatc	ccaattatgt	2280
gagtgacac	tttcttact	cattcctctg	tggccacca	gctgggttgg	ttccatatct	2340
gagctattgt	gcatggatt	gtctctgtgg	tgggtttagt	aaactccag	gaatgcctgt	2400
acatgtttgt	agaggccaga	agaaggcaca	aaatctttag	ccaggcttac	atgcacttgt	2460
gagtagcccc	acataggtgc	taagaaccca	gttcaggtcc	tctgctgtgg	gatgggtggc	2520
tgtcacac	aaggctgtc	ccggcttagc	aaaggtctgg	aactccggag	ccgggtgggct	2580
gtgatttaca	ccagcatggg	atggaaggag	ttggacctcg	cctcctggc	acctggctcc	2640
tgtcacatag	ctacagcctc	ccacagcccc	cctataaggga	ggtatgcagc	atcaatcaca	2700
tagtagctgc	actaaggccct	cccacatgca	aataaggttt	ccccaaactc	tcagtc当地	2760
ccaatgaaaa	gtacctgtc	tcaaacccta	aatcatcccc	aaaactctgt	aagtccatc	2820
agggaataaa	atgtgtgt	aaactaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2866

<210> 31  
<211> 1093  
<212> DNA  
<213> Mouse

<400> 31						
gcgaccactg	agacctttag	actcagacac	caagagagat	gtttctagtt	gggagcctcg	60
ttgtcctctg	tgggctgctg	gcccacagca	cagcacagct	ggcaggcttg	ccattgcccc	120
tggccaggg	tccaccctt	ccactgaacc	agggccccc	tttgccactg	aaccagggcc	180
agctgttgc	cctggctcag	ggtctgcctt	tggctgtaa	cccagca	ccttcaatc	240
ccacagatct	tcttgctt	aaattcacag	atgctctcag	cggtggctg	ctgtctgggg	300
ggctgctggg	cattttggaa	aatattccac	tcctggatgt	tataaagtct	ggaggaggca	360
attctaattgg	ccttgttggg	ggcctgctgg	gaaaactgac	gtcatca	ttctcttctga	420
acaacatcct	cgacataaaa	atcactgtatc	cgcagctgt	agaacttgg	tttgtgcaga	480
gtcctgtatgg	ccatcgctc	tatgtcacca	tccctctggg	tttgacactc	aacgtaaata	540
tgcccgtatgt	tggaaagtctt	ttgcaatttgg	ctgtgaagat	gaacattact	gcagaagtct	600
tagccgtgaa	agacaatcag	gggaggattc	atctgttct	tggtactgc	acccactccc	660
ctggcagcc	gaaaatcagc	ttgtctcaatg	gagtcaactc	tgttcaaa	tttttagaca	720
acccacagg	gatattgact	aaagtccctt	ctgagctgt	ccagggcaag	gtatgtcctc	780
tggtcaatgg	gattctcagc	ggtttggatg	tcaccctgg	gcacaacatt	gctgaattac	840
tgatccatgg	actacagtt	gtcatcaaa	tttaggcata	ccaggaagga	aggctatctt	900
ggctgagctg	aatcatttct	tgctgctcag	tctcctgcct	tttgccca	gttccatggc	960
tcacagaaa	gggcccacat	cctggaaaat	tatgtcttcc	ttctcctcac	ggagcctgtat	1020
ctcttccat	caggcacat	taatcctgt	atcctca	aataaaatag	ctcttcatct	1080
gcaaaaaaaa	aaa					1093

<210> 32

<211> 1353  
 <212> DNA  
 <213> Mouse

<400> 32

gaaacagtat	gagcaaacac	tgagctgagg	ggagcttctg	attaagagcg	ctccccagcg	60
aggcccgagg	ccgtgaacct	tcccagcaag	agggtggtgg	ttgctcctgg	aagcctgcgc	120
ccagcagctg	aagccatggc	caccaccacg	tgccaggtgg	tagggcttct	cctgtccctc	180
ctgggtctgg	ccggctgcat	agccgcccact	gggatggaca	tgtggagcac	tcaagacctg	240
tatgacaacc	cagtcaccgc	cgtgttccag	catgaaggc	tctggaggag	ttgcgtgcaa	300
cagagctcgg	ggttcaccga	gtgccggcca	tacttcacca	tcctgggct	tccagccatg	360
ctgcaagctg	tacgagccct	gatgatctgt	ggcattgttc	tgggggtcat	cggtatccctc	420
gtgtccatct	tcgcccgtaa	gtgcattcgc	attggtagca	tggatgactc	tgccaaggcc	480
aagatgactc	tgacttctgg	gatcttgttc	atcatctccg	gcatctgtgc	aatcattgg	540
gtgtctgtgt	ttgccaacat	gctgggtgacc	aacttctgga	tgtccacacgc	taacatgtac	600
agcggcatgg	gccccatggg	tggcatggtg	cagaccgttc	agaccaggt	cacccctcggt	660
gcagctctgt	tcgtgggctg	ggttgcgtgg	ggcctcaccc	tgattggggg	agtatgatgt	720
tgcattcgct	gccgtggcct	gacaccagat	gacagcaact	tcaaagctgt	gtcttaccat	780
gcctctggcc	aaaatgttgc	ctacaggcct	ggaggctta	aggccagcac	tggctttggg	840
tccaaacacca	gaaacaaagaa	gatctacgt	gggggtgccc	gcacagaaga	cgatgaacag	900
tctcatccta	ccaagtatga	ctatgtgtag	tgctctaaga	ccgcacaacc	tgtgtgcagg	960
aggaaccctt	ccccaaagaag	agctcaccac	aaagcaacgg	gagtctacct	tgttcccttg	1020
ttgatttcaa	ctgacatctg	aaagttggta	aagcctgatt	ttcatccata	gggaggctag	1080
acagcttgg	ccacatgtgt	ctgcctctaa	atatcccata	acaaaacacgc	ttagttatcg	1140
tttataggtt	agaggccata	acactcaatt	tagcccaacc	ctctgctttt	taccgtagac	1200
tttcttttca	tctggtgatg	gaatggaaatt	tgactcacag	actaataactt	taatggttta	1260
gagaaacttt	ccttcctcgt	acttaataag	cctgtgtatg	gtcgattttc	cagcttgacc	1320
accaaggaa	attttaaaaa	aaaaaaaaaa	aaa			1353

<210> 33  
 <211> 1046  
 <212> DNA  
 <213> Mouse

<400> 33

gcctcagtcc	acagctgtct	ccccagctgc	ttccagtgaa	caccccgca	gtctaggctc	60
ccacagcaat	gagttgggg	agggacaact	tctggatcat	cttagctatg	tccatcatct	120
tcatctccct	ggtcctgggt	ctcatcctgt	actgtgtctg	caggtggcag	cttagacaag	180
gcaggaactg	ggaaattgt	aagccctcaa	aacaggatgg	aagagatgaa	gaaaagatgt	240
atgagaatgt	tcttaattct	tcaccaggcc	agttacctgc	tctgccaccc	aggggttcac	300
cttttccagg	agacctagcc	ccacaggaag	ctccaagaca	accctcagct	tggtaactcat	360
cagtgaagaa	agtttaggaac	aagaaggct	ttgctatctc	gggctccacc	gagccagaaa	420
atgattatga	tgatgttgag	attccagca	ccaccgaaac	ccagcactct	aaaaccacac	480
ctttttggca	agctgaagt	ggtttacaca	gctcgttta	gaatactcta	gaatagccgg	540
attataacac	aagcacttcc	taatccccag	aggaagccac	ctcagccatg	tgaagactac	600
agcagaagac	aggacagctt	gatgttccc	aggctccaga	tgtttctgtt	gctccagatg	660
tttctgtgc	tccagatgtt	tctgttgctc	caaattttc	tgctgctcca	gatgtttctg	720
ttgctccaga	tggttctgtt	gctccagatg	ctcctgtgc	tccagatgt	cctgtatgttt	780
ctgacactgc	agaagctcta	ccccaaagatt	ctgaggatgt	ggccttgca	cctttgtgga	840
ggaagtttcc	ttagtgcaga	ccactggcc	tgtgagaact	gactcatttc	tcaacatttt	900
ctttcgttcc	ctgggtgaat	gtagctgtaa	ggcagtgtact	ctcaaccc	ctaattgcagg	960
gatccttcaa	tacaatttct	tatgtgtgt	gatcctcaac	cataaaat	ttttgttgct	1020
acttcaaaaa	aaaaaaaaaa	aaaaaa				1046

<210> 34  
 <211> 1261  
 <212> DNA

&lt;213&gt; Mouse

&lt;400&gt; 34

gcacagacgg	gtaaaccgct	tggAACCTC	gaggaaaaag	aggctacgaa	aacTTTTCC	60
taagaggcta	caaatttGGA	agcaggGAAA	acccagacat	gagatgtttt	tagTTTATTt	120
ctccagaagg	gggcactgta	tcaattatgt	gaaggacat	gcagacAGCC	tagTCCATG	180
gtgctgtgg	gttaggactga	ggagCCCTCT	ggccAGACCC	cagcacGGCC	atgtCTCTCC	240
caaggatcat	gttcctggag	gtcacGCCCC	tggTCCTCT	cataAGTGGC	tgtcacAGC	300
agctctctgg	aggtatttgg	aacattCTGC	tgtcacACAT	gggactGCTC	ttcCTGAAGC	360
ccacgctgtt	cgtggaaac	atggGAAGAA	aggaAGACGT	gttGtGtGt	gctcAGTAGA	420
cttccacaa	gccacCTCTC	tcttCTGAAA	cgtcactGAA	tggactGGAG	aggactGCGG	480
gtttataaaa	ctgCTTTTA	tctGAGAAcA	atggGTTGG	aaactAGTCT	cttttCTTCC	540
cactttaca	gagCTTCTCA	aatCATTCT	ccaggCCCTG	acttGGACAG	gtAGGGGGGC	600
agaccctggg	tcccaAGGTG	cactGTCCAG	gcacACTGCC	cacATTGCTA	agagaAGAGG	660
ccctgctgcc	agtggACCCt	tcacCCcaca	cgagACACCT	gttTGCCTT	tagGACACCC	720
tcctctagag	agtGGTGTG	gaaggAGGGG	acctATGTA	ggagttGGGG	caggcatGAA	780
tctgcCAAAT	actGGATAATG	gatCCAAAGGC	tggCCcAGGC	acctGCACT	ccAGTGAAGT	840
gtcagcaggT	ggcGCTGCTG	cccGCCAGGC	ttcacAGAGT	ccTTTAgGG	agtCTGCTCC	900
cagatCCCTT	ctggTGCACA	cttactGGAT	gtcactGCAA	gtCTCACCT	ctGAGCAGGT	960
gttgcaccac	agtGGCCTG	accCTGGCC	cgcaACGGCA	actGCTGAAG	gcAGCCATTG	1020
cctcaGGCCAT	tctcaAGACC	cttcaATTtT	taaaAGCAGT	tcgattCTGT	aatATTtTtT	1080
tttCTTTTtG	aggatGTTTc	gttGCCCCGc	agactGACTG	cagtGTGcAC	cattGcATGA	1140
gccCTGCCTC	agtGCCCTGT	ggctCCCTGG	gcactGCTGC	ccCTCTGTCT	aaAGCTGACT	1200
gtggcAGCAC	tGCCCAACAA	taaAGCTGAC	ctaaaAGCTG	aaaaaaaaaa	aaaaaaaaaa	1260
a						1261

&lt;210&gt; 35

&lt;211&gt; 995

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 35

gctcacCCGC	gtccGGGCGC	gcgcAGGCCC	cgtCTCCTTg	cTTCCAGGC	ctcatGCGCT	60
cccgCGCCTG	gctcccGCGA	ccgCTGCCG	gaggAGGGGG	gcccGCGTTG	tctGCGCGTC	120
tacgcAGGCC	tcatAGGCAC	cgtGGTcACC	cccaACTACC	tggacaACGT	gagcGCGCgc	180
gttgcGCCt	ggtGCGGCTG	tgcGGCCAGT	ggAAACCGGC	gcgaAGAAATG	cgaAGCCTTC	240
cgcaAGCTCT	ttacaAGGAA	ccCCTGCTTg	gatGGTGCcA	tacaAGCCTT	tgacAGCTTg	300
cagccatCAG	ttctGcAGGA	ccAGACTGCT	gggtGCTGTT	tcccGCGGt	gtcCTGGCTG	360
tatgcACTCA	ctgCCCTGGC	tctCCAGGC	ctgCTCTGAT	tagGAACATG	aaccGTGGAC	420
gacacAGCTG	actGCCATGT	ctcccGATGA	ctgCTCACTG	agCTGAAACT	ccCTTGCCT	480
caggTCTGCT	gccCTTtGCA	ggCCTGGACC	cttGtGtGGC	tgtCCTCTGG	attGGGGGCT	540
ggaggCTAGG	gtctGACTGA	aaAGCCTGTG	ttcccCTGTC	agtagGCATC	ttGtCCGTT	600
tcttCCCAT	cctAGAGCTG	agcACCCATA	gatGAGGCt	cattGGGtC	cctGGGCTTA	660
cagAGCAGGA	cAGAGACTAG	ccccCGCTCC	tagAAATTG	aactGTCCTT	ttccaAGATG	720
acaAGGCACT	aaggAGATCA	tatGAACAGG	ctgACAGACa	aggCTGCTA	aatACCCtCC	780
cagttagCCA	ttattCACCa	ttaAGCTTAC	ccgtGTCACA	gcactGACGT	ggctGtCAC	840
ctatgACACA	gtgtGTAAGAC	attaAGGAGA	gactGAGGTC	cCTCTGTC	agcACCCCCAC	900
tggCTTCCCA	ggCTTCCCT	gccATGGTT	ccccAGCACC	tgcAGGGGCT	caataAAACCC	960
atgtGCACTG	agaaaaaaaaa	aaaaaaaaaa	aaaaaa			995

&lt;210&gt; 36

&lt;211&gt; 747

&lt;212&gt; PRT

&lt;213&gt; Rat

&lt;400&gt; 36

Glu Ala Thr Val Ile Thr Thr Glu Lys Arg Glu Arg Pro Ala Pro Pro

1	5	10	15												
Arg	Glu	Leu	Leu	Val	Pro	Gln	Ala	Glu	Val	Thr	Ala	Arg	Ser	Leu	Arg
				20				25				30			
Leu	Gln	Trp	Val	Pro	Gly	Ser	Asp	Gly	Ala	Ser	Pro	Ile	Arg	Tyr	Phe
				35			40				45				
Thr	Val	Gln	Val	Arg	Glu	Leu	Pro	Gly	Gly	Glu	Trp	Gln	Thr	Tyr	Ser
				50			55			60					
Ser	Ser	Ile	Ser	His	Glu	Ala	Thr	Leu	Cys	Ala	Val	Glu	Arg	Leu	Arg
				65			70			75			80		
Pro	Phe	Thr	Ser	Tyr	Lys	Leu	Arg	Leu	Lys	Ala	Thr	Asn	Asp	Ile	Gly
				85				90				95			
Asp	Ser	Asp	Phe	Ser	Ala	Glu	Thr	Glu	Ala	Val	Thr	Thr	Leu	Gln	Asp
				100				105				110			
Val	Pro	Gly	Glu	Pro	Pro	Gly	Ser	Val	Ser	Ala	Thr	Pro	His	Thr	Thr
				115				120				125			
Ser	Ser	Val	Leu	Ile	Gln	Trp	Gln	Pro	Pro	Arg	Asp	Glu	Ser	Leu	Asn
				130				135				140			
Gly	Leu	Leu	Gln	Gly	Tyr	Arg	Ile	Tyr	Tyr	Arg	Glu	Leu	Glu	Ser	Glu
				145				150			155			160	
Thr	Gly	Leu	Ser	Pro	Glu	Pro	Lys	Thr	Leu	Lys	Ser	Pro	Ser	Ala	Leu
				165				170				175			
Arg	Ala	Glu	Leu	Thr	Ala	Gln	Ser	Ser	Phe	Lys	Thr	Val	Asn	Ser	Ser
				180					185				190		
Ser	Thr	Leu	Thr	Thr	Tyr	Glu	Leu	Thr	His	Leu	Lys	Lys	Tyr	Arg	Arg
				195				200				205			
Tyr	Glu	Val	Ile	Met	Thr	Ala	Tyr	Asn	Ile	Ile	Gly	Glu	Ser	Pro	Ala
				210				215				220			
Ser	Val	Pro	Val	Glu	Val	Phe	Val	Gly	Glu	Ala	Ala	Pro	Ala	Met	Ala
				225				230			235			240	
Pro	Gln	Asn	Ile	Gln	Val	Thr	Pro	Leu	Thr	Ala	Ser	Gln	Leu	Glu	Val
				245					250				255		
Thr	Trp	Asp	Pro	Pro	Pro	Glu	Ser	Gln	Asn	Gly	Asn	Ile	Gln	Gly	
				260				265				270			
Tyr	Lys	Val	Tyr	Tyr	Trp	Glu	Ala	Asp	Ser	Arg	Asn	Glu	Thr	Glu	Lys
				275				280				285			
Met	Lys	Val	Leu	Phe	Leu	Pro	Glu	Pro	Val	Val	Lys	Ile	Lys	Asp	Leu
				290				295				300			
Thr	Ser	His	Thr	Lys	Tyr	Leu	Val	Ser	Ile	Ser	Ala	Phe	Asn	Ala	Ala
				305				310				315			320
Gly	Asp	Gly	Pro	Arg	Ser	Asp	Pro	Cys	Gln	Gly	Arg	Thr	His	Gln	Ala
				325					330				335		
Ala	Pro	Gly	Pro	Pro	Ser	Phe	Leu	Glu	Phe	Ser	Glu	Ile	Thr	Ser	Thr
				340					345				350		
Thr	Leu	Asn	Val	Ser	Trp	Gly	Glu	Pro	Ser	Ala	Ala	Asn	Gly	Ile	Leu
				355				360				365			
Gln	Gly	Tyr	Arg	Val	Val	Tyr	Glu	Pro	Leu	Ala	Pro	Val	Gln	Gly	Val
				370				375				380			
Ser	Lys	Val	Val	Thr	Val	Asp	Val	Lys	Gly	Asn	Trp	Gln	Arg	Trp	Leu
				385				390				395			400
Lys	Val	Arg	Asp	Leu	Thr	Lys	Gly	Val	Thr	Tyr	Phe	Phe	Arg	Val	Gln
				405					410				415		
Ala	Arg	Thr	Ile	Ala	Tyr	Gly	Pro	Glu	Leu	Gln	Ala	Asn	Val	Thr	Ala
				420					425				430		
Gly	Pro	Ala	Glu	Gly	Ser	Pro	Gly	Ser	Pro	Arg	Asn	Val	Leu	Val	Thr
				435				440				445			
Lys	Ser	Ala	Ser	Glu	Leu	Thr	Leu	Gln	Trp	Thr	Glu	Gly	Asn	Thr	Gly
				450				455				460			

Asn Thr Pro Thr Thr Gly Tyr Val Ile Glu Ala Arg Pro Ser Asp Glu  
 465 470 475 480  
 Gly Leu Trp Asp Met Phe Ala Lys Asp Ile Pro Arg Ser Ala Thr Ser  
 485 490 495  
 Tyr Thr Val Gly Leu Asp Lys Leu Arg Gln Gly Val Thr Tyr Glu Phe  
 500 505 510  
 Arg Val Val Ala Val Asn Lys Ala Gly Phe Gly Glu Pro Ser Arg Pro  
 515 520 525  
 Ser Ile Ala Val Ser Ala Gln Ala Glu Ala Pro Phe Tyr Glu Glu Trp  
 530 535 540  
 Trp Phe Leu Leu Val Ile Ala Leu Ser Ser Leu Leu Leu Val Leu Leu  
 545 550 555 560  
 Val Val Phe Val Leu Val Leu His Gly Gln Ser Lys Lys Tyr Lys Asn  
 565 570 575  
 Cys Gly Ser Gly Lys Gly Ile Ser Asn Met Glu Glu Thr Val Thr Leu  
 580 585 590  
 Asp Asn Gly Gly Phe Ala Ala Leu Glu Leu Asn Ser Arg His Leu Asn  
 595 600 605  
 Val Lys Ser Thr Phe Ser Lys Lys Asn Gly Thr Arg Ser Pro Pro Arg  
 610 615 620  
 Pro Ser Pro Gly Gly Leu His Tyr Ser Asp Glu Asp Ile Cys Asn Lys  
 625 630 635 640  
 Tyr Asn Gly Ala Val Leu Thr Glu Ser Val Asn Leu Lys Glu Lys Ser  
 645 650 655  
 Val Asp Gly Ser Glu Ser Glu Ala Ser Asp Ser Asp Tyr Glu Glu Ala  
 660 665 670  
 Leu Pro Lys His Ser Phe Val Asn His Tyr Met Ser Asp Pro Thr Tyr  
 675 680 685  
 Tyr Asn Phe Trp Lys Arg Arg Pro Pro Ala Ala Ala Pro His Arg Tyr  
 690 695 700  
 Glu Ala Val Ala Gly Ala Glu Ala Gly Pro His Leu His Thr Val Ile  
 705 710 715 720  
 Thr Thr Gln Ser Ala Gly Gly Val Tyr Thr Pro Ala Gly Pro Gly Ala  
 725 730 735  
 Arg Ala Pro Leu Thr Gly Phe Ser Ser Phe Val  
 740 745

&lt;210&gt; 37

&lt;211&gt; 205

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 37

Met Leu Gly Thr Leu Val Trp Met Leu Ala Val Gly Phe Leu Leu Ala  
 1 5 10 15  
 Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro  
 20 25 30  
 Ala Arg Pro Arg Asp Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln  
 35 40 45  
 Leu Tyr Gly Arg Leu Ala Ala Gly Val Leu Ser Ala Phe His His Thr  
 50 55 60  
 Leu Gln Leu Gly Pro Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala  
 65 70 75 80  
 Gly Gly Arg Ala Ala Asp Arg Arg Phe Arg Pro Pro Thr Asn Leu Arg  
 85 90 95  
 Ser Val Ser Pro Trp Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Phe  
 100 105 110

Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr  
 115 120 125  
 Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Thr Pro Val Phe  
 130 135 140  
 Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala Cys Ala Gly Gly Arg  
 145 150 155 160  
 Ser Val Tyr Ala Glu His Tyr Ile Thr Ile Pro Val Gly Cys Thr Cys  
 165 170 175  
 Val Pro Glu Pro Asp Lys Ser Ala Asp Ser Ala Asn Ser Ser Met Asp  
 180 185 190  
 Lys Leu Leu Leu Gly Pro Ala Asp Arg Pro Ala Gly Arg  
 195 200 205

&lt;210&gt; 38

&lt;211&gt; 238

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 38

Met Leu Cys Phe Leu Arg Gly Met Ala Phe Val Pro Phe Leu Leu Val  
 1 5 10 15  
 Thr Trp Ser Ser Ala Ala Phe Ile Ile Ser Tyr Val Val Ala Val Leu  
 20 25 30  
 Ser Gly His Val Asn Pro Phe Leu Pro Tyr Ile Ser Asp Thr Gly Thr  
 35 40 45  
 Thr Pro Pro Glu Ser Gly Ile Phe Gly Phe Met Ile Asn Phe Ser Ala  
 50 55 60  
 Phe Leu Gly Ala Ala Thr Met Tyr Thr Arg Tyr Lys Ile Val Glu Lys  
 65 70 75 80  
 Gln Asn Glu Thr Cys Tyr Phe Ser Thr Pro Val Phe Asn Leu Val Ser  
 85 90 95  
 Leu Ala Leu Gly Leu Val Gly Cys Ile Gly Met Gly Ile Val Ala Asn  
 100 105 110  
 Phe Gln Glu Leu Ala Val Pro Val Val His Asp Gly Gly Ala Leu Leu  
 115 120 125  
 Ala Phe Val Cys Gly Val Val Tyr Thr Leu Leu Gln Ser Ile Ile Ser  
 130 135 140  
 Tyr Lys Ser Cys Pro Gln Trp Asn Ser Leu Thr Thr Cys His Val Arg  
 145 150 155 160  
 Met Ala Ile Ser Ala Val Ser Cys Ala Ala Val Val Pro Met Ile Ala  
 165 170 175  
 Cys Ala Ser Leu Ile Ser Ile Thr Lys Leu Glu Trp Asn Pro Lys Glu  
 180 185 190  
 Lys Asp Tyr Ile Tyr His Val Val Ser Ala Ile Cys Glu Trp Thr Val  
 195 200 205  
 Ala Phe Gly Phe Ile Phe Tyr Phe Leu Thr Phe Ile Gln Asp Phe Gln  
 210 215 220  
 Ser Val Thr Leu Arg Ile Ser Thr Glu Ile Asn Asp Asp Phe  
 225 230 235

&lt;210&gt; 39

&lt;211&gt; 492

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 39

Leu Arg Leu Leu Leu Ala Trp Val Ala Ala Val Pro Ala Leu Gly Gln

1	5	10	15
Val Pro Trp	Thr Pro Glu	Pro Arg Ala	Ala Cys Gly
20	25	30	Pro Ser Ser Cys
Tyr Ala Leu	Phe Pro Arg Arg	Arg Thr Phe Leu	Glu Ala Trp Arg Ala
35	40	45	
Cys Arg Glu	Leu Gly Gly	Asn Leu Ala	Thr Pro Arg Thr Pro Glu Glu
50	55	60	
Ala Gln Arg	Val Asp Ser	Leu Val Gly	Val Gly Pro Ala Asn Gly
65	70	75	Leu
Leu Trp Ile	Gly Leu Gln Arg	Gln Ala Arg Gln	Cys Gln Pro Gln Arg
85	90	95	
Pro Leu Arg	Gly Phe Ile Trp	Thr Thr Gly Asp Gln Asp	Thr Ala Phe
100	105	110	
Thr Asn Trp	Ala Gln Pro Ala	Thr Glu Gly	Pro Cys Pro Ala Gln Arg
115	120	125	
Cys Ala Ala	Leu Glu Ala Ser	Gly Glu His Arg	Trp Leu Glu Gly Ser
130	135	140	
Cys Thr Leu Ala	Val Asp Gly	Tyr Leu Cys	Gln Phe Gly Phe Glu Gly
145	150	155	160
Ala Cys Pro Ala	Leu Pro Leu Glu Val	Gly Gln Ala Gly	Pro Ala Val
165	170	175	
Tyr Thr Thr	Pro Phe Asn Leu Val	Ser Ser Glu Phe	Glu Trp Leu Pro
180	185	190	
Phe Gly Ser	Val Ala Ala Val	Gln Cys Gln Ala Gly	Arg Gly Ala Ser
195	200	205	
Leu Leu Cys Val	Lys Gln Pro Ser	Gly Gly Val	Gly Trp Ser Gln Thr
210	215	220	
Gly Pro Leu Cys	Pro Gly Thr Gly	Cys Gly Pro Asp Asn	Gly Gly Cys
225	230	235	240
Glu His Glu Cys	Val Glu Glu Val	Asp Gly Ala Val	Ser Cys Arg Cys
245	250	255	
Ser Glu Gly	Phe Arg Leu Ala Ala	Asp Gly His Ser	Cys Glu Asp Pro
260	265	270	
Cys Ala Gln Ala	Pro Cys Glu Gln	Gln Cys Glu Pro	Gly Gly Pro Gln
275	280	285	
Gly Tyr Ser	Cys His Cys Arg	Leu Gly Phe Arg	Pro Ala Glu Asp Asp
290	295	300	
Pro His Arg	Cys Val Asp	Thr Asp Glu Cys	Gln Ile Ala Gly Val
305	310	315	Cys
Gln Gln Met	Cys Val Asn	Tyr Val Gly	Gly Phe Glu Cys Tyr Cys Ser
325	330	335	
Glu Gly His	Glu Leu Glu Ala Asp	Gly Ile Ser Cys	Ser Pro Ala Gly
340	345	350	
Ala Met Gly	Ala Gln Ala Ser	Gln Asp Leu Arg	Asp Glu Leu Leu Asp
355	360	365	
Asp Gly	Glu Glu Gly	Glu Asp Glu Glu	Pro Trp Glu Asp Phe Asp
370	375	380	
Gly Thr Trp	Thr Glu Glu Gln	Gly Ile Leu	Trp Leu Ala Pro Thr His
385	390	395	400
Pro Pro Asp	Phe Gly Leu Pro	Tyr Arg Pro Asn	Phe Pro Gln Asp Gly
405	410	415	
Glu Pro Gln	Arg Leu His	Leu Glu Pro	Thr Trp Pro Pro Pro Leu Lys
420	425	430	
Ala Pro Lys	Gly Pro Gln	Gln Pro Pro Arg	Gly Ala Ala Lys Thr Pro
435	440	445	
Lys Gly Asn	Pro Ala Asn	Pro Thr His	Thr Thr Phe Cys Pro Gln Asp
450	455	460	

Leu Cys Tyr Phe Ser Tyr Thr Pro Thr Pro Glu Pro Cys Pro Pro Thr  
 465 470 475 480  
 Cys His Gly Pro Cys His Thr Ser Ser Cys Val Leu  
 485 490

<210> 40

<211> 464

<212> PRT

<213> Mouse

<400> 40

Met Gly Arg Ala Trp Gly Leu Leu Val Gly Leu Leu Gly Val Val Trp  
 1 5 10 15  
 Leu Leu Arg Leu Gly His Gly Glu Glu Arg Arg Pro Glu Thr Ala Ala  
 20 25 30  
 Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys  
 35 40 45  
 Asp Val Glu Thr Ile Asp Lys Phe Asn Asn Tyr Arg Leu Phe Pro Arg  
 50 55 60  
 Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn  
 65 70 75 80  
 Leu Lys Lys Pro Cys Pro Phe Trp Asn Asp Ile Asn Gln Cys Gly Arg  
 85 90 95  
 Arg Asp Cys Ala Val Lys Pro Cys His Ser Asp Glu Val Pro Asp Gly  
 100 105 110  
 Ile Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Arg Ile Glu  
 115 120 125  
 Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu Ser  
 130 135 140  
 Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp Ser  
 145 150 155 160  
 Ser Asp Ser Phe Cys Glu Ile Asp Asp Ile Gln Ser Pro Asp Ala Glu  
 165 170 175  
 Tyr Val Asp Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly  
 180 185 190  
 Pro Asp Ala Trp Arg Ile Trp Ser Val Ile Tyr Glu Glu Asn Cys Phe  
 195 200 205  
 Lys Pro Gln Thr Ile Gln Arg Pro Leu Ala Ser Gly Arg Gly Lys Ser  
 210 215 220  
 Lys Glu Asn Thr Phe Tyr Asn Trp Leu Glu Gly Leu Cys Val Glu Lys  
 225 230 235 240  
 Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala Ser Ile Asn Val  
 245 250 255  
 His Leu Ser Ala Arg Tyr Leu Leu Gln Asp Thr Trp Leu Glu Lys Lys  
 260 265 270  
 Trp Gly His Asn Val Thr Glu Phe Gln Gln Arg Phe Asp Gly Ile Leu  
 275 280 285  
 Thr Glu Gly Glu Gly Pro Arg Arg Leu Arg Asn Leu Tyr Phe Leu Tyr  
 290 295 300  
 Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro Phe Phe Glu Arg  
 305 310 315 320  
 Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Val Gln Asp Ala Glu Asn  
 325 330 335  
 Lys Ala Leu Leu Glu Ile Leu His Glu Ile Lys Ser Phe Pro Leu  
 340 345 350  
 His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys Asn Glu Ala His  
 355 360 365

Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg Ile  
 370 375 380  
 Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln  
 385 390 395 400  
 Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu  
 405 410 415  
 Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe Gln Leu Thr  
 420 425 430  
 Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr  
 435 440 445  
 Ser Val Arg Glu Leu Glu Asn Phe Arg His Leu Leu Gln Asn Val His  
 450 455 460

<210> 41  
 <211> 148  
 <212> PRT  
 <213> Rat

<400> 41  
 Leu Asn Trp Gln Ile Lys Lys Tyr Asp Thr Lys Ala Ala Tyr Cys Gln  
 1 5 10 15  
 Ser Lys Leu Ala Val Val Leu Phe Thr Lys Glu Leu Ser Arg Arg Leu  
 20 25 30  
 Gln Gly Thr Gly Val Thr Val Asn Ala Leu His Pro Gly Val Ala Arg  
 35 40 45  
 Thr Glu Leu Gly Arg His Thr Gly Met His Asn Ser Ala Phe Ser Gly  
 50 55 60  
 Phe Met Leu Gly Pro Phe Phe Trp Leu Leu Phe Lys Ser Pro Gln Leu  
 65 70 75 80  
 Ala Ala Gln Pro Ser Thr Tyr Leu Ala Val Ala Glu Glu Leu Glu Ser  
 85 90 95  
 Val Ser Gly Lys Tyr Phe Asp Gly Leu Arg Glu Lys Ala Pro Ser Pro  
 100 105 110  
 Glu Ala Glu Asp Glu Glu Val Ala Arg Arg Leu Trp Thr Glu Ser Ala  
 115 120 125  
 His Leu Val Gly Leu Asp Met Ala His Gly Ser Ser Gly Arg Gly His  
 130 135 140  
 Ser Ile Ser Arg  
 145

<210> 42  
 <211> 228  
 <212> PRT  
 <213> Mouse

<400> 42  
 Met Gly Phe Leu Leu Leu Leu Leu His Ala Ala Ile Ala Gly His  
 1 5 10 15  
 Lys Asn Tyr Gly Thr His Asn His Cys Trp Leu Ser Leu His Arg Gly  
 20 25 30  
 Phe Ile Trp Ser Phe Leu Gly Pro Ala Ala Ile Ile Leu Ile Asn  
 35 40 45  
 Leu Val Phe Tyr Phe Leu Ile Ile Trp Ile Leu Arg Ser Lys Leu Ser  
 50 55 60  
 Ser Leu Asn Lys Glu Val Ser Thr Leu Gln Asp Thr Lys Val Met Thr  
 65 70 75 80  
 Phe Lys Ala Ile Val Gln Leu Phe Val Leu Gly Cys Ser Trp Gly Ile

85	90	95	
Gly Leu Phe Ile Phe Ile Glu Val	Gly Lys Thr Val Arg	Leu Ile Val	
100	105	110	
Ala Tyr Leu Phe Thr Ile Ile Asn Val	Leu Gln Gly Val	Leu Ile Phe	
115	120	125	
Met Val His Cys Leu Leu Asn Arg Gln Val	Arg Met Glu Tyr Lys Lys		
130	135	140	
Trp Phe His Arg Leu Arg Lys Glu Val	Glu Ser Glu Ser Thr Glu Val		
145	150	155	160
Ser His Ser Thr Thr His Thr Lys Met	Gly Leu Ser Leu Asn Leu Glu		
165	170	175	
Asn Phe Cys Pro Thr Gly Asn Leu His	Asp Pro Ser Asp Ser Ile Leu		
180	185	190	
Pro Ser Thr Glu Val Ala Gly Val	Tyr Leu Ser Thr Pro Arg Ser His		
195	200	205	
Met Gly Ala Glu Asp Val Asn Ser	Gly Thr His Ala Tyr Trp Ser Arg		
210	215	220	
Thr Ile Ser Asp			
225			

&lt;210&gt; 43

&lt;211&gt; 373

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 43

Met Lys Glu Tyr Val Met Leu Leu Leu Ala Val Cys Ser Ala Lys			
1	5	10	15
Pro Phe Phe Ser Pro Ser His Thr Ala Leu Lys Asn Met	Met Leu Lys		
20	25	30	
Asp Met Glu Asp Thr Asp Asp Asp Asn Asp Asp Asp Asn Ser			
35	40	45	
Leu Phe Pro Thr Lys Glu Pro Val Asn Pro Phe Phe Pro Phe Asp Leu			
50	55	60	
Phe Pro Thr Cys Pro Phe Gly Cys Gln Cys Tyr Ser Arg Val Val His			
65	70	75	80
Cys Ser Asp Leu Gly Leu Thr Ser Val Pro Asn Asn Ile Pro Phe Asp			
85	90	95	
Thr Arg Met Val Asp Leu Gln Asn Asn Lys Ile Lys Glu Ile Lys Glu			
100	105	110	
Asn Asp Phe Lys Gly Leu Thr Ser Leu Tyr Ala Leu Ile Leu Asn Asn			
115	120	125	
Asn Lys Leu Thr Lys Ile His Pro Lys Thr Phe Leu Thr Thr Lys Lys			
130	135	140	
Leu Arg Arg Leu Tyr Leu Ser His Asn Gln Leu Ser Glu Ile Pro Leu			
145	150	155	160
Asn Leu Pro Lys Ser Leu Ala Glu Leu Arg Ile His Asp Asn Lys Val			
165	170	175	
Lys Lys Ile Gln Lys Asp Thr Phe Lys Gly Met Asn Ala Leu His Val			
180	185	190	
Leu Glu Met Ser Ala Asn Pro Leu Glu Asn Asn Gly Ile Glu Pro Gly			
195	200	205	
Ala Phe Glu Gly Val Thr Val Phe His Ile Arg Ile Ala Glu Ala Lys			
210	215	220	
Leu Thr Ser Ile Pro Lys Gly Leu Pro Pro Thr Leu Leu Glu Leu His			
225	230	235	240
Leu Asp Phe Asn Lys Ile Ser Thr Val Glu Leu Glu Asp Leu Lys Arg			

245	250	255	
Tyr Arg Glu Leu Gln Arg Leu Gly Leu Gly Asn Asn Arg Ile Thr Asp			
260	265	270	
Ile Glu Asn Gly Thr Phe Ala Asn Ile Pro Arg Val Arg Glu Ile His			
275	280	285	
Leu Glu His Asn Lys Leu Lys Ile Pro Ser Gly Leu Gln Glu Leu			
290	295	300	
Lys Tyr Leu Gln Ile Ile Phe Leu His Tyr Asn Ser Ile Ala Lys Val			
305	310	315	320
Gly Val Asn Asp Phe Cys Pro Thr Val Pro Lys Met Lys Lys Ser Leu			
325	330	335	
Tyr Ser Ala Ile Ser Leu Phe Asn Asn Pro Met Lys Tyr Trp Glu Ile			
340	345	350	
Gln Pro Ala Thr Phe Arg Cys Val Leu Gly Arg Met Ser Val Gln Leu			
355	360	365	
Gly Asn Val Gly Lys			
370			

&lt;210&gt; 44

&lt;211&gt; 466

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 44

Met Trp Gly Cys Trp Leu Gly Leu Leu Leu Leu Leu Ala Gly Gln			
1	5	10	15
Ala Ala Leu Glu Ala Arg Arg Ser Arg Trp Arg Arg Glu Leu Ala Pro			
20	25	30	
Gly Leu His Leu Arg Gly Ile Arg Asp Ala Gly Gly Arg Tyr Cys Gln			
35	40	45	
Glu Gln Asp Met Cys Cys Arg Gly Arg Ala Asp Glu Cys Ala Leu Pro			
50	55	60	
Tyr Leu Gly Ala Thr Cys Tyr Cys Asp Leu Phe Cys Asn Arg Thr Val			
65	70	75	80
Ser Asp Cys Cys Pro Asp Phe Trp Asp Phe Cys Leu Gly Ile Pro Pro			
85	90	95	
Pro Phe Pro Pro Val Gln Gly Cys Met His Gly Gly Arg Ile Tyr Pro			
100	105	110	
Val Phe Gly Thr Tyr Trp Asp Asn Cys Asn Arg Cys Thr Cys His Glu			
115	120	125	
Gly Gly His Trp Glu Cys Asp Gln Glu Pro Cys Leu Val Asp Pro Asp			
130	135	140	
Met Ile Lys Ala Ile Asn Arg Gly Asn Tyr Gly Trp Gln Ala Gly Asn			
145	150	155	160
His Ser Ala Phe Trp Gly Met Thr Leu Asp Glu Gly Ile Arg Tyr Arg			
165	170	175	
Leu Gly Thr Ile Arg Pro Ser Ser Thr Val Met Asn Met Asn Glu Ile			
180	185	190	
Tyr Thr Val Leu Gly Gln Gly Glu Val Leu Pro Thr Ala Phe Glu Ala			
195	200	205	
Ser Glu Lys Trp Pro Asn Leu Ile His Glu Pro Leu Asp Gln Gly Asn			
210	215	220	
Cys Ala Gly Ser Trp Ala Phe Ser Thr Ala Ala Val Ala Ser Asp Arg			
225	230	235	240
Val Ser Ile His Ser Leu Gly His Met Thr Pro Ile Leu Ser Pro Gln			
245	250	255	
Asn Leu Leu Ser Cys Asp Thr His His Gln Gln Gly Cys Arg Gly Gly			

260	265	270	
Arg Leu Asp Gly Ala Trp Trp Phe	Leu Arg Arg Arg Gly	Val Val Ser	
275	280	285	
Asp Asn Cys Tyr Pro Phe Ser Gly Arg Glu Gln Asn Glu Ala Ser Pro			
290	295	300	
Thr Pro Arg Cys Met Met His Ser Arg Ala Met Gly Arg Gly Lys Arg			
305	310	315	320
Gln Ala Thr Ser Arg Cys Pro Asn Gly Gln Val Asp Ser Asn Asp Ile			
325	330	335	
Tyr Gln Val Thr Pro Ala Tyr Arg Leu Gly Ser Asp Glu Lys Glu Ile			
340	345	350	
Met Lys Glu Leu Met Glu Asn Gly Pro Val Gln Ala Leu Met Glu Val			
355	360	365	
His Glu Asp Phe Phe Leu Tyr Gln Arg Gly Ile Tyr Ser His Thr Pro			
370	375	380	
Val Ser Gln Gly Arg Pro Glu Gln Tyr Arg Arg His Gly Thr His Ser			
385	390	395	400
Val Lys Ile Thr Gly Trp Gly Glu Glu Thr Leu Pro Asp Gly Arg Thr			
405	410	415	
Ile Lys Tyr Trp Thr Ala Ala Asn Ser Trp Gly Pro Trp Trp Gly Glu			
420	425	430	
Arg Gly His Phe Arg Ile Val Arg Gly Thr Asn Glu Cys Asp Ile Glu			
435	440	445	
Thr Phe Val Leu Gly Val Trp Gly Arg Val Gly Met Glu Asp Met Gly			
450	455	460	
His His			
465			

<210> 45  
 <211> 422  
 <212> PRT  
 <213> Mouse

<400> 45			
Met Asp Phe Trp Leu Trp Leu Leu Tyr Phe Leu Pro Val Ser Gly Ala			
1	5	10	15
Leu Arg Val Leu Pro Glu Val Gln Leu Asn Val Glu Trp Gly Gly Ser			
20	25	30	
Ile Ile Ile Glu Cys Pro Leu Pro Gln Leu His Val Arg Met Tyr Leu			
35	40	45	
Cys Arg Gln Met Ala Lys Pro Gly Ile Cys Ser Thr Val Val Ser Asn			
50	55	60	
Thr Phe Val Lys Lys Glu Tyr Glu Arg Arg Val Thr Leu Thr Pro Cys			
65	70	75	80
Leu Asp Lys Lys Leu Phe Leu Val Glu Met Thr Gln Leu Thr Glu Asn			
85	90	95	
Asp Asp Gly Ile Tyr Ala Cys Gly Val Gly Met Lys Thr Asp Lys Gly			
100	105	110	
Lys Thr Gln Ile Thr Leu Asn Val His Asn Glu Tyr Pro Glu Pro			
115	120	125	
Phe Trp Glu Asp Glu Trp Thr Ser Glu Arg Pro Arg Trp Leu His Arg			
130	135	140	
Phe Leu Gln His Gln Met Pro Trp Leu His Gly Ser Glu His Pro Ser			
145	150	155	160
Ser Ser Gly Val Ile Ala Lys Val Thr Thr Pro Ala Ser Lys Thr Glu			
165	170	175	
Ala Pro Pro Val His Gln Pro Ser Ser Ile Thr Ser Val Thr Gln His			

180	185	190
Pro Arg Val Tyr Arg Ala Phe Ser	Val Ser Ala Thr	Lys Ser Pro Ala
195	200	205
Leu Leu Pro Ala Thr Thr Ala Ser Lys Thr Ser Thr	Gln Gln Ala Ile	
210	215	220
Arg Pro Leu Glu Ala Ser Tyr Ser His His	Thr Arg Leu His Glu Gln	
225	230	235
Arg Thr Arg His His Gly Pro His Tyr Gly Arg Glu Asp Arg Gly Leu		240
245	250	255
His Ile Pro Ile Pro Glu Phe His Ile Leu Ile Pro Thr Phe Leu Gly		
260	265	270
Phe Leu Leu Leu Val Leu Leu Gly Leu Val Val Lys Arg Ala Ile Gln		
275	280	285
Arg Arg Arg Ala Ser Ser Arg Arg Ala Gly Arg Leu Ala Met Arg Arg		
290	295	300
Arg Gly Arg Gly Ala Ser Arg Pro Phe Pro Thr Gln Arg Arg Asp Ala		
305	310	315
Pro Gln Arg Pro Arg Ser Gln Asn Asn Val Tyr Ser Ala Cys Pro Arg		320
325	330	335
Arg Ala Arg Gly Pro Asp Ser Leu Gly Pro Ala Glu Ala Pro Leu Leu		
340	345	350
Asn Ala Pro Ala Ser Ala Ser Pro Ala Ser Pro Gln Val Leu Glu Ala		
355	360	365
Pro Trp Pro His Thr Pro Ser Leu Lys Met Ser Cys Glu Tyr Val Ser		
370	375	380
Leu Gly Tyr Gln Pro Ala Val Asn Leu Glu Asp Pro Asp Ser Asp Asp		
385	390	395
Tyr Ile Asn Ile Pro Asp Pro Ser His Leu Pro Ser Tyr Ala Pro Gly		400
405	410	415
Pro Arg Ser Ser Cys Gln		
420		

&lt;210&gt; 46

&lt;211&gt; 228

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 46

Met Lys Ala Leu Arg Ala Val Leu Leu Ile Leu Leu Leu Ser Gly Gln			
1	5	10	15
Pro Gly Ser Gly Trp Ala Gln Glu Asp Gly Asp Ala Asp Pro Glu Pro			
20	25	30	
Glu Asn Tyr Asn Tyr Asp Asp Asp Asp Asp Glu Glu Glu Glu Glu			
35	40	45	
Thr Asn Met Ile Pro Gly Ser Arg Asp Arg Ala Pro Leu Gln Cys Tyr			
50	55	60	
Phe Cys Gln Val Leu His Ser Gly Glu Ser Cys Asn Gln Thr Gln Ser			
65	70	75	80
Cys Ser Ser Ser Lys Pro Phe Cys Ile Thr Leu Val Ser His Ser Gly			
85	90	95	
Thr Asp Lys Gly Tyr Leu Thr Thr Tyr Ser Met Trp Cys Thr Asp Thr			
100	105	110	
Cys Gln Pro Ile Ile Lys Thr Val Gly Gly Thr Gln Met Thr Gln Thr			
115	120	125	
Cys Cys Gln Ser Thr Leu Cys Asn Ile Pro Pro Trp Gln Asn Pro Gln			
130	135	140	
Val Gln Asn Pro Leu Gly Gly Arg Ala Asp Ser Pro Leu Glu Ser Gly			

145	150	155	160
Thr Arg His Pro Gln Gly Gly Lys Phe Ser His Pro Gln Val Val Lys			
165	170	175	
Ala Ala His Pro Gln Ser Asp Gly Ala Asn Leu Pro Lys Ser Gly Lys			
180	185	190	
Ala Asn Gln Pro Gln Gly Ser Gly Ala Gly Tyr Pro Ser Gly Trp Thr			
195	200	205	
Lys Phe Gly Asn Ile Ala Leu Leu Leu Ser Phe Phe Thr Cys Leu Trp			
210	215	220	
Ala Ser Gly Ala			
225			

&lt;210&gt; 47

&lt;211&gt; 269

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 47

Gly Cys Ser Asp Gly Glu Asn Gln Arg Ser Gly His Leu Ser Val Ser			
1	5	10	15
Leu Gln Leu Ser Leu Lys Val Leu Leu Ile Arg Met Ala Ser Gly Trp			
20	25	30	
Phe Tyr Leu Ser Cys Met Val Leu Gly Ser Leu Gly Ser Met Cys Ile			
35	40	45	
Leu Phe Thr Ala Tyr Trp Met Gln Tyr Trp Arg Gly Gly Phe Ala Trp			
50	55	60	
Asp Gly Thr Val Leu Met Phe Asn Trp His Pro Val Leu Met Val Ala			
65	70	75	80
Gly Met Val Val Leu Tyr Gly Ala Ala Ser Leu Val Tyr Arg Leu Pro			
85	90	95	
Ser Ser Trp Val Gly Pro Arg Leu Pro Trp Lys Val Leu His Ala Ala			
100	105	110	
Leu His Leu Leu Ala Phe Thr Cys Thr Val Val Gly Leu Ile Ala Val			
115	120	125	
Phe Arg Phe His Asn His Ser Arg Ile Ala His Leu Tyr Ser Leu His			
130	135	140	
Ser Trp Leu Gly Ile Thr Thr Val Val Leu Phe Ala Cys Gln Trp Phe			
145	150	155	160
Leu Gly Phe Ala Val Phe Leu Leu Pro Trp Ala Ser Gln Trp Leu Arg			
165	170	175	
Ser Leu Leu Lys Pro Leu His Val Phe Phe Gly Ala Cys Ile Leu Ser			
180	185	190	
Leu Ser Ile Thr Ser Val Ile Ser Gly Ile Asn Glu Lys Leu Phe Phe			
195	200	205	
Val Leu Lys Asn Ala Thr Lys Pro Tyr Ser Ser Leu Pro Gly Glu Ala			
210	215	220	
Val Phe Ala Asn Ser Thr Gly Leu Leu Val Val Ala Phe Gly Leu Leu			
225	230	235	240
Val Leu Tyr Val Leu Leu Ala Ser Ser Trp Lys Arg Pro Asp Pro Gly			
245	250	255	
Ala Leu Thr Asp Arg Gln Pro Leu Leu His Asp Arg Glu			
260	265		

&lt;210&gt; 48

&lt;211&gt; 188

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 48

Met Arg Leu Pro Leu Pro Leu Leu Leu Phe Gly Cys Arg Ala Ile  
 1 5 10 15  
 Leu Gly Ser Ala Gly Asp Arg Val Ser Leu Ser Ala Ser Ala Pro Thr  
 20 25 30  
 Leu Asp Asp Glu Glu Lys Tyr Ser Ala His Met Pro Ala His Leu Arg  
 35 40 45  
 Cys Asp Ala Cys Arg Ala Val Ala Phe Gln Met Gly Gln Arg Leu Ala  
 50 55 60  
 Lys Ala Glu Ala Lys Ser His Thr Pro Asp Ala Ser Gly Leu Gln Glu  
 65 70 75 80  
 Leu Ser Glu Ser Thr Tyr Thr Asp Val Leu Asp Gln Thr Cys Ser Gln  
 85 90 95  
 Asn Trp Gln Ser Tyr Gly Val His Glu Val Asn Gln Met Lys Arg Leu  
 100 105 110  
 Thr Gly Pro Gly Leu Ser Lys Gly Pro Glu Pro Arg Ile Ser Val Met  
 115 120 125  
 Ile Ser Gly Gly Pro Trp Pro Asn Arg Leu Ser Lys Thr Cys Phe His  
 130 135 140  
 Tyr Leu Gly Glu Phe Gly Glu Asp Gln Ile Tyr Glu Ala Tyr Arg Gln  
 145 150 155 160  
 Gly Gln Ala Asn Leu Glu Ala Leu Leu Cys Gly Gly Thr His Gly Pro  
 165 170 175  
 Cys Ser Gln Glu Ile Leu Ala Gln Arg Glu Glu Leu  
 180 185

&lt;210&gt; 49

<211> 247  
 <212> PRT  
 <213> Mouse

&lt;400&gt; 49

Met Ile Pro Gln Val Val Thr Ser Glu Thr Val Thr Val Ile Ser Pro  
 1 5 10 15  
 Asn Gly Ile Ser Phe Pro Gln Thr Asp Lys Pro Gln Pro Ser His Gln  
 20 25 30  
 Ser Gln Asp Arg Leu Lys Lys His Leu Lys Ala Glu Ile Lys Val Met  
 35 40 45  
 Ala Ala Ile Gln Ile Met Cys Ala Val Met Val Leu Ser Leu Gly Ile  
 50 55 60  
 Ile Leu Ala Ser Val Pro Ser Asn Leu His Phe Thr Ser Val Phe Ser  
 65 70 75 80  
 Ile Leu Leu Glu Ser Gly Tyr Pro Phe Val Gly Ala Leu Phe Phe Ala  
 85 90 95  
 Ile Ser Gly Ile Leu Ser Ile Val Thr Glu Lys Lys Met Thr Lys Pro  
 100 105 110  
 Leu Val His Ser Ser Leu Ala Leu Ser Ile Leu Ser Val Leu Ser Ala  
 115 120 125  
 Leu Thr Gly Ile Ala Ile Leu Ser Val Ser Leu Ala Ala Leu Glu Pro  
 130 135 140  
 Ala Leu Gln Gln Cys Lys Leu Ala Phe Thr Gln Leu Asp Thr Thr Gln  
 145 150 155 160  
 Asp Ala Tyr His Phe Phe Ser Pro Glu Pro Leu Asn Ser Cys Phe Val  
 165 170 175  
 Ala Lys Ala Ala Leu Thr Gly Val Phe Ser Leu Met Leu Ile Ser Ser  
 180 185 190

Val Leu Glu Leu Gly Leu Ala Val Leu Thr Ala Thr Leu Trp Trp Lys  
 195 200 205  
 Gln Ser Ser Ser Ala Phe Ser Gly Asn Val Ile Phe Leu Ser Gln Asn  
 210 215 220  
 Ser Lys Asn Lys Ser Ser Val Ser Ser Glu Ser Leu Cys Asn Pro Thr  
 225 230 235 240  
 Tyr Glu Asn Ile Leu Thr Ser  
 245

&lt;210&gt; 50

&lt;211&gt; 182

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 50

Pro Phe His Cys His Val Trp Ser Leu Cys Leu Gln Gly Ser Lys Gln  
 1 5 10 15  
 Ser Gly Leu Cys Gln Val Gln Arg Asp Leu Gly Arg Asp Asp Arg Ser  
 20 25 30  
 Val Arg Gly Ser Lys Ala Ala Val Val Ala Gly Ala Val Val Gly Thr  
 35 40 45  
 Phe Val Gly Leu Val Leu Ile Ala Gly Leu Val Leu Leu Tyr Gln Arg  
 50 55 60  
 Arg Ser Lys Thr Leu Glu Glu Leu Ala Asn Asp Ile Lys Glu Asp Ala  
 65 70 75 80  
 Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser Asp Thr Ile Ser  
 85 90 95  
 Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg Pro  
 100 105 110  
 Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr Pro Thr Pro Ser  
 115 120 125  
 Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro Arg Val Asp Glu  
 130 135 140  
 Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly Val Ser Ser Ser  
 145 150 155 160  
 Ala Leu Ser Arg Met Gly Ala Val Pro Val Met Val Pro Ala Gln Ser  
 165 170 175  
 Gln Ala Gly Ser Leu Val  
 180

&lt;210&gt; 51

&lt;211&gt; 248

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 51

Met Ser Trp Ser Pro Ile Leu Pro Phe Leu Ser Leu Leu Leu Leu  
 1 5 10 15  
 Phe Pro Leu Glu Val Pro Arg Ala Ala Thr Ala Ser Leu Ser Gln Ala  
 20 25 30  
 Ser Ser Glu Gly Thr Thr Cys Lys Val His Asp Val Cys Leu Leu  
 35 40 45  
 Gly Pro Arg Pro Leu Pro Pro Ser Pro Pro Val Arg Val Ser Leu Tyr  
 50 55 60  
 Tyr Glu Ser Leu Cys Gly Ala Cys Arg Tyr Phe Leu Val Arg Asp Leu  
 65 70 75 80  
 Phe Pro Thr Trp Leu Met Val Met Glu Ile Met Asn Ile Thr Leu Val

85	90	95	
Pro Tyr Gly Asn Ala Gln Glu Arg Asn Val Ser Gly Thr Trp	Glu	Phe	
100	105	110	
Thr Cys Gln His Gly Glu Leu Glu Cys Arg Leu Asn Met Val	Glu Ala		
115	120	125	
Cys Leu Leu Asp Lys Leu Glu Lys Glu Ala Ala Phe Leu Thr Ile	Val		
130	135	140	
Cys Met Glu Glu Met Asp Asp Met Glu Lys Lys Leu Gly Pro Cys	Leu		
145	150	155	160
Gln Val Tyr Ala Pro Glu Val Ser Pro Glu Ser Ile Met Glu Cys	Ala		
165	170	175	
Thr Gly Lys Arg Gly Thr Gln Leu Met His Glu Asn Ala Gln	Leu	Thr	
180	185	190	
Asp Ala Leu His Pro Pro His Glu Tyr Val Pro Trp Val Leu Val	Asn		
195	200	205	
Glu Lys Pro Leu Lys Asp Pro Ser Glu Leu Leu Ser Ile Val Cys	Gln		
210	215	220	
Leu Asp Gln Gly Thr Glu Lys Pro Asp Ile Cys Ser Ser Ile Ala	Asp		
225	230	235	240
Ser Pro Arg Lys Val Cys Tyr Lys			
245			

&lt;210&gt; 52

&lt;211&gt; 278

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 52

Met Gln Thr Met Trp Gly Ser Gly Glu Leu Leu Val Ala Trp Phe	Leu		
1	5	10	15
Val Leu Ala Ala Asp Gly Thr Thr Glu His Val Tyr Arg Pro	Ser Arg		
20	25	30	
Arg Val Cys Thr Val Gly Ile Ser Gly Gly Ser Ile Ser Glu	Thr Phe		
35	40	45	
Val Gln Arg Val Tyr Gln Pro Tyr Leu Thr Thr Cys Asp Gly	His Arg		
50	55	60	
Ala Cys Ser Thr Tyr Arg Thr Ile Tyr Arg Thr Ala Tyr Arg	Ser		
65	70	75	80
Pro Gly Val Thr Pro Ala Arg Pro Arg Tyr Ala Cys Cys Pro	Gly Trp		
85	90	95	
Lys Arg Thr Ser Gly Leu Pro Gly Ala Cys Gly Ala Ala	Ile Cys Gln		
100	105	110	
Pro Pro Cys Gly Asn Gly Gly Ser Cys Ile Arg Pro Gly His	Cys Arg		
115	120	125	
Cys Pro Val Gly Trp Gln Gly Asp Thr Cys Gln Thr Asp Val	Asp Glu		
130	135	140	
Cys Ser Thr Gly Glu Ala Ser Cys Pro Gln Arg Cys Val Asn	Thr Val		
145	150	155	160
Gly Ser Tyr Trp Cys Gln Gly Trp Glu Gly Gln Ser Pro Ser	Ala Asp		
165	170	175	
Gly Thr Arg Cys Leu Ser Lys Glu Gly Pro Ser Pro Val Ala	Pro Asn		
180	185	190	
Pro Thr Ala Gly Val Asp Ser Met Ala Arg Glu Glu Val Tyr	Arg Leu		
195	200	205	
Gln Ala Arg Val Asp Val Leu Glu Gln Lys Leu Gln Leu Val	Leu Ala		
210	215	220	
Pro Leu His Ser Leu Ala Ser Arg Ser Thr Glu His Gly Leu	Gln Asp		

225	230	235	240												
Pro	Gly	Ser	Leu	Leu	Ala	His	Ser	Phe	Gln	Gln	Leu	Asp	Arg	Ile	Asp
			245					250				255			
Ser	Leu	Ser	Glu	Gln	Val	Ser	Phe	Leu	Glu	Glu	His	Leu	Gly	Ser	Cys
			260					265			270				
Ser	Cys	Lys	Lys	Asp	Leu										
			275												

&lt;210&gt; 53

&lt;211&gt; 409

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 53

Met	Lys	Leu	Lys	Gln	Arg	Val	Val	Leu	Leu	Ala	Ile	Leu	Leu	Val	Ile
1				5				10						15	
Phe	Ile	Phe	Thr	Lys	Val	Phe	Leu	Ile	Asp	Asn	Leu	Asp	Thr	Ser	Ala
					20			25					30		
Ala	Asn	Arg	Glu	Asp	Gln	Arg	Ala	Phe	His	Arg	Met	Met	Thr	Gly	Leu
					35			40			45				
Arg	Val	Glu	Leu	Val	Pro	Lys	Leu	Asp	His	Thr	Leu	Gln	Ser	Pro	Trp
					50			55			60				
Glu	Ile	Ala	Ala	Gln	Trp	Val	Val	Pro	Arg	Glu	Val	Tyr	Pro	Glu	Glu
					65			70		75			80		
Thr	Pro	Glu	Leu	Gly	Ala	Ile	Met	His	Ala	Met	Ala	Thr	Lys	Lys	Ile
					85			90				95			
Ile	Lys	Ala	Asp	Val	Gly	Tyr	Lys	Gly	Thr	Gln	Leu	Lys	Ala	Leu	Leu
					100			105			110				
Ile	Leu	Glu	Gly	Gly	Gln	Lys	Val	Val	Phe	Lys	Pro	Lys	Arg	Tyr	Ser
					115			120			125				
Arg	Asp	Tyr	Val	Val	Glu	Gly	Glu	Pro	Tyr	Ala	Gly	Tyr	Asp	Arg	His
					130			135			140				
Asn	Ala	Glu	Val	Ala	Ala	Phe	His	Leu	Asp	Arg	Ile	Leu	Gly	Phe	Arg
					145			150		155			160		
Arg	Ala	Pro	Leu	Val	Val	Gly	Arg	Tyr	Val	Asn	Leu	Arg	Thr	Glu	Val
					165			170				175			
Lys	Pro	Val	Ala	Thr	Glu	Gln	Leu	Leu	Ser	Thr	Phe	Leu	Thr	Val	Gly
					180			185			190				
Asn	Asn	Thr	Cys	Phe	Tyr	Gly	Lys	Cys	Tyr	Tyr	Cys	Arg	Glu	Thr	Glu
					195			200			205				
Pro	Ala	Cys	Ala	Asp	Gly	Asp	Met	Met	Glu	Gly	Ser	Val	Thr	Leu	Trp
					210			215			220				
Leu	Pro	Asp	Val	Trp	Pro	Leu	Gln	Lys	His	Arg	His	Pro	Trp	Gly	Arg
					225			230		235		240			
Thr	Tyr	Arg	Glu	Gly	Lys	Leu	Ala	Arg	Trp	Glu	Tyr	Asp	Glu	Ser	Tyr
					245			250			255				
Cys	Asp	Ala	Val	Lys	Lys	Thr	Ser	Pro	Tyr	Asp	Ser	Gly	Pro	Arg	Leu
					260			265			270				
Leu	Asp	Ile	Ile	Asp	Thr	Ala	Val	Phe	Asp	Tyr	Leu	Ile	Gly	Asn	Ala
					275			280			285				
Asp	Arg	His	His	Tyr	Glu	Ser	Phe	Gln	Asp	Asp	Glu	Gly	Ala	Ser	Met
					290			295			300				
Leu	Ile	Leu	Leu	Asp	Asn	Ala	Lys	Ser	Phe	Gly	Asn	Pro	Ser	Leu	Asp
					305			310		315			320		
Glu	Arg	Ser	Ile	Leu	Ala	Pro	Leu	Tyr	Gln	Cys	Cys	Ile	Ile	Arg	Val
					325			330			335				
Ser	Thr	Trp	Asn	Arg	Leu	Asn	Tyr	Leu	Lys	Asn	Gly	Val	Leu	Lys	Ser

340	345	350
Ala Leu Lys Ser Ala Met Ala His Asp Pro Ile Ser Pro Val Leu Ser		
355	360	365
Asp Pro His Leu Asp Thr Val Asp Gln Arg Leu Leu Asn Val Leu Ala		
370	375	380
Thr Ile Lys Gln Cys Thr Asp Gln Phe Gly Thr Asp Thr Val Leu Val		
385	390	395
Glu Asp Arg Met Pro Leu Ser His Leu		400
	405	

&lt;210&gt; 54

&lt;211&gt; 697

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 54

Met Arg Leu Thr Val Gly Ala Leu Leu Ala Cys Ala Ala Leu Gly Leu			
1	5	10	15
Cys Leu Ala Val Pro Asp Lys Thr Val Lys Trp Cys Ala Val Ser Glu			
20	25	30	
His Glu Asn Thr Lys Cys Ile Ser Phe Arg Asp His Met Lys Thr Val			
35	40	45	
Leu Pro Pro Asp Gly Pro Arg Leu Ala Cys Val Lys Lys Thr Ser Tyr			
50	55	60	
Pro Asp Cys Ile Lys Ala Ile Ser Ala Ser Glu Ala Asp Ala Met Thr			
65	70	75	80
Leu Asp Gly Gly Trp Val Tyr Asp Ala Gly Leu Thr Pro Asn Asn Leu			
85	90	95	
Lys Pro Val Ala Ala Glu Phe Tyr Gly Ser Val Glu His Pro Gln Thr			
100	105	110	
Tyr Tyr Tyr Ala Val Ala Val Val Lys Lys Gly Thr Asp Phe Gln Leu			
115	120	125	
Asn Gln Leu Glu Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg Ser			
130	135	140	
Ala Gly Trp Val Ile Pro Ile Gly Leu Leu Phe Cys Lys Leu Ser Glu			
145	150	155	160
Pro Arg Ser Pro Leu Glu Lys Ala Val Ser Ser Phe Phe Ser Gly Ser			
165	170	175	
Cys Val Pro Cys Ala Asp Pro Val Ala Phe Pro Lys Leu Cys Gln Leu			
180	185	190	
Cys Pro Gly Cys Gly Cys Ser Ser Thr Gln Pro Phe Phe Gly Tyr Val			
195	200	205	
Gly Ala Phe Lys Cys Leu Lys Asp Gly Gly Gly Asp Val Ala Phe Val			
210	215	220	
Lys His Thr Thr Ile Phe Glu Val Leu Pro Glu Lys Ala Asp Arg Asp			
225	230	235	240
Gln Tyr Glu Leu Leu Cys Leu Asp Asn Thr Arg Lys Pro Val Asp Gln			
245	250	255	
Tyr Glu Asp Cys Tyr Leu Ala Arg Ile Pro Ser His Ala Val Val Ala			
260	265	270	
Arg Lys Asn Asn Gly Lys Glu Asp Leu Ile Trp Glu Ile Leu Lys Val			
275	280	285	
Ala Gln Glu His Phe Gly Lys Gly Lys Ser Lys Asp Phe Gln Leu Phe			
290	295	300	
Ser Ser Pro Leu Gly Lys Asp Leu Leu Phe Lys Asp Ser Ala Phe Gly			
305	310	315	320
Leu Leu Arg Val Pro Pro Arg Met Asp Tyr Arg Leu Tyr Leu Gly His			

	325		330		335										
Asn	Tyr	Val	Thr	Ala	Ile	Arg	Asn	Gln	Gln	Glu	Gly	Val	Cys	Pro	Glu
				340				345					350		
Gly	Ser	Ile	Asp	Asn	Ser	Pro	Val	Lys	Trp	Cys	Ala	Leu	Ser	His	Leu
				355				360				365			
Glu	Arg	Thr	Lys	Cys	Asp	Glu	Trp	Ser	Ile	Ile	Ser	Glu	Gly	Lys	Ile
				370				375				380			
Glu	Cys	Glu	Ser	Ala	Glu	Thr	Thr	Glu	Asp	Cys	Ile	Glu	Lys	Ile	Val
				385				390			395			400	
Asn	Gly	Glu	Ala	Asp	Ala	Met	Thr	Leu	Asp	Gly	Gly	His	Ala	Tyr	Ile
						405			410				415		
Ala	Gly	Gln	Cys	Gly	Leu	Val	Pro	Val	Met	Ala	Glu	Tyr	Tyr	Glu	Ser
					420			425			430				
Ser	Asn	Cys	Ala	Ile	Pro	Ser	Gln	Gln	Gly	Ile	Phe	Pro	Lys	Gly	Tyr
					435			440			445				
Tyr	Ala	Val	Ala	Val	Val	Lys	Ala	Ser	Asp	Thr	Ser	Ile	Thr	Trp	Asn
					450			455			460				
Asn	Leu	Lys	Gly	Lys	Lys	Ser	Cys	His	Thr	Gly	Val	Asp	Arg	Thr	Ala
					465			470			475			480	
Gly	Trp	Asn	Ile	Pro	Met	Gly	Met	Leu	Tyr	Asn	Arg	Ile	Asn	His	Cys
					485				490			495			
Lys	Phe	Asp	Glu	Phe	Phe	Ser	Gln	Gly	Cys	Ala	Pro	Gly	Tyr	Glu	Lys
					500				505			510			
Asn	Ser	Thr	Leu	Cys	Asp	Leu	Cys	Ile	Gly	Pro	Leu	Lys	Cys	Ala	Pro
					515				520			525			
Asn	Asn	Lys	Glu	Glu	Tyr	Asn	Gly	Tyr	Thr	Gly	Ala	Phe	Arg	Cys	Leu
					530			535			540				
Val	Glu	Lys	Gly	Asp	Val	Ala	Phe	Val	Lys	His	Gln	Thr	Val	Leu	Asp
					545			550			555			560	
Asn	Thr	Glu	Gly	Lys	Asn	Pro	Ala	Glu	Trp	Ala	Lys	Asn	Leu	Lys	Gln
					565				570			575			
Glu	Asp	Phe	Glu	Leu	Leu	Cys	Pro	Asp	Gly	Thr	Arg	Lys	Pro	Val	Lys
					580				585			590			
Asp	Phe	Ala	Ser	Cys	His	Leu	Ala	Gln	Ala	Pro	Asn	His	Val	Val	Val
					595				600			605			
Ser	Arg	Lys	Glu	Lys	Ala	Ala	Arg	Val	Lys	Ala	Val	Leu	Thr	Ser	Gln
					610			615			620				
Glu	Thr	Leu	Phe	Gly	Gly	Ser	Asp	Cys	Thr	Gly	Asn	Phe	Cys	Leu	Phe
					625			630			635			640	
Lys	Ser	Thr	Thr	Lys	Asp	Leu	Leu	Phe	Arg	Asp	Asp	Thr	Lys	Cys	Phe
					645				650			655			
Val	Lys	Leu	Pro	Glu	Gly	Thr	Thr	Pro	Glu	Lys	Tyr	Leu	Gly	Ala	Glu
					660				665			670			
Tyr	Met	Gln	Ser	Val	Gly	Asn	Met	Arg	Lys	Cys	Ser	Thr	Ser	Arg	Leu
					675				680			685			
Leu	Glu	Ala	Cys	Thr	Phe	His	Lys	His							
					690			695							

&lt;210&gt; 55

&lt;211&gt; 400

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 55

Gly Ala Pro Thr Pro Ala Tyr Val Arg Ser Ala Arg Arg Thr Glu Pro

1 5 10 15

Leu Ala Ser Gly Ala Arg Ser Arg Leu Cys Gln Cys Arg Arg Val Pro

20	25	30	
Ala Arg Lys Gln Gln Pro Gln Glu Gln Gly Ser Gly	Glu Ser Thr		
35	40	45	
Thr Ser Ser Pro Gln Trp Trp Arg Arg Trp Arg Arg	Leu Trp Ser Thr		
50	55	60	
Cys Ser Cys Ser Ala Asp Asp Arg His Thr Gly Ser His	Thr Asp Leu		
65	70	75	80
Lys Glu Glu Thr Pro Ser Trp Thr Gln Ile Ser Val Val	Phe Arg Lys		
85	90	95	
Asp Gly Gln Asp Glu Leu Gln Ala Ala His Lys Ala His	Gly Ser Gly		
100	105	110	
Ser Pro Leu Thr Asn Gln Glu Ile Pro Ser Ser Ser Gly	Ser Gly Phe		
115	120	125	
Ile Val Ser Glu Asp Gly Leu Ile Val Thr Asn Ala His	Val Leu Thr		
130	135	140	
Asn Gln Gln Lys Ile Gln Val Glu Leu Gln Ser Gly Ala	Arg Tyr Glu		
145	150	155	160
Ala Thr Val Lys Asp Ile Asp His Lys Leu Asp Leu Ala	Leu Ile Lys		
165	170	175	
Ile Glu Pro Asp Thr Glu Leu Pro Val Leu Leu Leu Gly	Arg Ser Ser		
180	185	190	
Asp Leu Arg Ala Gly Glu Phe Val Val Ala Leu Gly Ser	Pro Phe Ser		
195	200	205	
Leu Gln Asn Thr Val Thr Ala Gly Ile Val Ser Thr Thr	Gln Arg Gly		
210	215	220	
Gly Arg Glu Leu Gly Leu Lys Asn Ser Asp Ile Asp Tyr	Ile Gln Thr		
225	230	235	240
Asp Ala Ile Ile Asn His Gly Asn Ser Gly Gly Pro Leu	Val Asn Leu		
245	250	255	
Asp Gly Asp Val Ile Gly Ile Asn Thr Leu Lys Val Thr	Ala Gly Ile		
260	265	270	
Ser Phe Ala Ile Pro Ser Asp Arg Ile Arg Gln Phe Leu	Glu Asp Tyr		
275	280	285	
His Glu Arg Gln Leu Lys Gly Lys Ala Pro Leu Gln Lys	Lys Tyr Leu		
290	295	300	
Gly Leu Arg Met Leu Pro Leu Thr Leu Asn Leu Leu Gln	Glu Met Lys		
305	310	315	320
Arg Gln Asp Pro Glu Phe Pro Asp Val Ser Ser Gly Val	Phe Val Tyr		
325	330	335	
Glu Val Ile Gln Gly Ser Ala Ala Ala Ser Ser Gly Leu	Arg Asp His		
340	345	350	
Asp Val Ile Val Ser Ile Asn Gly Gln Pro Val Thr Thr	Thr Asp		
355	360	365	
Val Ile Glu Ala Val Lys Asp Asn Asp Phe Leu Ser Ile	Ile Val Leu		
370	375	380	
Arg Gly Ser Gln Thr Leu Phe Leu Thr Val Thr Pro Glu	Ile Ile Asn		
385	390	395	400

&lt;210&gt; 56

&lt;211&gt; 174

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 56

Met Pro Ala Cys Arg Leu Cys Leu Leu Ala Ala Gly	Leu Leu Leu Gly		
1	5	10	15
Leu Leu Leu Phe Thr Pro Ile Ser Ala Thr Gly	Thr Asp Ala Glu Lys		

	20		25		30										
Pro	Gly	Glu	Cys	Pro	Gln	Leu	Glu	Pro	Ile	Thr	Asp	Cys	Val	Leu	Glu
		35					40					45			
Cys	Thr	Leu	Asp	Lys	Asp	Cys	Ala	Asp	Asn	Arg	Lys	Cys	Cys	Gln	Ala
		50				55				60					
Gly	Cys	Ser	Ser	Val	Cys	Ser	Lys	Pro	Asn	Gly	Pro	Ser	Glu	Gly	Glu
		65				70				75				80	
Leu	Ser	Gly	Thr	Asp	Thr	Lys	Leu	Ser	Glu	Thr	Gly	Thr	Thr	Thr	Gln
				85					90					95	
Ser	Ala	Gly	Leu	Asp	His	Thr	Thr	Lys	Pro	Pro	Gly	Gly	Gln	Val	Ser
			100					105						110	
Thr	Lys	Pro	Pro	Ala	Val	Thr	Arg	Glu	Gly	Leu	Gly	Val	Arg	Glu	Lys
				115			120					125			
Gln	Gly	Thr	Cys	Pro	Ser	Val	Asp	Ile	Pro	Lys	Leu	Gly	Leu	Cys	Glu
				130			135				140				
Asp	Gln	Cys	Gln	Val	Asp	Ser	Gln	Cys	Ser	Gly	Asn	Met	Lys	Cys	Cys
				145			150				155				160
Arg	Asn	Gly	Cys	Gly	Lys	Met	Ala	Cys	Thr	Thr	Pro	Lys	Phe		
				165					170						

<210> 57  
<211> 173  
<212> PRT  
<213> Mouse

```

<400> 57
Val Arg Asn Gly Asp Leu Phe Phe Lys Lys Val Gln Val Glu Asp Gly
1 5 10 15
Gly Val Tyr Thr Cys Tyr Ala Met Gly Glu Thr Phe Asn Glu Thr Leu
20 25 30
Ser Val Glu Leu Lys Val Tyr Asn Phe Thr Leu His Gly His His Asp
35 40 45
Thr Leu Asn Thr Ala Tyr Thr Thr Leu Val Gly Cys Ile Leu Ser Val
50 55 60
Val Leu Val Leu Ile Tyr Leu Tyr Leu Thr Pro Cys Arg Cys Trp Cys
65 70 75 80
Arg Gly Val Glu Lys Pro Ser Ser His Gln Gly Asp Ser Leu Ser Ser
85 90 95
Ser Met Leu Ser Thr Thr Pro Asn His Asp Pro Met Ala Gly Gly Asp
100 105 110
Lys Asp Asp Gly Phe Asp Arg Arg Val Ala Phe Leu Glu Pro Ala Gly
115 120 125
Pro Gly Gln Gly Gln Asn Gly Lys Leu Lys Pro Gly Asn Thr Leu Pro
130 135 140
Val Pro Glu Ala Thr Gly Lys Gly Gln Arg Arg Met Ser Asp Pro Glu
145 150 155 160
Ser Val Ser Ser Val Phe Ser Asp Thr Pro Ile Val Val
165 170

```

<210> 58  
<211> 88  
<212> PRT  
<213> Mouse

<400> 58  
Met Glu Glu Ile Thr Cys Ala Phe Leu Leu Leu Leu Ala Gly Leu Pro  
1 5 10 15

Ala Leu Glu Ala Ser Asp Pro Val Asp Lys Asp Ser Pro Phe Tyr Tyr  
 20 25 30  
 Asp Trp Glu Ser Leu Gln Leu Gly Gly Leu Ile Phe Gly Gly Leu Leu  
 35 40 45  
 Cys Ile Ala Gly Ile Ala Met Ala Leu Ser Gly Lys Cys Lys Cys Arg  
 50 55 60  
 Arg Thr His Lys Pro Ser Ser Leu Pro Gly Lys Ala Thr Pro Leu Ile  
 65 70 75 80  
 Ile Pro Gly Ser Ala Asn Thr Cys  
 85

<210> 59  
 <211> 171  
 <212> PRT  
 <213> Mouse

<400> 59  
 Leu Ser Val Val Leu Gly Gly Thr Leu Tyr Ile Gly His Tyr Leu Ala  
 1 5 10 15  
 Met Tyr Ser Glu Gly Ala Pro Phe Trp Thr Gly Ile Val Ala Met Leu  
 20 25 30  
 Ala Gly Ala Val Ala Phe Leu His Lys Lys Arg Gly Gly Thr Cys Trp  
 35 40 45  
 Ala Leu Met Arg Thr Leu Leu Val Ala Ser Phe Cys Thr Ala Val  
 50 55 60  
 Ala Ala Ile Val Ile Gly Ser Arg Glu Leu Asn Tyr Tyr Trp Tyr Phe  
 65 70 75 80  
 Leu Gly Asp Asp Val Cys Gln Arg Asp Ser Ser Tyr Gly Trp Ser Thr  
 85 90 95  
 Met Pro Arg Thr Thr Pro Val Pro Glu Glu Ala Asp Arg Ile Ala Leu  
 100 105 110  
 Cys Ile Tyr Tyr Thr Ser Met Leu Lys Thr Leu Leu Met Ser Leu Gln  
 115 120 125  
 Ala Met Leu Leu Gly Ile Trp Val Leu Leu Leu Ala Ser Leu Thr  
 130 135 140  
 Pro Val Cys Val Tyr Ile Trp Lys Arg Phe Phe Thr Lys Ala Glu Thr  
 145 150 155 160  
 Glu Glu Lys Lys Leu Leu Gly Ala Ala Val Ile  
 165 170

<210> 60  
 <211> 318  
 <212> PRT  
 <213> Mouse

<400> 60  
 Met Leu Gln His Thr Ser Leu Val Leu Leu Ala Ser Ile Trp Thr  
 1 5 10 15  
 Thr Arg His Pro Val Gln Gly Ala Asp Leu Val Gln Asp Leu Ser Ile  
 20 25 30  
 Ser Thr Cys Arg Ile Met Gly Val Ala Leu Val Gly Arg Asn Lys Asn  
 35 40 45  
 Pro Gln Met Asn Phe Thr Glu Ala Asn Glu Ala Cys Lys Met Leu Gly  
 50 55 60  
 Leu Thr Leu Ala Ser Arg Asp Gln Val Glu Ser Ala Gln Lys Ser Gly  
 65 70 75 80  
 Phe Glu Thr Cys Ser Tyr Gly Trp Val Gly Glu Gln Phe Ser Val Ile

85	90	95
Pro Arg Ile Phe Ser Asn Pro Arg Cys Gly Lys Asn Gly Lys Gly Val		
100	105	110
Leu Ile Trp Asn Ala Pro Ser Ser Gln Lys Phe Lys Ala Tyr Cys His		
115	120	125
Asn Ser Ser Asp Thr Trp Val Asn Ser Cys Ile Pro Glu Ile Val Thr		
130	135	140
Thr Phe Tyr Pro Val Leu Asp Thr Gln Thr Pro Ala Thr Glu Phe Ser		
145	150	155
Val Ser Ser Ser Ala Tyr Leu Ala Ser Ser Pro Asp Ser Thr Thr Pro		
165	170	175
Val Ser Ala Thr Thr Arg Ala Pro Pro Leu Thr Ser Met Ala Arg Lys		
180	185	190
Thr Lys Lys Ile Cys Ile Thr Glu Val Tyr Thr Glu Pro Ile Thr Met		
195	200	205
Ala Thr Glu Thr Glu Ala Phe Val Ala Ser Gly Ala Ala Phe Lys Asn		
210	215	220
Glu Ala Ala Gly Phe Gly Gly Val Pro Thr Ala Leu Leu Val Leu Ala		
225	230	235
Leu Leu Phe Phe Gly Ala Ala Ala Val Leu Ala Val Cys Tyr Val Lys		
245	250	255
Arg Tyr Val Lys Ala Phe Pro Phe Thr Thr Lys Asn Gln Gln Lys Glu		
260	265	270
Met Ile Glu Thr Lys Val Val Lys Glu Glu Lys Ala Asp Asp Val Asn		
275	280	285
Ala Asn Glu Glu Ser Lys Lys Thr Ile Lys Asn Pro Glu Glu Ala Lys		
290	295	300
Ser Pro Pro Lys Thr Thr Val Arg Cys Leu Glu Ala Glu Val		
305	310	315

&lt;210&gt; 61

&lt;211&gt; 93

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 61

Ala His Met Val Trp Ala Asn Leu Ala Val Phe Val Ile Cys Phe Leu			
1	5	10	15
Pro Leu His Val Val Leu Thr Val Gln Val Ser Leu Asn Leu Asn Thr			
20	25	30	
Cys Ala Ala Arg Asp Thr Phe Ser Arg Ala Leu Ser Ile Thr Gly Lys			
35	40	45	
Leu Ser Asp Thr Asn Cys Cys Leu Asp Ala Ile Cys Tyr Tyr Tyr Met			
50	55	60	
Ala Arg Glu Phe Gln Glu Ala Ser Lys Pro Ala Thr Ser Ser Asn Thr			
65	70	75	80
Pro His Lys Ser Gln Asp Ser Gln Ile Leu Ser Leu Thr			
85	90		

&lt;210&gt; 62

&lt;211&gt; 408

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 62

Met Ala Gln Leu Ala Arg Ala Thr Arg Ser Pro Leu Ser Trp Leu Leu			
1	5	10	15

Leu Leu Phe Cys Tyr Ala Leu Arg Lys Ala Gly Gly Asp Ile Arg Val  
 20 25 30  
 Leu Val Pro Tyr Asn Ser Thr Gly Val Leu Gly Gly Ser Thr Thr Leu  
 35 40 45  
 His Cys Ser Leu Thr Ser Asn Glu Asn Val Thr Ile Thr Gln Ile Thr  
 50 55 60  
 Trp Met Lys Lys Asp Ser Gly Gly Ser His Ala Leu Val Ala Val Phe  
 65 70 75 80  
 His Pro Lys Lys Gly Pro Asn Ile Lys Glu Pro Glu Arg Val Lys Phe  
 85 90 95  
 Leu Ala Ala Gln Gln Asp Leu Arg Asn Ala Ser Leu Ala Ile Ser Asn  
 100 105 110  
 Leu Ser Val Glu Asp Glu Gly Ile Tyr Glu Cys Gln Ile Ala Thr Phe  
 115 120 125  
 Pro Arg Gly Ser Arg Ser Thr Asn Ala Trp Leu Lys Val Gln Ala Arg  
 130 135 140  
 Pro Lys Asn Thr Ala Glu Ala Leu Glu Pro Ser Pro Thr Leu Ile Leu  
 145 150 155 160  
 Gln Asp Val Ala Lys Cys Ile Ser Ala Asn Gly His Pro Pro Gly Arg  
 165 170 175  
 Ile Ser Trp Pro Ser Asn Val Asn Gly Ser His Arg Glu Met Lys Glu  
 180 185 190  
 Pro Gly Ser Gln Pro Gly Thr Thr Val Thr Ser Tyr Leu Ser Met  
 195 200 205  
 Val Pro Ser Arg Gln Ala Asp Gly Lys Asn Ile Thr Cys Thr Val Glu  
 210 215 220  
 His Glu Ser Leu Gln Glu Leu Asp Gln Leu Leu Val Thr Leu Ser Gln  
 225 230 235 240  
 Pro Tyr Pro Pro Glu Asn Val Ser Ile Ser Gly Tyr Asp Gly Asn Trp  
 245 250 255  
 Tyr Val Gly Leu Thr Asn Leu Thr Leu Thr Cys Glu Ala His Ser Lys  
 260 265 270  
 Pro Ala Pro Asp Met Ala Gly Tyr Asn Trp Ser Thr Asn Thr Gly Asp  
 275 280 285  
 Phe Pro Asn Ser Val Lys Arg Gln Gly Asn Met Leu Leu Ile Ser Thr  
 290 295 300  
 Val Glu Asp Gly Leu Asn Asn Thr Val Ile Val Cys Glu Val Thr Asn  
 305 310 315 320  
 Ala Leu Gly Ser Gly Gln Gly Gln Val His Ile Ile Val Lys Glu Lys  
 325 330 335  
 Pro Glu Asn Met Gln Gln Asn Thr Arg Leu His Leu Gly Tyr Ile Phe  
 340 345 350  
 Leu Ile Val Phe Val Leu Ala Val Val Ile Ile Ile Ala Ala Leu Tyr  
 355 360 365  
 Thr Ile Arg Arg Cys Arg His Gly Arg Ala Leu Gln Ser Asn Pro Ser  
 370 375 380  
 Glu Arg Glu Asn Val Gln Tyr Ser Ser Val Asn Gly Asp Cys Arg Leu  
 385 390 395 400  
 Asn Met Glu Pro Asn Ser Thr Arg  
 405

&lt;210&gt; 63

&lt;211&gt; 278

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 63

Met Phe Leu Val Gly Ser Leu Val Val Leu Cys Gly Leu Leu Ala His  
 1 5 10 15  
 Ser Thr Ala Gln Leu Ala Gly Leu Pro Leu Pro Leu Gly Gln Gly Pro  
 20 25 30  
 Pro Leu Pro Leu Asn Gln Gly Pro Pro Leu Pro Leu Asn Gln Gly Gln  
 35 40 45  
 Leu Leu Pro Leu Ala Gln Gly Leu Pro Leu Ala Val Ser Pro Ala Leu  
 50 55 60  
 Pro Ser Asn Pro Thr Asp Leu Leu Ala Gly Lys Phe Thr Asp Ala Leu  
 65 70 75 80  
 Ser Gly Gly Leu Leu Ser Gly Gly Leu Leu Gly Ile Leu Glu Asn Ile  
 85 90 95  
 Pro Leu Leu Asp Val Ile Lys Ser Gly Gly Asn Ser Asn Gly Leu  
 100 105 110  
 Val Gly Gly Leu Leu Gly Lys Leu Thr Ser Ser Val Pro Leu Leu Asn  
 115 120 125  
 Asn Ile Leu Asp Ile Lys Ile Thr Asp Pro Gln Leu Leu Glu Leu Gly  
 130 135 140  
 Leu Val Gln Ser Pro Asp Gly His Arg Leu Tyr Val Thr Ile Pro Leu  
 145 150 155 160  
 Gly Leu Thr Leu Asn Val Asn Met Pro Val Val Gly Ser Leu Leu Gln  
 165 170 175  
 Leu Ala Val Lys Leu Asn Ile Thr Ala Glu Val Leu Ala Val Lys Asp  
 180 185 190  
 Asn Gln Gly Arg Ile His Leu Val Leu Gly Asp Cys Thr His Ser Pro  
 195 200 205  
 Gly Ser Leu Lys Ile Ser Leu Leu Asn Gly Val Thr Pro Val Gln Ser  
 210 215 220  
 Phe Leu Asp Asn Leu Thr Gly Ile Leu Thr Lys Val Leu Pro Glu Leu  
 225 230 235 240  
 Ile Gln Gly Lys Val Cys Pro Leu Val Asn Gly Ile Leu Ser Gly Leu  
 245 250 255  
 Asp Val Thr Leu Val His Asn Ile Ala Glu Leu Leu Ile His Gly Leu  
 260 265 270  
 Gln Phe Val Ile Lys Val  
 275

<210> 64  
 <211> 264  
 <212> PRT  
 <213> Mouse

<400> 64

Met Ala Thr Thr Thr Cys Gln Val Val Gly Leu Leu Leu Ser Leu Leu  
 1 5 10 15  
 Gly Leu Ala Gly Cys Ile Ala Ala Thr Gly Met Asp Met Trp Ser Thr  
 20 25 30  
 Gln Asp Leu Tyr Asp Asn Pro Val Thr Ala Val Phe Gln His Glu Gly  
 35 40 45  
 Leu Trp Arg Ser Cys Val Gln Gln Ser Ser Gly Phe Thr Glu Cys Arg  
 50 55 60  
 Pro Tyr Phe Thr Ile Leu Gly Leu Pro Ala Met Leu Gln Ala Val Arg  
 65 70 75 80  
 Ala Leu Met Ile Val Gly Ile Val Leu Gly Val Ile Gly Ile Leu Val  
 85 90 95  
 Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Asp Asp Ser  
 100 105 110

Ala Lys Ala Lys Met Thr Leu Thr Ser Gly Ile Leu Phe Ile Ile Ser  
 115 120 125  
 Gly Ile Cys Ala Ile Ile Gly Val Ser Val Phe Ala Asn Met Leu Val  
 130 135 140  
 Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Ser Gly Met Gly Gly  
 145 150 155 160  
 Met Gly Gly Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe Gly Ala  
 165 170 175  
 Ala Leu Phe Val Gly Trp Val Ala Gly Gly Leu Thr Leu Ile Gly Gly  
 180 185 190  
 Val Met Met Cys Ile Ala Cys Arg Gly Leu Thr Pro Asp Asp Ser Asn  
 195 200 205  
 Phe Lys Ala Val Ser Tyr His Ala Ser Gly Gln Asn Val Ala Tyr Arg  
 210 215 220  
 Pro Gly Gly Phe Lys Ala Ser Thr Gly Phe Gly Ser Asn Thr Arg Asn  
 225 230 235 240  
 Lys Lys Ile Tyr Asp Gly Gly Ala Arg Thr Glu Asp Asp Glu Gln Ser  
 245 250 255  
 His Pro Thr Lys Tyr Asp Tyr Val  
 260

&lt;210&gt; 65

&lt;211&gt; 132

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 65

Ala His Pro Arg Pro Gly Ala Arg Arg Pro Arg Leu Leu Ala Phe Gln  
 1 5 10 15  
 Ala Ser Cys Ala Pro Ala Pro Gly Ser Arg Asp Arg Cys Pro Glu Glu  
 20 25 30  
 Gly Gly Pro Arg Cys Leu Arg Val Tyr Ala Gly Leu Ile Gly Thr Val  
 35 40 45  
 Val Thr Pro Asn Tyr Leu Asp Asn Val Ser Ala Arg Val Ala Pro Trp  
 50 55 60  
 Cys Gly Cys Ala Ala Ser Gly Asn Arg Arg Glu Glu Cys Glu Ala Phe  
 65 70 75 80  
 Arg Lys Leu Phe Thr Arg Asn Pro Cys Leu Asp Gly Ala Ile Gln Ala  
 85 90 95  
 Phe Asp Ser Leu Gln Pro Ser Val Leu Gln Asp Gln Thr Ala Gly Cys  
 100 105 110  
 Cys Phe Pro Arg Val Ser Trp Leu Tyr Ala Leu Thr Ala Leu Ala Leu  
 115 120 125  
 Gln Ala Leu Leu  
 130

&lt;210&gt; 66

&lt;211&gt; 764

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 66

gcagcaccca	gcccggcaagcg	caccaggcac	cgcgacagac	ggcaggagca	cccatcgacg	60
ggcggtactgg	agcgagccga	gcagagcaga	gagaggcgtg	cttggaaaccg	agaacccaagc	120
cggggggcat	ccccggccg	ccgcacgcac	aggccggcgc	cctccttgcc	tccctgctcc	180
ccaccggcgcc	cctccggcca	gcatgaggct	cctggcggcc	gcgctgctcc	tgctgctcct	240
ggcgctgtgc	gcctcgccg	tggacgggtc	caagtgttaag	tgttcccgga	agggggcccaa	300

gatccgctac	agcgacgtga	agaagctgga	aatgaagcca	aagtaccac	actgcgagga	360
gaagatggtt	atcgtcacca	ccaagagcat	gtccaggtac	cggggccagg	agcaactgcct	420
gcaccctaag	ctgcagagca	ccaaacgcct	catcaagtgg	tacaatgcct	ggaacgagaa	480
gcgcagggtc	tacgaagaat	agggtggacg	atcatggaaa	aaaaactcc	aggccagttg	540
agagacttca	gcagaggact	ttgcagattt	aaataaaaagc	cctttcttc	tcacaagcat	600
aagacaaatt	atataattgct	atgaagctct	tcttaccagg	gtcagtttt	acatttata	660
gctgtgtgt	aaaggcttcc	agatgtgaga	tccagctcgc	ctgcgcacca	gacttcatta	720
caagtggctt	tttgctgggc	ggttggcggg	ggcggggggg	acct		764

&lt;210&gt; 67

&lt;211&gt; 288

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 67

gcggccgcgc	tgctcctgct	gctgctggcg	ctgtacaccg	cgcgtgtgga	cgggtccaaa	60
tgcaagtgt	cccgaaagg	acccaagatc	cgctacagcg	acgtgaagaa	gctggaaatg	120
aagccaaagt	acccgcactg	cgaggagaag	atggttatca	tcaccacca	gagcgtgtcc	180
aggtaccgag	gtcaggagca	ctgcctgcac	cccaagctgc	agagcacca	gcgcattcattc	240
aagtggtaca	acgcctggaa	cgagaagcgc	agggtctacg	aagaatag		288

&lt;210&gt; 68

&lt;211&gt; 95

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 68

Ala	Ala	Ala	Leu	Leu	Leu	Leu	Leu	Leu	Ala	Leu	Tyr	Thr	Ala	Arg	Val
1			5			10					15				
Asp	Gly	Ser	Lys	Cys	Lys	Cys	Ser	Arg	Lys	Gly	Pro	Lys	Ile	Arg	Tyr
			20			25					30				
Ser	Asp	Val	Lys	Lys	Leu	Glu	Met	Lys	Pro	Tyr	Pro	His	Cys	Glu	
			35			40				45					
Glu	Lys	Met	Val	Ile	Ile	Thr	Thr	Lys	Ser	Val	Ser	Arg	Tyr	Arg	Gly
			50			55				60					
Gln	Glu	His	Cys	Leu	His	Pro	Lys	Leu	Gln	Ser	Thr	Lys	Arg	Phe	Ile
			65			70				75				80	
Lys	Trp	Tyr	Asn	Ala	Trp	Asn	Glu	Lys	Arg	Arg	Val	Tyr	Glu	Glu	
						85				90					

&lt;210&gt; 69

&lt;211&gt; 234

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 69

tccaaagtgt	agtgttcccg	gaaggggccc	aagatccgt	acagcgacgt	gaagaagctg	60
gaaatgaagc	caaagtaccc	acactgcgag	gagaagatgg	ttatcgac	caccaagagc	120
atgtccaggt	accggggcca	ggagcactgc	ctgcacccta	agctgcagag	cacccaaacgc	180
ttccatcaagt	ggtacaatgc	ctggAACGAG	aagcgcaggg	tctacgaaga	atag	234

&lt;210&gt; 70

&lt;211&gt; 77

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 70

Ser Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp  
 1 5 10 15  
 Val Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys  
 20 25 30  
 Met Val Ile Val Thr Thr Lys Ser Met Ser Arg Tyr Arg Gly Gln Glu  
 35 40 45  
 His Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp  
 50 55 60  
 Tyr Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu  
 65 70 75

<210> 71  
 <211> 234  
 <212> DNA  
 <213> Human

<400> 71  
 tccaaatgca agtgctcccg gaagggaccc aagatccgct acagcgacgt gaagaagctg 60  
 gaaatgaagc caaagtaccc gcaactgcgag gagaagatgg ttatcatcac caccaagagc 120  
 gtgtccaggt accgaggtca ggagcactgc ctgcacccca agctgcagag caccaagcgc 180  
 ttcatcaagt ggtacaacgc ctggaacgag aagcgcaggg tctacgaaga atag 234

<210> 72  
 <211> 77  
 <212> PRT  
 <213> Human

<400> 72  
 Ser Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp  
 1 5 10 15  
 Val Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys  
 20 25 30  
 Met Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu  
 35 40 45  
 His Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp  
 50 55 60  
 Tyr Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu  
 65 70 75

<210> 73  
 <211> 1460  
 <212> DNA  
 <213> Pinus radiata

<400> 73  
 aaaacgtcca tagcttcctt gccaactgca agcaatacag tacaagagcc agacgatcga 60  
 atcctgtgaa gtggttctga agtgatggg agcttggat ctgaaaaaac tggtaacgg 120  
 tatcagctc gggactccag tggccacttg tcccttaca cttacaatct cagaaagaaa 180  
 ggacctgagg atgttaattgt aaagggtcatt tactgcggaa tctgccactc tgatttagtt 240  
 caaatgcgtat atgaaatggat catgtctcat taccatgg tccctggca tgaagtgg 300  
 gggattgtaa cagagattgg cagcgagggtg aagaaattca aagtggaga gcatgttaggg 360  
 gttggttgca ttgtgggtc ctgtcgcaat tgccgttatt gcaatcgag catgaaacaa 420  
 tactgcagca agaggatttg gacctacaat gatgtgaacc atgacggcac acctactcg 480  
 ggcggatttg caagcgttat ggtgggtgat cagatgttg tggttcgaat cccggagaat 540  
 cttccctctgg aacaagcggc ccctctgtta tgtgcagggg ttacagttt cagcccaatg 600  
 aagcatttcg ccatgacaga gcccggaaag aaatgtgggat ttttgggttt aggaggcgtg 660  
 gggcacatgg gtgtcaagat tgccaaagcc tttggactcc acgtgacggc tatcagttcg 720

tctgataaaa agaaagaaga agccatggaa gtcctcggcg ccgatgccta tcttgttagc	780
aaggatactg aaaagatgtt ggaagcagca gagaggcttag attacataat ggacaccatt	840
ccagttgctc atcctcttgg accatatctt gccctcttga agacaaatgg aaagcttagt	900
atgctggcg ttgttccaga gccgttgcac ttctgtactc ctctcttaat acttgggaga	960
aggagcatag ctggaaagttt cattggcagc atggagggaaa cacagggaaac tctagatttc	1020
tgtcagaga agaaggatc atcgatgatt gaggttgggg gcctggacta catcaacacg	1080
gccatggaaa ggttggagaa gaacgatgtc cgttacagat ttgtggggttga tgggtctaga	1140
agcaagttgg ataattatgc tgcaatcaat caatcagatc aatgcctgca tgcaagatga	1200
atagatctgg actagtagct taacatgaaa gggaaattaa atttttttt aggaactcga	1260
tactggtttt tggttacttta gtttagcttt tggggggggaa aaacaattca gatgtttttt	1320
taacttgtat atgtaaagat caatttctcg tgacagtaaa taataatcca atgtcttctg	1380
ccaaatataat atatgtatttgc gtatttttt atgaaaaaaaaaaaaaaaaaaaaaaaaaaaa	1440
aaaaaaaaaaaa aaaaaaaaaaaa	1460

&lt;210&gt; 74

&lt;211&gt; 363

&lt;212&gt; DNA

<213> *Eucalyptus grandis*

&lt;400&gt; 74

aaagcaacac attgaactct ctctctctct ctctctctct ccccccccccc	60
ccctttccaa ccccacccac atacagacaa gtagatacgc gcacacagaa gaagaaaaaga	120
tgggggtttc aatgcagtc atcgacttag cgacgggtct ggccgtcttta acgacatggg	180
cgtggggggc ggtgaactgg gtgtggctga ggccgaagag gctcgagagg cttctgagac	240
agcaaggctt ctccggcaag tcctacaccc tcctggcg cgacctcaag gagaacctgc	300
ggatgctcaa ggaagccaa tccaaagccca tcggccgtctc cgatgacatc aagcctcgtc	360
tct	363

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/NZ00/00256

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int. Cl. <sup>7</sup> : C12N 15/11		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) SEE ELECTRONIC DATA BASES		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE ELECTRONIC DATA BASES		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EMBL, GenBank, PIR, GenePept: Sequence IDs 1, 36, 2, 37, 3, 38, 4, 39, 5, 40		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenBank Accession No. AL034558 28 July 1999 Whole Sequence w.r.t. Sequence ID 3	1 - 14
X	GenPept Accession No. CAA29045 21 March 1995 Whole Seqence Frame +2 w.r.t. Sequence ID 4	1 - 14
X	GenBank Accession No. AR018857 5 December 1998 & US 5783182 Whole Sequence w.r.t. Seqence ID 5	1 - 14
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		
"&" document member of the same patent family		
Date of the actual completion of the international search <b>28 March 2001</b>	Date of mailing of the international search report <b>29.03.2001</b>	
Name and mailing address of the ISA/AU <b>AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929</b>		
Authorized officer <b>CRAIG ALLATT</b> Telephone No : (02) 6283 2414		

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/NZ00/00256

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenPept Accession No. CAB4Q181 14 December 1999 Whole Sequence w.r.t. Sequence ID 40	1 - 14

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/NZ00/00256

### Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos :  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos :  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos :  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

### Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Supplemental Box

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
Claims 1 - 14 partially.(See Supplemental Box)

Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.  
**PCT/NZ00/00256**

**Supplemental Box**

(To be used when the space in any of Boxes I to VIII is not sufficient)

**Continuation of Box No: II**

In the present application, the feature that all sequences come from "mammalian sources" does not provide a special technical feature. Genes and their expressed proteins from "mammalian sources" have been sequenced. Cells from "mammalian sources" comprise a variety of different animals and cell types. Moreover the applicant has provided no evidence that the nucleotide sequences of the present application, and the peptides they express, form a unique group of protein types. On the contrary, putative peptides derived from the nucleotide sequences of the application have functions assigned on the basis of their similarity to known proteins expressed by a variety of cell types.

The applicant has grouped the polynucleotides of the application into activity categories according to putative functions of the proteins they encode. However, most of the applicants' groupings do not form a homogenous set of proteins either in structure or function. Moreover, it is noted that most of the peptides encoded by the polynucleotides are assigned to more than one activity category.

The ISA considers that each nucleotide/peptide sequence pair (defined in Table 1 pages 8 - 19) comprises one invention and that there are 35 different inventions (the inventions being numbered sequentially).

However, as a service to the applicants, the ISA will search the first five inventions without inviting additional search fees.

Therefore the ISA has searched SEQ IDs 1, 36, 2, 37, 3, 38, 4, 39, 5, and 40.

## INTERNATIONAL SEARCH REPORT

#### Information on patent family members

International application No.  
**PCT/NZ00/00256**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	5783182	AU	11609/97	CA	2237929	EP	870057
		WO	9718454				